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Abbreviations: 
ADAM(T)    A disintegrin and metalloproteinase (with thrombospondin motive) 
APC          Adenomatous polyposis coli 
ALK         Activin receptor-like kinase 
BIA          Bioactivity assay 
bFGF         basic Fibroblast growth factor 
BMP         Bone morphogenic protein 
BSA          Bovine serum albumin 
CAF          Cancer-associated fibroblast 
CM           Conditioned medium 
CRC          Colorectal cancer 
CTGF        Connective tissue growth factor 
DMEM       Dulbecco’s modified eagle medium 
ECM         Extracellular matrix 
EMMPRIN   Extracellular matrix metalloproteinase inducer 
EMT         Epithelial to mesenchymal transition 
FAP          Familiar adenomatous polyposis 
HNPCC      Heriditary non-polyposis colorectal cancer 
HB-EGF      Heparin binding epidermal growth factor 
HIF          Hypoxia inducible factor 
HRP          Horse radish peroxidase 
HSPG        Heparan sulphate proteoglycan 
HUVEC      Human umbilical vein endothelial cells 
IGF          Insulin like growth factor 
IL            Interleukin 
kDa          kilo Dalton 
LAP          Latency associated protein 
LLC          Large latent TGF-β complex 
LTBP        Latent TGF-β binding protein 
MAPK       Mitogen activated protein kinases 
MCP-1       Monocyte chemoattractant protein-1 
MHC         Major histocompatibility complex 
MMP         Matrix metalloproteinases 
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MT-MMP   Membrane type matrix metalloproteinases 
PAI-1       Plasminogen activator inhibitor-1 
RT          Room temperature 
SDS         Sodium dodecyl sulphate 
SLC         Small latent TGF-β complex 
SMA        Smooth muscle actin 
TGF-β       Transforming growth factor-β 
TGF-β RII   Transforming growth factor-β receptor II 
TIMP        Tissue inhibitor of metalloproteinase 
TNF-α       Tumour necrosis factor-α 
TNM        Tumour node metastasis 
tPA          tissue-type Plasminogen activator 
TSP         Thrombospondin 
uPA         urokinase type Plasminogen activator 
uPAR       uPA receptor 
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1    Gastrointestinal cancer  
Cancer is the second cause of death worldwide and shows increasing incidence during the last 
decades1,2. Among the different types of neoplasia, cancer of the colon and rectum (CRC) is 
the second most diagnosed cancer with according numbers of deaths in western Europe2. 
Hereditary CRC accounts for 5-10% of the CRC and includes HNPCC (Lynch syndrome) and 
familiar adenomatous polyposis (FAP)3, 4. Apart from familiar predisposition, the majority of 
the CRC arise from environmental factors (sporadic CRC). Risk factors include age, physical 
inactivity, consumption of red meat and smoking. The development of colorectal tumours 
consists of different steps (Figure 1). Adenomas (polyps) arise from normal colonic mucosa 
by (environmentally induced) genetic alternations in the mucosal epithelial cells, like 
mutation in the APC gene and K-ras5. Additional mutations lead to the development of in situ 
and eventually invasive cancers6. Tumours cannot exceed the size of 1-2 mm without 
acquiring its own vasculature system, a phenomenon known as the angiogenic switch. The 
vascular system provides the tumour with nutrients and oxygen, preventing tumour cell 
necrosis, leading to further outgrowth, invasion and eventually formation of distant metastasis 
(Figure 1). The primary treatment of CRC consists of surgical resection of the tumour 








Figure 1. Schematic presentation of colorectal crypts showing different stages in the development of CRC. 
Hyper-proliferation of epithelial cells leads to the formation of pre-malignant colorectal adenomas, 
progressing into early carcinomas by additional mutations. When tumours reach a critical size, they acquire 
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Gastric cancers show large geographic differences and about 5% is due to hereditary 
etiology9. Two major histopathological types are described by Laurén et al10, an intestinal and 
a diffuse-type gastric cancer. Risk factors for developing gastric cancer include diet, cigarette 
smoking, alcohol consumption and Helicobacter pylori infection. Tumours arise from 
precursor lesions that include chronic atrophic gastritis, which can proceed into intestinal 
metaplasia9. Primary treatment for gastric carcinomas is resection of the tumour with or 
without adjuvant chemo- or radiation therapy.   
For both CRC and gastric cancer the prognosis strongly depends on the stage of tumour at the 
time of diagnosis and decreases with increasing stage and the presence of lymph node or 
distant metastasis2,7.  
 
2     Cell-cell interactions in the tumour-microenvironment 
Tumours consist of different cell types together creating the tumour-microenvironment. These 
cell types include tumour cells and the tumour stroma, consisting of surrounding fibroblasts 
and myofibroblast, tumour-associated endothelial cells creating the tumour’s vasculature 
system and infiltrating immune cells, including macrophages, T-lymphocytes and 
neutrophils11,12. For a long time tumour cells have been the only focus of research, whereas 
the role of the tumour stroma was neglected. During the last decade more attention has been 
given to the role of the tissue stroma in the initiation, progression and metastasis of cancers13-
17. All the distinct hallmarks in cancer, self-sufficiency in growth factors, insensitivity to anti-
growth signals, evasion of apoptosis, limitless replication potential, sustained angiogenesis, 
tissue invasion and metastasis18, involve interactions between different cell types and the 
extracellular matrix (ECM) within the tumour-microenvironment. Not surprisingly, it was 
shown that the carcinoma-stromal ratio in CRC is an independent prognostic factor for 
survival19. This thesis focusses on interactions between tumour cells, fibroblasts, endothelial 
and inflammatory cells. Cross-talk between cells can occur via direct cell-cell contact or via 
soluble factors12, 13, 16, 20, 21. 
 
2.1   Cell-cell interactions via direct contact 
Under normal condition cells interact via the formation of cell-cell and cell-matrix adhesions. 
Cadherins are Ca2+ dependent cell adhesion molecules, mediating cell-cell contact via their 
extracellular domains. Through their intracellular domain cadherins influence rearrangement 
of the cytoskeleton via β-catenin22. Besides interaction with catenins, cadherins also interact 
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with integrins, like αvβ3 integrin, and growth factor receptors like the TGF-β receptor II 
(TGF-βRII)23,24. Interactions between cells are required to maintain normal tissue morphology 
and function. In cancer these cell-cell adhesions change by rearrangement or excessive 
cleavage of adhesion molecules. Besides interaction of cells from similar origin (like 
epithelial interactions), cell-cell contact between tumour epithelial and stromal cells can 
influence many processes. One of the most well described molecules capable of doing so is 
extracellular matrix metalloproteinase inducer (EMMPRIN). EMMPRIN is a trans-membrane 
protein consisting of two immunoglobulin chains and a short cytoplasmic domain25. It is 
mainly expressed by epithelial cells and was shown to have an important role in cancer26,27. 
EMMPRIN expressed on malignant epithelial cells evokes the hyper-activation of 
neighbouring fibroblasts leading to enhanced MMP-2 expression28,29. Furthermore in gastric 
cancers a correlation was observed between EMMPRIN and the expression of VEGF, MMP-2 
and MMP-9, indicating a clear relation with angiogenesis30. Recently a soluble form of 
EMMPRIN has been indentified, which is also capable of inducing MMP expression31. 
 
2.2   Cell-cell interactions involving soluble factors 
Cells communicate via soluble factors like cytokines, chemokines and matrix-derived 
peptides. The extracellular matrix (ECM) of cancers is next to its supportive and nutritious 
functions also an excessive pool of growth factors, stimuli and chemoattractants that enable 
the tumour cells to grow, invade and metastasise. For instance, ECM-derived molecules like 
tenascin-C play a role in the recruitment of myofibroblasts32, whereas tumour cell-derived 
monocyte chemoattractant protein (MCP)-1 mediates macrophage infiltration. In turn these 
cells secrete interleukin (IL)-8, capable of inducing angiogenesis in endothelial cells33. The 
expression of growth factors like vascular endothelial growth factor (VEGF) can be regulated 
via epithelial-stromal interactions34,35. The majority of the growth factors in the ECM are 
present in an inactive conformation and need processing or release. Within the tumour-
microenvironment proteolytic enzymes, especially MMPs, play an important role in 
regulating growth factor bio-availability36-40(Figure 2). For example, IL-8 can be activated 
through proteolytic processing via MMP-941, which results in a cascade of tumour cell-
fibroblast-endothelial-inflammatory cell interactions. Another example is the initiation of the 
fibroblast angiogenic switch, regulated by tumour cell-derived MMP-742. Next to proteolytic 
enzymes also integrins play a major role in activation of growth factors. Integrins consist of a 
group of 24 heterodimers and are involved in nearly all stages of cancer development.  
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Integrin αvβ3 and αvβ4 have been shown to be involved in regulating VEGF expression43, 
and αvβ5, αvβ6 and αvβ8 integrin have been show to be involved in TGF-β binding and 
activation44,45. Besides activation of growth factors some integrins bind to MMPs46 and 
interact with growth factor receptors like VEGF-Receptor-243,45.  
Because of these important regulation mechanisms, targeting cell-cell interactions in the 
tumour-microenvironment is now considered as a promising candidate for therapeutic 
intervention13,16,21,47. This thesis focuses primarily on two major cell-cell interactions in the 
tumour-microenvironment: Tumour angiogenesis and the generation of myofibroblasts. 
 
3    Angiogenesis 
Angiogenic activity of endothelial cells is in general low, except during embryonic 
development, tissue repair after injury or pathological processes. The initiation phase of 
angiogenesis consists of endothelial cell activation, degradation of the basement membrane, 
subsequently followed by migration of endothelial cells. Then, in response to angiogenic 
stimuli, endothelial cells proliferate and differentiate to re-establish cell-cell contacts and 
form a lumen. Next is the so-called resolution phase in which the basement membrane is 
restored and the endothelial cells return to a non-activated state by inhibition of proliferation 
and vessel wall assembly48,49. Tumours depend on neo-vascularisation processes to provide 
oxygen and nutrients, allowing them to exceed a size of 1-2 mm50,51.  
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In hypoxic environments tumour cells start secreting pro-angiogenic factors which results in 
endothelial branching (sprouting) towards the tumour51. Molecules capable of inducing 
endothelial sprouting are VEGF48,50,52-54, bFGF, TGF-β55,56, Laminin-5 γ2 chain57, IL-8 and 
several others58. Various cell types within the tumour-microenvironment contribute to the 
angiogenic processes. Neutrophils have been indicated to mediate the initial angiogenic 
switch59, whereas macrophages and fibroblasts contribute to angiogenesis via the secretion of 
various soluble factors and proteinases leading to the release of angiogenic molecules from 
the ECM (e.g. VEGF release from connective tissue growth factor (CTGF)60. 
In contrast, various types of cells can also mediate anti-angiogenic properties via proteinases-
mediated degradation of pro-angiogenic molecules61 or the release of anti-angiogenic ECM 
molecules62. Especially the role of MMPs seems dualistic and complex as they might act pro- 
and anti-angiogenic41. Together these data indicate that the response of endothelial cells to 
angiogenic stimuli is a delicate interaction between tumour cells, fibroblasts and 
inflammatory cells. 
4    Origin and function of myofibroblasts 
Already in the 1980s Dvorak et al63 described tumours as “wounds that do not heal”, because 
there are great similarities between tumours and wound healing processes. One of the cell 
types crucial in both conditions are the myofibroblasts. Myofibroblasts are a heterogeneous 
population of hyperactivated fibroblasts which simultaneously express the fibroblast marker 
vimentin and α-Smooth Muscle Actin (SMA)64-66. Myofibroblasts are characterized by 
increased matrix deposition together with enhanced synthesis of proteolytic enzymes and 
growth factors67. In normal colon the presence of myofibroblasts is restricted to a thin single 
layer along the crypt axis68,69. In adenomas and carcinomas a strong increase in number of 
myofibroblast has been shown70. Although their origin has not been clarified yet, several 
theories have been postulated71. Firstly, normal colonic myofibroblasts could strongly 
proliferate. Secondly, pericytes, vascular smooth muscle cells, or smooth muscle cells from 
the muscularis mucosa could differentiate and contribute to the myofibroblast population71-73. 
Thirdly, circulating precursor cells (fibrocytes) have been shown to migrate to tumours where 
they trans-differentiate by TGF-β1 into myofibroblasts74-77. Fourthly, epithelial-mesenchymal 
transition (EMT) of tumour cells67,78,79 or differentiation of tumour infiltrating macrophages80, 
could contribute to the carcinoma myofibroblast population. Finally, the most commonly 
accepted hypothesis is that myofibroblasts arise from TGF-β1 mediated trans-differentiation 
of resident fibroblasts73, 81-87. Interestingly, in most of these proposed models TGF-β plays a 
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major role. TGF-β can differentiate fibrocytes into myofibroblasts, initiate EMT and trans-
differentiate macrophages or fibroblasts into myofibroblasts in vitro. Within the tumour-
microenvironment tumour cells are the major TGF-β producers. However, the bio-activity of 
the secreted ECM-bound latent TGF-β strongly depends on the presence of activation 
cascades, finally leading to the fibroblast trans-differentiation. In turn, myofibroblasts interact 
with surrounding epithelial cells, via secreted growth factors and proteinases. In colon cancer, 
for example, it was shown that myofibroblasts up-regulate MMP expression88,89, increase 
growth of epithelial cells15,78,90 and stimulate the invasion of colon cancer cells87,91-93. 
Furthermore, myofibroblasts can contribute to angiogenic processes by enhanced secretion 
pro-angiogenic molecules94,95, providing matrix growth factor binding proteins (like CTGF), 
morphogens or releasing inactive angiogenic factors from the ECM via secreted proteinases96. 
5    Growth factors in gastrointestinal cancer  
Angiogenic processes as well as the generation of myofibroblasts depend on the presence of 
growth factors in the tumour-microenvironment. In this thesis focus is on two major growth 
factors involved in these processes leading to cancer progression and metastasis: Vascular 
Endothelial Growth Factor (VEGF) and Transforming Growth Factor (TGF)-β1. 
 
5.1   Vascular Endothelial Growth Factor  
In 1971 Folkman et al. described a factor secreted by tumour cells which is capable of 
inducing angiogenesis51, called Vascular Endothelial Growth factor (VEGF). VEGF is a key 
mediator of angiogenesis, both in physiological as well as pathological conditions48,50. 
Besides angiogenesis recent reports also show a role for VEGF in the suppression of epithelial 
apoptosis induced by chemotherapeutic agents97. The expression of VEGF is regulated by 
different cytokines including TGF-β, bFGF and a hypoxic environment via Hypoxia Inducible 
Factor (HIF)-1α48,50,52. At least four different subtypes of VEGF are known, VEGF-121, -165, 
-189 and -206, referring to the number of amino acids53,98. Except VEGF-121 all isoforms 
contain a heparin-binding domain which enables binding to the ECM via interactions with 
Heparan Sulphate Proteoglycans (HSPGs)99,100. VEGF-165 is the most abundant form present 
in the human body. This 45 kDa, disulfide bond-linked homodimer can bind to VEGF 
receptor type 1 and 2 with high affinity. Receptor binding results in downstream signal 
transduction via different signalling pathways and endothelial sprouting by stimulating 
proliferation and migration (Figure 3).  In tumours these vessels are irregular, dilated and 
leaky and do not differentiate into arteries and venes50.  
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This provides an effective route for tumour 
cells to enter the bloodstream and form distant 
metastasis. Furthermore, because these vessels 
are inefficient, a hypoxic environment remains 
present resulting in the release of VEGF and 
subsequent more angiogenesis. The ability of 
VEGF to induce angiogenesis depends on the 
presence of soluble VEGF99. Therefore, the 
release of ECM-bound VEGF is a critical step 
in the induction of angiogenesis. There are 
indications that proteinases play a role in the 
release of VEGF and in the degradation of 
ECM components enabling endothelial cells to form new microvessels. Proteinases which are 
involved in both the release and/or cleavage of VEGF include plasmin99,101,102 and MMPs58, 
103-105. The clinical relevance of tumour angiogenesis and especially VEGF is clearly shown 
by the clinical use of the VEGF inhibiting antibody bevacizumab (Avastin®),  in the treatment 
of metastatic CRC106,107. Several other therapeutic agents targeting angiogenesis via blockade 
of the VEGF receptors or downstream receptor kinases are currently tested in clinical trails or 
already therapeutically applied101,108,109.  
 
5.2   Transforming Growth Factor-β 
The TGF-β superfamily consists of 33 proteins which all have distinct functions in cell 
homeostasis. This family of pleiotropic cytokines contains the TGF-βs, the Bone 
Morphogenic Proteins (BMPs), the actividins, and several others110,111. In humans the TGF-β 
subfamily consist of three members, TGF-β1, -2 and -3, which are encoded by different 
genes, but show high homology112,113. TGF-β1, a 25 kDa disulphide-bond linked homodimer, 
is the most abundantly and universally expressed TGF-β member114-118. It is produced as a 
latent complex consisting of TGF-β1, non-covalently bound to the latency-associated protein 
(LAP) dimer, and covalently bound to Latent TGF-β Binding Protein (LTBP) for binding to 
the ECM56,95,119-121. Four subtypes of LTBPs are known in humans of which in the colon 
LTBP-4 is most important for the localisation122. Before TGF-β1 can exert its effects removal 








Figure 3. VEGF signalling in endothelial cells
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First the small latent 
complex (SLC) consisting 
of the TGF-β dimer and 
LAP is released from the 
LTBP. This occurs 
generally via proteolytic 
cleavage of the LTBP by 
MMPs, serine proteases like 
plasmin, or BMP-156,124-127. 
Secondly LAP is removed, 
which is mainly mediated via a conformational change involving thrombospondin-1 (TSP-
1)128,129, integrins56, 130-132 or the neuropilin-1 receptor133. Furthermore, in vivo TGF-β1 can be 
activated via irradiation134 or mechanical stress135 and in vitro by extremes in pH or heat136,137.  
After active TGF-β1 is released it can bind to TGF-β Receptor type II (TGF-βRII). In 
epithelial cells and fibroblasts this receptor recruits TGF-βRI, generally the activin receptor-
like kinase type-5 (ALK-5), which is 
transphosphorylated by TGF-βRII. This results in 
phosphorylation of the Smad-2/Smad-3 complex. 
Subsequent complexation with Smad-4 leads to 
trans-localisation to the nucleus, where the 
complex binds to specific promoter regions and 
transcription is initiated (Figure 5). Typical targets 
genes of TGF-β include plasminogen activator 
inhibitor-1 (PAI-1), fibronectin and, in fibroblasts, 
collagen type-I138-141. The Smad complex is 
dephosphorylated by phosphatases and the Smads 
are released back into the cytosol110,111.  
Depending on the specific cell type, TGF-β can signal via other pathways including Mitogen-
Activated Protein Kinases (MAPK), Phospho-Inositide-3 (PI-3) kinases and signalling via 
other ALKs and Smads117,142,143. Besides TGF-βRI and TGF-βRII several co-receptors for 
TGF-β have been identified including betaglycan (TGF-βRIII)144-146 and endoglin147. 
Endoglin (CD105) is mainly expressed on angiogenic endothelial cells and seems to be 
important for the effects of TGF-β on (tumour)-angiogenesis148-153.  























Figure 5. Smad dependent TGF-β 
signalling pathway 
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In normal tissue homeostasis effects of TGF-β1 on cells include inhibition of proliferation, 
induction of apoptosis, suppression of the immune system and inhibition of endothelial cell 
proliferation and migration. In pre-malignant and early stages of cancer, TGF-β1 inhibits the 
proliferation of epithelial cells, thereby acting as a tumour-suppressor. In later stages the cells 
become refractory to the inhibition of proliferation by TGF-β1 and can even be growth 
stimulated by TGF-β1. Furthermore, TGF-β1 affects stromal cells by mediating trans-
differentiation of fibroblasts into hyper-activated myofibroblasts, thereby increasing synthesis 
of growth factors, ECM components and proteolytic enzymes. The effects of TGF-β on 
endothelial cells include induction of angiogenesis via stimulation of proliferation and 
migration149. Finally, TGF-β represses the immune response, for example, via prevention of 
activation and proliferation of cytotoxic T-lymphocytes, directly inhibiting the cytolytic 
activity of NK-cells95,136, but also converting CD8+ T-cells into IL-17 producing cells 
enhancing growth by pro-survival signals154. All these processes and the differences in 
cellular responses to TGF-β contribute to the dual role of  TGF-β1 in cancer progression95,114-
118,155-160. Also in gastrointestinal cancers the TGF-β pathway functions as a key mediator in 
different stages of cancer. Several mutations in the TGF-β signalling pathway contribute to 
CRC carcinogenesis. In mice it was shown that in colon adenomas, initiated by a mutation in 
the APC gene, additional epithelial TGF-βRII mutations induces malignant transformation of 
these adenomas158, and that Smad-3 knock-out mice develop metastatic CRC already at four 
months of age161, indicating the involvement of the TGF-β pathway in the development of 
CRC. In patients, TGF-βRII is mutated in 90% of the microsatellite instable colorectal 
tumours162 and mutation in the TGF-βRI mutations seem to be causally involved in a subset 
of HNPCC occurrences163. In the downstream signalling cascade several mutations in the 
Smad pathway, especially Smad-4, have been described5,164-167. Disruption of the gene 
encoding LTBP-4, important for latent TGF-β localisation in the colon, causes CRC122. 
Besides mutations in the receptors, associated proteins or downstream signalling cascade 
components, mutations in the TGF-β1 gene itself enhances TGF-β production by four to six 
fold168, increasing the CRC risk169. Increased tissue and plasma TGF-β1 levels have indeed 
been shown in CRC, which correlate with different clinico-pathological parameters including 
survival166,170-174. In gastric cancer TGF-β expression is observed in malignant epithelial and 
stromal cells and it was shown that both serum and tissue TGF-β1 levels are up-regulated, 
correlating with lymph node metastasis and poor prognosis112,175-183.  
These data suggest a crucial role for TGF-β1 in the progression of gastrointestinal cancers. 
However, only a few studies focussed on the interplay between the different cells in the 
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tumour-microenvironment influencing the production, effects, and, of crucial importance123, 
activation of latent TGF-β1. 
6    Proteinases implicated in growth factor activation and receptor shedding 
Proteolytic enzymes or proteinases cleave targets proteins which include basement membrane 
components, ECM molecules, membrane bound receptors, and growth factors (Figure 6)37,39, 
184. The role of proteinases in the progression and metastasis of cancer has extensively been 
studied. Among the many groups of proteases much focus has been on components of the 















6.1   The urokinase plasminogen activation system 
Plasmin is a serine protease, which is synthesised as the pro-enzyme plasminogen. Activation 
occurs through removal of the pro-peptide and is mediated via tissue-type plasminogen 
activator (tPA) or urokinase-type plasminogen activator (uPA). The role of uPA in cancer has 
extensively been studied revealing a clear role for uPA, its receptor uPAR and plasminogen 
activator inhibitor-1 (PAI-1) in cancer progression via the generation of plasmin, regulation of 
cell/ECM interactions, cell recruitment, and in signal transduction185,189,190. Furthermore, 
clinically the plasminogen activator system has been shown to be related to tumour-
parameters and to patient survival190,191. uPA can induce chemotaxis after binding to uPAR, 
but also via direct activation of pro-HGF. Furthermore, uPA activates plasmin which in turn 
can increase bio-availability of growth factors like bFGF, VEGF, and TGF-β185. 
Figure 6. Contribution of proteinases to specific cleavage events in cancer 
Degradation of the basement membrane Activation or release of latent growth factors
Generation of ECM signaling molecules Shedding of receptors and membrane molecules
Chapter 1 
- 22 -  
6.2   The cathepsins 
Cathepsins belong to the group of lysosomal cystein proteases and 11 members of this family 
have been identified192. Activation of the pro-enzyme occurs via proteolytic removal of the N-
terminal propeptide sequence193. They have a role in the lysososmal processing of 
incorporated molecules in the cell194, but can also be secreted into the pericellular space. 
Especially the role of cathepsin B and cathepsin S has been studied in cancer progression. 
Cathepsin B is up-regulated in CRC195,196, displaying involvement in angiogenesis197 and 
tumour invasion, for example directly via the activation of HB-EGF186 or via the activation of 
indirectly via processing of proteins like uPA186,198,199. Cathepsin S is one of the most potent 
lysosomal cystein proteinases. It has a low pH optimum, around pH 5, and is mainly produced 
by macrophages and tumour cells. Activation of the pro-molecule occurs via removal of the 
N-terminal propeptide186,194. It has been shown to be involved in MHC class II antigen 
presentation194,200 and is therefore involved in many immune disorders. Cathepsin S is also 
up-regulated in prostate cancer201 and glioblastomas201-205, and has a role in tumour 
angiogenesis206, probably by its ability to generate pro-angiogenic matrix-derived peptides 
like laminin-5 γ2 chains57, 206. 
 
6.3   The matrix metalloproteinases 
The first matrix metalloproteinase, MMP-1, was discovered in 1962 in tadpole tails207. Since 
then the MMP family has extended to a group of at least 23 zinc-bound proteinases, which are 
involved in remodelling of the ECM208 and implicated in many physiological processes 
including embryonic development, organogenesis, wound healing processes and bone 
remodelling188. Furthermore, MMPs are involved in many pathological conditions like 
inflammation and the invasion of cancer cells by ECM remodelling, including degradation of 
the basement membrane36,38,55,187,209. Regulation of MMP activity is mediated via activation of 
the inactive zymogens and further by the expression of their natural inhibitors, α-2 
macroglobulin, the Tissue Inhibitors of Matrix Metalloproteinases (TIMPs) and the 
membrane anchored inhibitor RECK105,210. Biological processes involving MMPs are 
therefore always strongly dependent on the balance between activation of the zymogen, and 
the presence of the inhibitors38. Recently, the MMP family was expanded with a special group 
of metalloproteinases, the ADAM(T)s [a Disintegrin And Metalloproteinase (with 
Thrombospondin motive)], which have a similar catalytic structure to MMPs and are also 
inhibited by TIMPs38,104,105. Besides their role in ECM degradation MMPs also have a 
prominent role in the activation of latent growth factors and hence in the communication 
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between cells within the tumour-microenvironment40,41,188,209,211,212.  The role of MMPs in 
different stages of tumour development has been studied, showing up-regulation of various 
MMPs in CRC39, 190, 213, 214. After it was shown that MMPs contribute significantly to tumour 
progression clinical trials started using broad spectrum MMP inhibitors. However, these trials 
did not show the results expected from pre-clinical tests in vitro and in mice215. Severe side-
effects combined with only minor therapeutical effects on tumour-progression led to a rapid 
withdrawal of the initial clinical trials215,216. Afterwards, more studies have focused on the 
specific role of MMPs within the human tumour-microenvironment to reveal the more 
sophisticated role of MMPs in releasing or activating growth factors and the generation of 
signalling molecules38,188. Currently more specific MMP inhibitors are developed and tested 
in clinical trials for various pathologic conditions36,38,217,218.  
The following MMP classification into collagenases, gelatinases, stromelysins or membrane 
type MMPs is based on their structural domains, natural substrates and localisation38, 213, 219. 
 
6.3.1   The collagenases 
The collagenases consist of MMP-1, MMP-8, MMP-13 and MMP-14. Their ECM substrates 
include different collagens and HSPGs and the collagenases are activated by several other 
MMPs and plasmin. MMP-13, which can be activated by MMP-3219, seems to have a central 
role in the MMP activation cascade220, activating both MMP-2 and MMP-9 (Figure 7). 
Furthermore, MMP-13 expression is 
low in normal epithelial cells but 
strongly up-regulated in tumour cells, 
inflammatory cells and occasionally 
fibroblasts221,222. MMP-13 has a role 
in angiogenesis223, and is associated 
with poor survival in CRC patients220 
and several other cancers221,224-226. In 
addition, MMP-1 and MMP-13 have 
both been implicated in LTBP 
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6.3.2   The gelatinases 
MMP-2 and MMP-9 belong to the gelatinases, because of their ability to degrade gelatine 
(denatured collagen). Physiological substrates include collagen type IV, the major constituent 
of the basement membrane. Therefore, the gelatinases have been often associated with 
invasive processes and metastasis in CRC229-234. Expression of MMP-2 is mainly observed in 
fibroblasts, but also tumour cells are capable of producing MMP-239. MMP-9 expression is 
found in fibroblasts and infiltrating immune cells, including macrophages and neutrophils, 
where MMP-9 is stored in granules33,39. Both MMP-2 and MMP-9 are up-regulated when 
cells are stimulated with TGF-β1235-238. Furthermore, via direct cell-cell interaction, epithelial 
EMMPRIN upregulates stromal MMP-2 expression29,239.  The major activator of MMP-2 is 
MMP-14 in a complex also containing TIMP-2240. In turn MMP-2 can activate MMP-9 and 
MMP-13219. Besides by MMP-2, MMP-9 can be activated by several other MMPs and by 
plasmin (Figure 7). Both MMP-2 and MMP-9 have a role in angiogenic processes241,242. 
Especially MMP-9 might have a role in regulating VEGF bioavailability during the 
angiogenic switch103, but the exact mechanism of this process is not known. The gelatinases 
are also involved in regulating TGF-β bio-activity. MMP-9, localised to the cell surface by 
binding to CD44, and MMP-2 have both been implicated in the proteolytic processing 
activation of the large latent TGF-β complex126, 243-245.  
 
6.3.3   The stromelysins 
MMP-3, -10, and -11 belong to the stromelysins. Besides degradation of different ECM 
components and various cell surface molecules104,  MMP-3, which can be activated by 
plasmin190, seems to be very important because of its ability to activate a large number of 
other MMPs including MMP-1, -7, -8, -9 and -13219 (Figure 7). Expression of MMP-3 is 
mainly observed in fibroblasts and is strongly upregulated in CRC39,246. MMP-3 is capable of 
generating active insulin like growth factor (IGF)41 and cleaving mouse VEGF-164 to smaller 
isoforms247. Interestingly, a short form of MMP-3 has also been detected in the nucleus of 
myofibroblasts, where it has a role in apoptosis248. Finally, MMP-3 has also been implicated 
in TGF-β activation104. 
 
6.3.4   The membrane type MMPs 
Until now six membrane type MMPs (MT-MMPs) have been identified, which all contain a 
transmembrane domain. MT-1, -2 and -3 MMP are the only MMPs which have been show to 
be directly capable of dissolving the basement membrane, facilitating invasion41. The most 
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studied MT-MMP is MMP-14 (MT-1 MMP), which is strongly expressed by epithelial cells, 
endothelial cells and myofibroblasts39,249,250. Intracellularly MMP-14 is processed to the 
active form by furin251,252 and displayed on the membrane MMP-14 is capable of activating 
MMP-2253. Besides promoting invasion by degradation of ECM components254,255 and 
HSPGs251, MMP-14 has been shown to be involved in vascular tubulogenesis256, receptor 
shedding144 and TGF-β activation257. MT4-MMP seems to have a role in angiogenesis, by the 
normalisation of tumour blood vessels258. 
 
6.3.5   Other MMPs 
The smallest member of the MMP family is MMP-7 (matrilysin), which is mainly expressed 
by epithelial cells. This MMP is activated by MMP-3, -10 and plasmin and is in turn capable 
of activating MMP-2219 (Figure 7). Besides degradation of ECM components, MMP-7 
increases fibroblast proliferation259, cleaves E-cadherin104,260,261 and HB-EGF209 and is 
capable of generating soluble Fas-ligand262. This increases apoptosis of normal epithelial 
cells, but not affecting tumour cells as they have decreased sensitivity to Fas-ligand induced 
apotosis. In addition, MMP-7 is capable of releasing active TGF-β1 bound to decorin, an 
ECM molecule263. 
MMP-28 (epilysin) is one of the most recently discovered MMPs264. It is widely expressed in 
the gastrointestinal epithelial cells and in several tumours264. Interestingly, one study 
described MMP-28 to be down-regulated in CRC265. Furthermore, MMP-28 is up-regulated 
during wound healing processes and is capable of activating TGF-β via cleavage of the 
LTBP-1266. 
 
6.3.6   The ADAM(T)s 
The ADAMs are membrane anchored proteins, whereas the ADAM(T)s are secreted. At least 
25 ADAMs have been described in humans, which are intracellularly activated by furin-like 
convertases. Several ADAMs have been linked to cancer, like ADAM-17, which is capable of 
shedding HB-EGF, IL-1 receptor, tumour necrosis factor receptor I and II and pro-TNF-α 
processing, and ADAM-10 which also contributes to pro-HB-EGF, pro-TNF-α, notch and E-
cadherin shedding267. In contrast, ADAM-1 and -8 have been shown to be anti-angiogenic 
factors, possibly via binding of VEGF268. 
 
Chapter 1 
- 26 -  
7    MMPs activating TGF-β and VEGF 
The role of MMPs in the release or activation of growth factors like TGF-β and VEGF has 
been subject of several studies104. It has been shown that, in vitro, latent TGF-β can be 
activated by MMP-1227, MMP-2243, 245, MMP-3119, 138, MMP-9126, 245, MMP-13228, MMP-14132, 
269 and MMP-28266. Which MMP is crucial for the activation of latent TGF-β and whether the 
MMPs are involved in a proteolytic cascade and therefore inhibiting one of the MMPs would 
block the proteolytic activation cascade, is not known yet. Not only MMPs, but also plasmin 
has been described to be able to activate latent TGF-β125, 270 directly in vitro, but it is possible 
that this activation occurs indirectly via activation of MMP-3. Besides direct activation of the 
latent TGF-β complex the MMPs also play a role in releasing active TGF-β when it is bound 
to other molecules. For example, active TGF-β binds to the ECM molecule decorin, from 
which it can be proteolytically released by MMP-7263. In turn, activated TGF-β up-regulates 
various invasion-associated MMPs and other proteinases235. 
Several studies examined the role of MMPs in the release or activation of VEGF, but none of 
them has been able to elucidate the mechanism how VEGF bioavailability is regulated. 
Upregulation of availability can occur via cleavage of the VEGF molecule itself, generating a 
smaller, more soluble isoform247, whereas VEGF release is mediated via cleavage of ECM 
components which bind VEGF100. 
8    Shedding of membrane molecules and receptors by MMPs  
Besides the activation of growth factors MMPs and other proteinases are also involved in 
shedding of other membrane-bound molecules (Figure 6)271 like integrins and receptors 
including Fibroblast Growth Factor Receptor-1 (FGFRI), uPAR and Her-2 and various others 
(reviewed in104). For example one of the hallmarks of Epithelial Mesenchymal Transition 
(EMT), a process in which epithelial cells lose expression of epithelial markers and 
morphology and synthesize de novo mesenchymal markers (e.g. vimentin)272, is the loss of E-
cadherin expression on epithelial cells. It has been shown that MMP-7 and MMP-3 can 
mediate this cleavage process260,271. Furthermore betaglycan (TGF-βRIII), can be shed from 
the membrane by MMP-14, releasing a soluble form of betaglycan144. Endoglin, a TGF-β co-
receptor, which also can bind BMP-9273, has a crucial role in angiogenesis and exists also a 
soluble form56,148,274. However, the release mechanism and the possible involvement of 
proteinases have not been elucidated yet.  
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9    3-dimensional cell culture models 
In order to investigate complex pathological processes and cell regulatory mechanisms often 
model systems are used. Models can be simple by growing human primary cells or cell-lines 
in monolayer conditions or complex by the use of  animals. Although these models are 
valuable and gain insight into aforementioned processes, they do not have to be representative 
for the human in vivo situation59,275-277, especially when more than one cell type is involved. 
In this thesis, which focusses on the interaction between cells in the human tumour-
microenvironment, we used various 3-dimensional model systems. 
 
9.1   Multi-cellular tumour spheroids 
Spheroids are aggregates of cells in a 3-dimensional conformation. The first paper describing 
the often applied agarose liquid overlay technique already dates from 30 years ago278. Wells 
are coated with agarose, which prevents attachment of the cells. In this way after 2-7 days 
multi-cellular aggregates (100-500 μm) are formed275. In contrast to cells growing in 
monolayers, culturing them as spheroids restores the morphological and functional features of 
cells as observed in vivo279, 280. Cells in the hypoxic centre of the spheroid die, whereas cells 
in the outer layers are viable cells, like cells in vivo surrounding blood vessels. Therefore,  
spheroids closely represent small avascular solid tumours or micro-metastasis279, 281-283. The 
genes upregulated in 3-dimensionally cultured cells represent the genes which are also 
upregulated in tumours, whereas cells grown as monolayers show different or sometimes even 
contradictory responses275,284-287. The fact that results in spheroids are in general more closely 
resembling the in vivo situation288 is caused by a difference in the expression of growth factor 
receptors (like EGF of TGF-β receptors), but also by the deposition of ECM proteins, a 
phenomenon far less observed by cells cultures under monolayer conditions, and differences 
in cell adhesion molecules288. 
To study chemotaxis between tumour cells and immune cells often the Boyden chamber is 
used, first described by Boyden in 1961289. Spheroids form a good alternative to study 
tumour-cell immune cell interaction because spheroids are capable of modulating infiltrating 
immune cells as observed in vivo290. In addition, co-culture of spheroids with host cells, like 
fibroblast, can represent good models to study the influence of tumour cells on the resident 
fibroblasts in advanced tumours279,291. In conclusion, multi-cellular tumour spheroids form a 
very valuable tool to study tumour biology275,279,280,288,290,292-294. A special application of 
spheroids is to study angiogenesis of endothelial cells. 
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9.2   Endothelial spheroids 
3-dimensional in vitro angiogenesis models are used to study all phases of angiogenesis 
(matrix degradation, migration, proliferation, survival and morphogenesis295). In contrast to 
monolayers, spheroids of endothelial cells do not proliferate once embedded in a collagen 
matrix and only form sprouts after stimulation with an angiogenic stimulus like VEGF296, 297, 
therefore better representing the human setting. There are critical advantages of studying 
(tumour)-angiogenesis using in vitro models compared to animal models. As was already 
mentioned by Rangarajan et al276 “mice are not small people” and therefore do not have to 
reflect the human tumour-microenvironment. For example the VEGF neutralizing antibody 
Bevacizumab does not bind to mouse VEGF-164, whereas it strongly inhibits human VEGF-
165 induced angiogenesis298. Although mouse models will still be indispensable to study the 
pharmakinetics and toxicologic aspect of new drugs, recent advancements in the development 
of model systems include 3-D lymphangiogenesis models299, and also grafting human 
endothelial spheroids into mice to study tumour angiogenesis300. This combination gives the 
opportunity to study the angiogenesis in a human setting, but with the advantages of studying 
it in the complexity of a whole organism. 
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In normal tissue homeostasis as well as in pathological conditions cells are influenced by 
surrounding cells both via direct cell-cell contact and soluble factors. Interactions of 
malignant cells with the tumour-microenvironment have been shown to be very important in 
the progression of carcinomas. However, the tumour-microenvironment is very complex and 
although animal models provide the complexity of the different cell types in a living animal, 
they do not necessarily reflect of the human tumour-microenvironment due to interspecies 
differences in for example growth factors and their receptors. Therefore, when studying 
cancer cells one should preferentially take their human tumour-microenvironment into 
account. This thesis evaluates cell-cell interactions by using various in vitro 3-dimensional 
cell culture models. After analysis of the human tissue by determination of protein expression 
levels and cellular localisation by immunohistochemistry, in vitro human cell models, closely 
resembling the in vivo situation, are developed. The aim is to elucidate the interaction 
between colon cancer cells with two prominent cell types in the tumour-microenvironment: 
angiogenic endothelial cells and myofibroblasts.  
Chapter 3 describes the expression and cellular localization of TGF-β1 in gastric cancer, 
focusing on the active TGF-β1 molecule, as this is presumably the key mediator of 
myofibroblast differentiation. In chapter 4 these observations are confirmed in a larger series 
colorectal cancer samples and a new method to quantify the myofibroblast content in these 
samples is described. These chapters reveal that enhanced active TGF-β levels are clinically 
important and correlate to the presence of myofibroblasts. Subsequent studies described in 
chapter 5 evaluate the activation mechanism of TGF-β and illustrates that the interaction 
between tumour cells and fibroblasts leads to myofibroblast differentiation and subsequent 
upregulation of MMPs in both tumour cells and myofibroblasts, reflecting a double paracrine 
tumour-promoting mechanism. 
The contribution of myofibroblast and neutrophil derived MMPs to the initiation of the 
angiogenic switch by liberation of VEGF from colon cancer extracellular matrix, is described 
in chapter 6, showing a key role for neutrophil-derived MMP-9 in the initiation of the 
angiogenic switch. Besides MMP-9 also endothelial MMP-7 contributes the angiogenesis as 
described in chapter 7. To be able to quantify MMP-7 activity levels, chapter 8 describes the 
development of a MMP-7 bioactivity assay. Furthermore the contribution of cathepsin S to 
the angiogenic process, by liberating pro-angiogenic molecules for colon cancer extracellular 
matrix and a new method for the identification of specific inhibiting peptides using phage 
display is described in chapter 9. Finally, chapter 10 describes the role of the TGF-β co-
receptor Endoglin as an additional factor in colorectal cancer angiogenesis. This receptor is 
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mainly expressed by angiogenic endothelial cells and has been implicated in the pro-
angiogenic effects of TGF-β. The role of MMPs in the cleavage of this membrane receptor 
into soluble Endoglin is also investigated. The different studies in this thesis are summarized 
and discussed in chapter 11. 
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Abstract 
Transforming Growth Factor-Beta 1 (TGF-β1), a tumour suppressing as well as tumour-
promoting cytokine, is stored as an extracellular matrix bound latent complex. We examined 
TGF-β1 activation and localization of TGF-β1 activity in gastric cancer. 
Gastric tumours showed increased stromal and epithelial total TGF-β1 staining by 
immunohistochemistry. Active TGF-β1 was present in malignant epithelial cells, but most 
strongly in smooth muscle actin expressing fibroblasts. Normal gastric mucosa from the same 
patient showed some staining for total and little for active TGF-β1. Active TGF-β1 levels 
were determined by ELISA on tissue homogenates, confirming a strong increase of active 
TGF-β1 in tumours compared to corresponding normal mucosa. Moreover, high tumour TGF-
β1 activity levels were significantly associated with clinical parameters, including worse 
survival of the patients. Total and active TGF-β1 levels were not correlated, suggesting a 
specific activation process. Of the different proteases tested, active TGF-β1 levels were only 
correlated with urokinase activity levels. The correlation with urokinase activity suggests a 
role for plasmin in TGF-β1 activation in the tumour-microenvironment, resulting in 
transformation of resident fibroblasts to tumour-promoting myofibroblasts. In conclusion we 
have shown localisation and clinical relevance of TGF-β1 activity levels in gastric cancer. 
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Introduction 
Transforming Growth Factor-beta (TGF-β) is a multifunctional cytokine, which influences 
cell differentiation, proliferation, motility and apoptosis1,2. Among the TGF-β family, which 
comprises TGF-β1, -β2 and -β3, TGF-β1 is most abundantly expressed, especially in various 
pathological conditions including chronic inflammatory diseases3, and cancer1,2,4,5. TGF-β1 
has been shown to reduce the immune response6, stimulate angiogenesis7-9, increase synthesis 
of proteolytic enzymes10,11 and stimulate extra cellular matrix (ECM) deposition12 in the 
tumour-microenvironment. 
Several studies examined the role of TGF-β1 in gastric cancer. Studies on TGF-β1 mRNA 
showed expression in both normal and tumour tissue, but levels in gastric tumours were 
strongly upregulated13,14. Immunohistochemical studies  showed TGF-β expression in tumour 
cells13,15-17 and sporadic in fibroblasts13. Positive TGF-β1 immunostaining was found to be 
related to invasion and metastasis of gastric cancer17,18. Finally, gastric cancer patients 
showed strongly increased tissue TGF-β1 levels and, unexpectedly, reduced serum TGF-β1 
levels16.   
TGF-β1 is synthesized as an inactive precursor, the large latent complex consisting of a   
TGF-β dimer, the Latency Associated Protein (LAP) and Latent TGF-β Binding Protein 
(LTBP) for localisation and binding to the ECM19. Before TGF-β1 can exert its biological 
effects LAP and LTBP have to be dissociated. This can occur by conformational changes20-22, 
proteolytic cleavage23-26, irradiation27,28 or by an acid environment29. The complex release 
mechanism of TGF-β1 might implicate that high total TGF-β1 has no biological consequences 
without the presence of appropriate activation mechanisms in the tumour-microenvironment. 
Therefore, measuring TGF-β1 activity levels and the localisation in cancer could be more 
informative regarding the state of cancer progression.  
We studied cellular localisation and levels of active TGF-β1 and the activation process in 
gastric cancer. We used an ELISA, which specifically detects active TGF-β1, to examine 
endogenously active as well as total (acid-activated) TGF-β1 levels in gastric cancer tissue 
and showed cellular localisation of active TGF-β1 by immunohistochemical staining. To 
study the activation process, tissue levels of several proteases, putatively involved in the 
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Materials and methods 
Patient population 
Fresh tissue specimens from in total 51 patients (34 ♂, 17 ♀) undergoing resection for 
primary gastric adenocarcinoma at the department of Oncologic Surgery, Leiden University 
Medical Centre, were collected as described before30. Patient characteristics and 
clinicopathological parameters are shown in table 1.  Tissue specimens were homogenized in 
Tris/Tween-80 buffer and protein concentrations were determined as described previously31.  
 
ELISA for Total and Active TGF-β1 
The levels of total and active TGF-β were measured using a human TGF-β1 duo-set (DY240)   
with a substrate reagent pack (DY999) according to the manufacturers’ instructions (both 
R&D Systems Europe, Abingdon, UK). This ELISA specifically detects active TGF-β1 and 
does not cross-react with other subtypes of TGF-β. Total TGF-β1 levels were determined by 
acid activation (1M hydrochloric acid, 30 minutes, room temperature) of the latent TGF-β1 in 
the homogenate. Untreated and activated (30µl) samples from the same homogenate were 
assayed in parallel.  
 
Assays for urokinase, urokinase receptor, plasminogen activator inhibitors, matrix 
metalloproteinases, and tissue inhibitors of matrix metalloproteinases  
Total antigen levels of urokinase plasminogen activator (uPA), plasminogen activator 
inhibitors (PAI-1 and PAI-2), urokinase plasminogen activator receptor (uPAR), matrix 
metalloproteinases (MMP-2,-7,-8,-9) and tissue inhibitors of matrix metalloproteinases 
(TIMP-1 and TIMP-2) were determined using previously described ELISAs30,32-34. The 




Tissue samples from the same tumours as used for homogenates were formalin fixed, 
dehydrated and embedded in paraffin. For cryosections unfixed tissue was embedded in OCT  
(Sakura Finetek Europe BV, Zoeterwoude, the Netherlands) and snap frozen in liquid 
nitrogen. Paraffin sections (5 μm) were deparaffinised, blocked in 0.3% hydrogen peroxide 
(H2O2) in methanol for 20 minutes and rehydrated through graded alcohol. Antigen retrieval 
was performed by boiling in a 0.01 M citrate solution (pH 6.0) for 10 minutes in a microwave 
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oven. After being rinsed in Phosphate Buffered Saline (PBS), the sections were incubated 
with the primary antibodies [in PBS/1% Bovine Serum Albumin (BSA)]: mouse anti-pan-
Cytokeratin (1:1000, clone C11, Santa Cruz biotechnologies, Santa Cruz, CA, USA), mouse 
anti-Vimentin (1:400, clone V9 Santa Cruz biotechnologies), mouse anti-Smooth Muscle 
Actin (1:1000, clone ASM-1, Progen, Heidelberg, Germany), mouse anti TGF-β1 (1:1000, 
Anogen Mississauga, Ontario, Canada), or rabbit anti-phospho-smad-2 (p-smad-2; 1:1000, 
kindly provided by Prof. dr. P. ten Dijke36) overnight at room temperature. After washing, the 
sections were incubated with biotinylated goat anti-mouse (1:200) or goat anti-rabbit (1:400, 
both Dako, Denmark) secondary antibodies (in PBS/1% BSA) for 30 minutes, followed by 
washing and incubation with Streptavidin-Avidin-Biotin Complex/HRP (Dako) for 30 
minutes. The brown colour was developed by 0.004 % H2O2 (Merck, Darmstadt, Germany) 
and 0.05 % diaminobenzidine tetrahydrochloride (Sigma, Schnelldorf, Germany) in 0.01 M 
Tris-HCl pH 7.6 for 10 minutes. The slides were counterstained with Mayer's haematoxylin 
(Merck) except for the p-smad-2 staining, which were shortly counterstained with methyl 
green, diluted in 0.1 M sodium acetate buffer pH 4.2. Sections were dehydrated and mounted 
in Entellan (Merck).  
Frozen sections (4 μm) were fixated in ice cold acetone (10 minutes), washed with PBS and 
incubated overnight (40 C) with the primary antibodies described above: anti-pan-Cytokeratin 
(1:16000), anti-Vimentin (1:800), mouse anti-Smooth Muscle Actin (1:2000),  rabbit anti-
active TGF-β1 (1:800, Promega, Madison, USA), or phospho-smad-2 antibody (1:800). 
Further the sections were treated as described above and were counterstained with Mayer's 
Haematoxylin. Negative control sections were included by omitting the primary antibodies. 
Photomicrographs of representative sections were taken with a Leica DMLB microscope  
equipped with a Leica DC500 camera. 
 
Statistical analysis 
Differences between normal and tumour values were calculated using the Mann-Whitney U 
test. For survival analyses the clinicopathological parameters were dichotomized as described 
before31. Cut off values for TGF-β1 were optimized using ROC analyses.  Multivariate 
survival analyses were performed with the Cox proportional hazards method by separately 
adding variables to the dichotomized clinicopathological parameters. Survival curves were 
constructed using the method of Kaplan and Meier including Log-rank tests. Differences were 
considered significant when P≤ 0.05. The analyses were performed using the SPSS Statistical 
Package (Release 12.01, SPSS Inc., Chicago, USA). 
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Results 
Tissue TGF-β1 levels and clinicopathological characteristics 
Active TGF-β1 was detectable in all 51 tumour homogenates with concentrations of 1.6-81.3 
pg/mg protein. Total TGF-β1 levels ranged from 21.1- 620.1 pg/mg protein. Active and total 
TGF-β1 levels were significantly (P<0.0001) increased in gastric cancer tissue compared with 











































ROC analyses revealed that total as well as active TGF-β1 were good diagnostic 
discriminators between normal and tumour tissue with AUC values of respectively 0.91 
(P=0.03) and 0.82 (P=0.05). Tumour levels of active TGF-β1 did not correlate significantly 
with total levels (Rho=0.255; P=0.071, n=51), indicating that the amount of active form is not 
dependent on the total TGF-β1 pool present. The correlation of TGF-β1 levels with 
clinicopathological parameters is presented in Table 1.  
Active TGF-β1 levels were significantly increased in tumours localized in the cardia, in 
tumours with invasion limited to the subserosa, and in tumours with a high inflammation 
grade. Total TGF-β1 levels were enhanced in tumours with high Tumour Node Metastasis 




Figure 1. Total and active TGF-β1 levels in tumour and corresponding normal tissue homogenates.  
Total (A) and active (B) TGF-β1 levels are significantly upregulated in tumours (T) compared  
to corresponding normal (N) tissue (Both P<0.0001) 
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Table 1. Median levelsa of total and active TGF-β1 in gastric carcinomas in relation with clinicopathological 
parameters 
         Active TGF-β1 Total TGF-β1 

























































































































































































































aMedian and range in pg/mg protein 
bTNM=Tumour Node Metastasis classification 
cTumour-associated death 
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Cellular localisation of active and total TGF-β1 in gastric cancer 
 To determine the cellular localisation of active TGF-β1 in gastric cancer, we stained frozen 
sections for active TGF-β1 (Figure 2A). To confirm the staining being representative for 
TGF-β1 activity, sections were also stained for phosphorylated smad-2 (p-smad-2), indicating 
TGF-β signalling and therefore the presence of active TGF-β37,38 (Figure 2B).  Nuclear 
localisation of p-smad-2 in myofibroblasts and in malignant cells is shown in respectively 








Staining for both TGF-β1 and p-smad-2 was most pronounced in vimentin (Figure 2D) and 
Smooth Muscle Actin (SMA, Figure 2E) positive myofibroblasts and in pan-cytokeratin 
(Figure 2C) positive malignant cells. Because, in our hands, staining for total TGF-β1 was not 
detectable on frozen sections from gastric cancer specimens, we stained 10 paraffin embedded 
tissue sections from the above described patient group. Tumours showed strongly increased 
epithelial and stromal staining for total TGF-β1 (Figure 3C) compared to normal gastric 
mucosa (Figure 3A). Active TGF-β1, represented by p-smad-2 staining (Figure 3D, staining 
Figure 2. Cellular localisation of active TGF-β1 in gastric cancer. Immunohistochemical staining of gastric 
carcinomas (sequential frozen sections). Staining pattern for active TGF-β1 (A) corresponds to phospho-smad 
2 staining (B). Inserts B1 and B2 show respectively nuclear localisation (arrowheads) of p-smad-2 in the 
myofibroblasts and malignant cells. As shown by staining for pan-Cytokeratin (C, epithelial marker), Vimentin 
(Vim, D, mesenchymal marker) and Smooth Muscle Actin (SMA, E smooth muscle/myofibroblast marker ) 
TGF-β1 activity is observed in malignant cells and in Vim+/SMA+ cells (myofibroblasts). Magnification 200x, 
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for active TGF-β1 was not applicable to paraffin sections), was increased in both epithelial as 









Figure 3E-G illustrates the association between active TGF-β1 ELISA data and the p-smad-2 
immunohistochemical staining, indicating TGF-β activity. Three carcinomas with decreasing 
active TGF-β1 tissue levels (high, median, low) were stained for p-smad-2 showing decreased 
nuclear staining for p-smad-2 in the malignant cells and even stronger in the smooth muscle 
actin positive myofibroblasts (SMA, vimentin and pan-cytokeratin staining on sequential 
sections, not shown).  
 
Prognostic relevance tissue TGF-β1 levels 
Kaplan-Meier survival curves, using tertiles (cut-off values <12.56; 12.56-21.28; >21.28 
pg/TGF-β1/mg protein, Figure 4A) or quartiles (not shown), showed a stepwise correlation 
for active and total TGF-β1 levels with tumour-associated survival. Because of the small 
group size, the patients were dichotomized for active and total TGF-β1 using ROC-based 
Figure 3. Total TGF-β and p-smad-2 staining on paraffin embedded gastric cancer tissue sections. 
Staining on normal gastric mucosa shows some staining for total TGF-β (A) and almost no staining for p-
smad-2 (B, insert 400x). Both are strongly increased in corresponding tumour tissue (C, total TGF-β1, D, p-
smad-2, insert 400x). Figure E-G shows p-smad 2 staining in 3 different gastric carcinomas with high (81.3 
pg/mg, E), median (21.1 pg/mg, F) and low active TGF-β1 levels (1.6 pg/mg, G). A strong decrease in 
nuclear staining (inserts E-G, magnification 630x, arrowheads indicate intense nuclear staining in 
myofibroblasts in E) is observed with especially in myofibroblasts (staining for pan-Cytokeratin, Vimentin 






- 58 -  
optimal cut-of values (15 [active] and 400 [total] pg TGF-β1/mg protein, respectively) for 
further analyses. High tumour levels of active and total TGF-β1 were significantly correlated 
with worse survival (Log Rank 4.88, P=0.027 and Log Rank 3.96, P=0.047, respectively). 
Figure 4B shows a Kaplan Meier curve, presenting a combination of either high total or high 
active TGF-β1, which resulted in a higher significance value, confirming the independence of 
both parameters. To evaluate the validity of the chosen TGF-β1 cut off values, we used the 
same cut off values again for the group including 29 more recently collected gastric cancer 
patients, where active TGF-β1 kept its prognostic significance and the hazard ratio increased 


















The prognostic value of TGF-β1 was further evaluated using Cox proportional hazard 
analyses (Table 2). Particularly active TGF-β1 and the combined TGF-β1 levels were 
statistically significantly correlated with survival. In multivariate analysis with the 
clinicopathological parameters (Table 2), the combined TGF-β1 level remained statistically 
significant in multivariate tests.  
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Figure 4. Kaplan-Meier survival analysis for tumour TGF-β1 tissue levels 
A: Kaplan-Meier analysis shown a stepwise decrease in survival for patients divided in tertiles based on 
active TGF-β1 levels L=low (< 12.56 pg TGF-β1/mg protein), I= intermediate (12.56-21.28 TGF-β1/mg 
protein), H= high (>21.28 TGF-β1/mg protein), x/y† = number of patients/number of patients deceased.B: 
Kaplan-Meier analysis showed a significant shorter survival for patients with either high active or high total 
TGF-β1 tissue levels. L=low (active TGF-β1< 15 pg TGF-β1/mg protein or total TGF-β <400 pg/ml) 
H=high (active TGF-β1> 15 pg TGF-β1/mg protein or total TGF-β >400 pg/ml).   
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Table 2. Uni- and multivariate Cox’s proportional hazards analyses of total and active TGF-β1 levels in relation 
to tumour-associated survival of 51 gastric cancer patients 
  Univariate   Multivariate  
Parameter HR CI 95% P-value HR CI 95% P-value 
Age 1.258 0.637-2.484 0.509 1.584 0.662-2.716 0.240 
Laurén classification 0.699 0.348-1.402 0.313 0.932 0.348-1.402 0.865 
Differentiation 1.953 0.906-4.208 0.088 1.866 0.906-4.208 0.195 
TNM classification 2.755 1.057-7.179 0.038 1.534 1.057-7.179 0.440 
Tumour localization 2.379 1.092-5.180 0.029 1.916 1.092-5.180 0.151 
Total TGF-β1 2.234 0.979-5.098 0.056 1.796 0.753-4.287 0.187 
Active TGF-β1 2.339 1.065-5.138 0.034 2.125 0.934-4.836 0.072 
High Total/high  
active TGF-β1 
3.108 1.240-7.788 0.016 2.763 1.061-7.199 0.037 
Description of variables is shown in table 1. 
 
Proteolytic TGF-β1 activation 
Because TGF-β1 is at least partly activated by proteolytic cleavage, we evaluated the total and 
active TGF-β1 levels for correlations with likely candidate proteinases involved in TGF-β1 
activation and with PAI-1, a presumed secondary marker of TGF-β1 activity, in the gastric 
cancer homogenates (Table 3). Total TGF-β1 levels showed significant correlation only with 
total MMP-2 antigen levels, whereas active TGF-β1 levels only showed statistical significant 
correlation with urokinase (uPA) activity, not with total uPA protein levels.  
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Table 3. Spearman’s correlations between the levels of total and active TGF-β1 and various proteinases and 
proteinase inhibitors in 51 gastric cancer homogenates (ELISA total antigen level, BIA activity level) 
  Active TGF-β1 Total TGF-β1 
 Assay Rho P-value Rho P-value
uPA ELISA 0.202 0.163 0.259 0.072
uPA BIA 0.284 0.048 0.125 0.394
uPAR ELISA 0.076 0.605 0.126 0.389
PAI-1 ELISA 0.195 0.185 0.198 0.176
PAI-2 ELISA -0.181 0.219 -0.210 0.151
MMP-2 ELISA 0.219 0.149 0.296 0.048
MMP-2 BIA 0.253 0.111 -0.060 0.709
MMP-7 ELISA -0.091 0.568 0.248 0.114
MMP-8 ELISA 0.717 0.240 0.111 0.449
MMP-9 ELISA 0.023 0.878 0.082 0.579
MMP-9 BIA 0.121 0.424 0.268 0.071
TIMP-1 ELISA -0.039 0.821 0.045 0.794
TIMP-2 ELISA -0.209 0.221 -0.064 0.711
 
Discussion 
Numerous studies have shown the involvement of TGF-β1 in different types of cancer, 
including gastric, colorectal, and breast cancer13,15,17,18,39. Most of these studies assessed tissue 
TGF-β1 levels by mRNA expression, immunohistochemistry or serum TGF-β1 levels, which 
give either less information on the actual protein levels, are difficult to quantify or do not 
reflect local effects. A recent study on TGF-β1 levels in breast cancer tissue homogenates 
showed a significant relation of increased tissue total TGF-β1 levels with disease-free 
survival39. In the present study we observed a similar relation of tissue total TGF-β1 level 
with survival of gastric cancer patients. Although upregulation of TGF-β1 is common in 
various types of cancer it is not commonly regarded as a prognostic factor for survival. This is 
probably due to the fact that the release of the biologically active TGF-β1 from the latent 
complex is crucial for the involvement of TGF-β1 in pathological processes. Active TGF-β1 
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levels have hardly been studied because of the absence of sensitive assays which specifically 
detect active TGF-β1 in the low concentrations observed in vivo. We optimised an existing 
ELISA and were able to detect endogenous TGF-β1 levels (without acid activation) in all 
gastric cancer homogenates. Further, the localisation of active TGF-β1 in these cancers was 
shown by immunohistochemical staining for active TGF-β1 and its signalling molecule p-
smad-2. In a sequential series of tumours with decreasing active TGF-β1 levels (ELISA) we 
also observed strongly decreasing nuclear staining pattern in the myofibroblasts. Active TGF-
β1 levels showed association with localisation, invasion, inflammation and survival of gastric 
cancer patients. As expected the association of active TGF-β1 levels with survival was indeed 
stronger compared to total TGF-β1 level. There was no correlation between active and total 
TGF-β1 levels implying that the activation was not dependent of the total pool latent TGF-β1 
present in the tumour-microenvironment. As a consequence total TGF-β1 levels showed 
association with other parameters, i.e. tumour diameter and TNM stage, whereas there was no 
association of these parameters with active TGF-β1 levels. 
Localization of active TGF-β1 is observed in inflammatory- and tumour cells and especially 
in tumour associated myofibroblasts, implying that increased levels of activated TGF-β1, 
more than overall TGF-β1 levels, are associated with accumulation of myofibroblasts in 
gastric cancer. Indeed, active TGF-β1 can induce transdifferentiation from fibroblasts to 
myofibroblasts in the tumour-microenvironment, which show an increased expression of 
various proteolytic enzymes including MMPs40. In turn, these proteases, including plasmin41 
MMP-242, MMP-343 and MMP-1344, have been showed to be involved in TGF-β1 activation. 
In our study we observed a significant relation between active TGF-β1 levels and urokinase 
activity, implying plasmin, via urokinase mediated plasminogen activation, as a principal 
candidate of latent TGF-β1 activation. The investigated MMPs showed no significant 
correlations with active TGF-β1 levels. For TIMP-1 and -2 we observed a weak negative 
correlation with TGF-β1 activity, also observed in vivo in a recent study45. Total TGF-β1 
levels only correlated significantly with MMP-2 levels in homogenates. 
Immunohistochemistry showed TGF-β1 activity present in different cell types, probably with 
different activators in the tumour-microenvironment. This explains why in a homogenate it is 
unlikely that a strong significant association with one specific MMP will be observed. 
In conclusion, we have shown that total and active TGF-β1 levels are increased in gastric 
tumour tissue and that both are of prognostic relevance in gastric cancer. Active tissue TGF-
Chapter 3 
- 62 -  
β1 levels showed association with clinicopathological parameters and with uPA activity, 
indicating a possible role for plasmin in TGF-β1 activation in gastric cancer. 
Immunohistochemical studies showed strong expression of active TGF-β1 in the 
myofibroblast population. We propose that increased proteinase activity in the tumour-
microenvironment lead to increased ECM bound latent TGF-β1 activation, resulting in 
transformation of resident fibroblasts to tumour promoting myofibroblasts. Further studies on 
a larger group of patients should be performed to establish the prognostic value of active 
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Abstract  
Transforming growth factor-β1 (TGF-β1), a cytokine involved in various stages of cancer, is 
produced as a latent complex and requires processing to become active. We have determined 
total and active TGF-β1 levels in homogenates of colorectal cancer tissue. Active TGF-β1 
levels are increased in carcinomas but not in pre-malignant adenomas, in contrast to total 
TGF-β levels, which show a stepwise increase in the mucosa-adenoma-carcinoma sequence. 
Furthermore solely active TGF-β1 levels are associated with tumour stage and worse patients’ 
prognosis. Active TGF-β1 levels correlated significantly with PAI-1, α-smooth muscle actin 
(SMA) and several matrix-remodelling proteinases. SMA levels are significantly increased in 
colorectal carcinomas compared to adjacent mucosa, but not in adenomas, indicating the 
absence of myofibroblast-accumulation in early tumour stages despite the enhanced total 
TGF-β1 levels. 
This study shows that although total levels TGF-β are already enhanced in the pre-malignant 
colorectal adenomas, activation of TGF-β is indicative for malignant progression. In tumours, 
active TGF-β1 correlates significantly with SMA expression, indicating that tumour-
promoting myofibroblasts might arise as a result of increased TGF-β1 activation. These data 
underline the significance of the interaction between malignant cells and (myo)-fibroblasts in 
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Introduction 
The tumour-microenvironment is increasingly recognized as an important factor in cancer 
progression1-3. Malignant cells induce host reactions, i.e. immune reactions, angiogenesis, and 
desmoplasia/fibrosis within and around tumour tissue. Tumour fibrosis consists of an 
accumulation of extracellular matrix-producing myofibroblasts and was initially regarded as 
the host’s barrier against cancer dissemination4. Myofibroblasts are hyper-activated 
fibroblasts that simultaneous express vimentin, fibroblast-activation protein (FAP), and α-
smooth muscle actin (SMA)5. Physiologically, myofibroblasts play a role in wound healing in 
which they rearrange the extracellular matrix (ECM) and contract wound edges by SMA 
mediated contractile properties6. In cancer, myofibroblasts circumvent apoptosis and remain 
hyper-activated, secreting high amounts of ECM molecules, cytokines, and matrix degrading 
enzymes including matrix metalloproteinases (MMPs)7. In addition, they influence the 
immune response8, induce pro-invasive signals for tumour cells9, and influence epithelial-
mesenchymal transitions7. The origin of myofibroblasts has not been fully elucidated and is 
likely a combination of bone-marrow derived fibrocytes and transition of resident 
fibroblasts10. In cancer tissues the majority of myofibroblasts arise presumably from 
activation of fibroblasts by direct cell-cell contact, e.g. via EMMPRIN5,11 or via growth 
factors like Transforming Growth Factor-β (TGF- β)12,13.  
TGF-β1 is synthesized as a latent, ECM-bound molecule which is activated via proteolytic 
and non-proteolytic pathways14. Activation of the latent TGF-β complex is crucial, because 
up-regulation without activation will have little biological and clinical consequences15,16. In 
cancer, TGF-β has tumour-inhibiting as well as tumour-promoting effects17,18. Although many 
details of the working mechanisms of TGF-β in cancer still have to be elucidated, the 
induction of SMA expression in fibroblasts, leading to myofibroblast trans-differentiation, is 
well established, at least in vitro19.  
In this study, we examined the presence of total and active TGF-β1 in the colorectal mucosa-
adenoma-carcinoma sequence using tissue homogenates. The clinical relevance of TGF-β1 
levels was evaluated by correlations with the grade and stage of the tumour and the survival 
of the patients. Furthermore, TGF-β1 levels were compared with various known target 
proteins like PAI-1, urokinase (uPA), and matrix metalloproteinases MMP-2 and MMP-9. To 
evaluate the role of TGF-β1 in myofibroblast generation, an ELISA for SMA, an established 
myofibroblast marker19-21, was developed. The results of this study indicate the clinical 
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importance of especially active TGF-β1 levels and its relation with the quantity of 
myofibroblasts in colorectal carcinomas. 
 
Materials and methods 
Patient material and homogenates 
Representative tissue specimens from endoscopically or surgically resected colorectal 
adenomas (Female n=14, Male n=21), carcinomas (Female n=77, Male n=102; Dukes A, n=3, 
B, n=105, C, n=45, D, n=26) and adjacent mucosa (n=179) were collected from the 
Departments of Oncologic Surgery and Gastroenterology of the Leiden University Medical 
Centre according to the guidelines of the Medical Ethics Committee of the Leiden University 
Medical Centre. Macroscopic and microscopic parameters were obtained from the pathology 
reports, clinical data and follow-up were available for at least 10 years. The tissues were 
homogenised using a micro-potter in Tris/Tween-80 (pH 7.5) and protein concentrations were 
determined according to Lowry as previously described22. 
 
TGF-β1 ELISA 
Total and active TGF-β1 levels were determined as described before16. In short, plates were 
coated O/N with TGF-β1 capture antibody, blocked, and 30 μl sample, with or without acid 
activation, was incubated to determine respectively endogenous active and total tissue TGF-
β1 levels. Immune-detection was performed with biotinylated antibodies and a substrate 
reagent pack according to the manufacturer’s protocol (R&D systems, Abington, UK). 
 
ELISAs for uPA, tPA, PAI-1, PAI-2, MMP-2 and MMP-9 
The levels of uPA, tPA, PAI-1, PAI-2, MMP-2 and MMP-9 were determined with established 
ELISAs as described before22,23. 
 
SMA ELISA 
To determine SMA levels in colorectal tissue homogenates an ELISA was developed. 
Maxisorp 96-wells plates (Nunc, Denmark) were coated with rabbit polyclonal anti-SMA 
antibodies (Abcam, UK, 1:5000, stock 0.5 mg/ml) overnight at 4°C in coating buffer 
(NaHCO3 buffer, pH 9.6). Plates were washed after each step with PBS containing 0.05% 
Tween-20 (PBST, Merck, Darmstadt, Germany). Non-specific binding was blocked with PBS 
containing 5% Tween-20, 0.05% NaN3 during 1 hour at 37°C. Samples were 1:10 diluted in 
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PBS containing 1% Bovine Serum Albumin (BSA, Sigma, Darmstadt, Germany)/0.05% 
Tween-20 and allowed to bind 2 hours at 37°C. Immunodetection was performed with mouse 
monoclonal anti-SMA antibodies (stock 50 μg/ml, 1:32,000 diluted in PBS/1% BSA, clone 
ASM-1, Progen, Heidelberg, Germany) overnight at 4°C, biotinylated goat anti-mouse 
antibodies (Dako, Glostrup, Denmark, 1:4000, 2h RT) and Streptavidin-HRP (1:200, R&D 
systems). Colour development was performed with a substrate reagent kit according to the 
manufacturers protocol (Dy999, R&D systems). Absorbance was measured at 450 nm. SMA 
content was calculated in arbitrary units (AU)/mg protein, using a colonic muscle homogenate 
and TGF-β1 stimulated colonic fibroblasts as positive controls. 
 
SMA ELISA validation 
Colon cancer samples and corresponding mucosa samples were homogenised using the 
previously described conventional potter method (in Tris/Tween-80), or using an Ultra Turrax 
(IKA labortechnik, Staufen, Germany) on ice in 50 mM Tris/HCL buffer, pH 7.6 containing 
1% Triton X-100 (BDH chemicals, Poole, UK) or using a mikro-dismembrator (Sartorius, 
Aubagne, France) during 30 sec at 3000 RPM followed by extraction with Tris-HCl, pH7.6 
containing 1% triton X-100 for 5h at 4°C. After centrifugation, the extracts were used for 
TGF-β1 determination, whereas the pellets containing the insoluble actin filaments were 
further extracted with a 10 mM Tris/HCL buffer, pH 7.5 with 1% Sodium Dodecyl Sulphate 
(SDS), 1.25% β-mercaptoethanol and 2 mM EDTA by boiling for 3 minutes and subsequent 
sonification for 30 seconds24. Final protein concentrations were determined according to 
Lowry25. SMA levels were analysed using an ELISA and western blotting as described below. 
The sensitivity of the SMA ELISA was evaluated on four tissue samples using Turrax 
homogenation: Two colorectal cancer samples, one colon cancer derived liver metastasis and 
one gastrointestinal stromal tumour (GIST). For these samples ELISA-derived SMA levels 
were compared with western blot analysis and immunohistochemistry on the same samples. 
For Western blot analysis 10 μg protein was analysed on a 10% SDS-PAGE gel under 
reducing conditions. Proteins were transferred to a nitrocellulose membrane (Whatman, 
Dasel, Germany) overnight. Non-specific binding was blocked with 0.2% gelatin (30 minutes 
at room temperature (RT)). After washing with PBS containing 0.05% Tween (PBST), 
immunodetection was performed with the antibody used as detection antibody in the ELISA, 
mouse monoclonal anti-SMA (1:5000, 2h RT). Next, blots were incubated with biotinylated 
goat-anti mouse antibodies, HRP-conjugated streptavidin (both Dako) and finally detection 
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was performed using a chemoluminescent substrate according to the manufacturer’s protocol 
(Super Signal West Pico, Pierce, Rockford, IL, USA). 
 
Immunohistochemistry 
Tissue samples were fixated, dehydrated through graded alcohol and xylene and embedded in 
paraffin. Consecutive sections of four μm were deparaffinised and rehydrated. Subsequent 
antigen retrieval was performed by boiling in sodium citrate buffer pH 6.0 during 10 minutes. 
Immunostaining was performed using mouse monoclonal anti-SMA, mouse monoclonal anti-
vimentin, mouse monoclonal anti-pan-cytokeratin (both Santa Cruz Biotechnologies, Santa 
Cruz, USA) and mouse monoclonal anti-desmin (clone 33, kindly provided by the 
Department of Pathology, Leiden University Medical Centre) as described previously 16. In 
short, primary antibodies were incubated overnight at RT followed by detection with 
biotinylated goat anti mouse antibodies and StreptAvidin-Biotin Complex (All Dako). 
Staining was visualized using diaminobenzidine with H2O2. Positive- and negative controls 
(by omitting primary antibodies) were included for all stainings. Representative 
photomicrographs were taken using a Nikon Eclipse E800 microscope equipped with a Nikon 
DXM 1200 digital camera. 
 
Isolation and characterisation of primary human colonic fibroblasts 
Normal human mucosa was prepared from surgical obtained resection specimens by 
removing the muscle fraction. Tissue pieces of 5 mm were repeatedly treated with 0.5 M 
EDTA/PBS in a Wheaton chamber at 37°C until no epithelial cells were recovered from the 
tissue. The remaining tissue was washed with DMEM/F12 + Glutamax (Invitrogen, the 
Netherlands), containing 10% Fetal Calf Serum (FCS, Perbio Science, Erebodegem, 
Belgium), 10 mM HEPES, 50 μg/ml Gentamycin, 100 U/ml penicillin and 100 μg/ml 
streptomycin (all Invitrogen) and subsequently incubated in 75 cm2 flasks until outgrowth of 
fibroblast-like cells was observed (7-10 days). The fibroblast origin of the cells was 
established by morphologic characteristics and immunohistochemical staining of cell-
markers. Staining was performed by preparing cytospin preparations, fixation with ice cold 
acetone (10 min), followed by overnight incubation with primary antibodies against vimentin 
and pan-cytokeratin at 4°C and immunodetection. To generate myofibroblasts, subconfluent 
growing fibroblasts were stimulated with 5 ng/ml active recombinant human TGF-β1 
(Peprotech, London, UK) during 24 hours. Myofibroblast differentiation was confirmed by 
positive staining for SMA (>95%) on cytospin preparations. 
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Statistical analysis 
Statistical analyses were performed using the SPSS 12.0 Statistical Package (2004, SPSS Inc., 
Chicago, IL, USA). Group means are accompanied by standard errors of the mean. 
Differences between groups were calculated using the Student’s t-test. Correlations between 
SMA and TGF-β levels were calculated according to Spearman. Log rank statistics were used 
for optimal cut-off point analysis. Survival curves were according to Kaplan and Meier. P-
values ≤0.05 were considered significant. 
 
Results 
TGF-β1 levels in colorectal (pre-)malignancies  
Total and endogenously active TGF-β1 levels determined in tissue homogenates of colorectal 
mucosa, adenomas and carcinomas are depicted in Figure 1. Total TGF-β1 levels were 
significantly increased in adenomas (116.8 ± 12.0 pg/mg protein, P<0.0005) and carcinomas 
(372.0 ± 21.4 pg/mg, P<0.0005) versus normal mucosa (41.2 ± 2.3 pg/mg) and adenomas 
(P<0.0005), but showed no clear relation with the presence of dysplasia in adenomas, nor 
with the differentiation grade (Figure 1A) or Dukes’ stage of the carcinomas (Figure 1B).  
In contrast, active TGF-β1 levels were not significantly increased in adenomas (9.2 ± 0.8 
pg/mg, P=0.120) compared to colorectal mucosa (8.6 ± 0.8 pg/mg). In carcinomas there was a 
significant (32.5 ± 2.9 pg/mg, P<0.0005 versus normal mucosa) and stepwise increase with 
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To establish the correlation between TGF-β1 levels and overall survival of the patients, we 
calculated optimal cut-off points. Only for active TGF-β1 a significant cut-off point was 
found (13.7 pg/mg, Figure 2A), resulting in a Log Rank of 4.06 with a P-value of 0.0439 





Figure 1. Total (A/B) and endogenous active (C/D) TGF-β1 levels in homogenates from respectively 
colorectal normal mucosa, adenomas and carcinomas. The adenomas are subdivided by dysplasia and the 
carcinomas by differentiation (A/C) and Dukes stage (B/D). The box-plots represent median, quartiles, 
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Next, we analysed the correlation of TGF-β1 levels in colorectal tissues with various TGF-β1 
target genes (Table 1). Active and total TGF-β1 correlated significantly with urokinase type 
plasminogen activator (uPA), the inhibitors PAI-1 and PAI-2 and matrix metalloproteinase 
MMP-2, but not with non-TGF-β1 depending tissue-type plasminogen activator (tPA). 
Interestingly, MMP-9 correlated with total but not with active TGF- β1. 
 
Table 1. Correlation of TGF-β with target proteins in colorectal mucosal, adenomatous and carcinomatous 
tissue. Protein levels were determined using ELISAs in tissue homogenates.  
 Active TGF-β (pg/mg) Total TGF-β (pg/mg) 
Proteins (ng/mg) Spearman’s Rho P Spearman’s Rho P 
uPA 0.491 <0.0005 0.650 <0.0005 
tPA 0.164 0.057 -0.217 0.011 
PAI-1 0.495 <0.0005 0.599 <0.0005 
PAI-2 0.412 <0.0005 0.328 0.002 
MMP-2 0.343 <0.0005 0.264 <0.0005 
MMP-9 0.095 0.210 0.343 <0.0005 
uPA:    urokinase-type plasminogen activator, tPA:   tissue-type plasminogen activator 
PAI: plasminogen activator inhibitor, MMP: matrix metalloproteinase 
 
Figure 2. Optimal cut-point analysis for active TGF-β1 with respect to overall survival of colorectal cancer 
patients (A). Kaplan Meier survival curve showing that patients with high active TGF-β1 levels (>13.7 pg/mg 
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Development and validation of a SMA-ELISA 
Because TGF-β1 is in vitro able to differentiate fibroblasts into SMA-expressing 
myofibroblasts, we examined the relation between TGF-β1 and SMA levels in colorectal 
tissue samples using a newly developed ELISA. Our conventional potter/Tris-Tween based 
method of homogenization proved not stringent enough to extract detectable amounts of actin 
filaments from colorectal tissues (Figure 3A). Two alternative homogenization methods were 
capable of extracting detectable amounts of SMA from these tissue samples, as shown on the 
same western blot. Homogenization by Turrax or extracted pellets from dismembrator 
homogenates revealed similar levels of SMA. A Turrax muscle homogenate was subsequently 
used for evaluation of the ELISA. The absorbance units decreased linearly with increasing 
dilution of the samples (Figure 3B). As a more relevant positive control for our purposes we 
prepared a series of 5 homogenates consisting of cultures of respectively 0, 25, 50, 75 and 
100% SMA positive myofibroblast (>95%) completed with inversely decreasing numbers of 
non-SMA expressing HT29 colon cancer cells. As expected, the ELISA levels showed a 





























































Figure 3. Legend see next page. 
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One hundred percent HT29 homogenate gave no detectable signal above background. To 
evaluate the ELISA further, four different gastrointestinal tumours were selected showing 
varying levels in the ELISA (Figure 3D): Tu1 and Tu2 being colon carcinomas, Tu3 a colon 
cancer-derived liver metastasis and Tu4 a gastrointestinal stromal tumour (GIST, connective 
tissue carcinoma) located in the ileum. Figure 3e shows intense bands for the samples with the 
highest ELISA signal (Muscle, Tu1, Tu2) and low levels observed for Tu3 and 4.  
The SMA-levels of all tissue samples were in between the absent signal of HT29 cells and the 
high signal of the myofibroblast homogenate. Immunohistochemistry confirmed that the 
SMA-signal as detected by western blot and ELISA was derived from myofibroblasts (Figure 
3F). SMA immunoreactivity was mainly present in vimentin- and SMA-positive 
myofibroblasts. In normal colorectal tissues SMA-staining was observed in a thin layer of 
myofibroblasts along the crypt axis and in the muscularis mucosa beneath the colonic crypts 
(not shown). In carcinoma Tu1 very strong SMA expression was observed in the vast 
majority of the vimentin-positive myofibroblasts, whereas cytokeratin-positive tumour cells 
did not stain. Desmin staining, normally restricted to smooth muscle cells, revealed a few 
positive myofibroblasts. Carcinoma Tu2 also showed SMA expression in myofibroblasts, but 
to a lesser extent than observed in Tu1. Tu3, the colonic liver metastasis showed lower 
numbers of fibroblasts of which some were SMA positive and desmin negative. Finally the 
GIST (Tu4) showed almost exclusively vimentin-positive fibroblasts, but hardly any SMA 
positive cells, reflecting the data obtained by ELISA. 








Figure 3. Development of an ELISA for smooth muscle actin (SMA). A) Western blot showing variations in SMA 
content of tissue homogenates generated with different extraction method. SMA absorption levels were measured 
in increasing dilution of a colonic muscle homogenate (B) or decreasing amount myofibroblasts versus non SMA 
expressing HT29 colon cancer cells (C). Four different gastrointestinal cancers show different SMA expression 
values (D) (Tu1 and Tu2 colon carcinoma, Tu3 colon cancer derived liver metastasis, Tu4 GIST located in the 
ileum). SMA western blot analysis (E) and immunohistochemistry (F) on the same samples to confirm the data 
obtained by ELISA.  
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SMA levels in colorectal (pre-) malignancies 
SMA levels were determined by ELISA in dismembrator type homogenates from normal 
colorectal mucosa, adenomas and carcinomas. Figure 4a shows significantly increased SMA 
levels for malignant tumours (1.50±0.15 AU/mg protein, n=16) compared to normal mucosa 
(1.0±0.08, n=18, P=0.005), whereas benign adenomas appeared to have even lower SMA 
expression levels (0.55±0.07, n=17, P=0.0005) than mucosa. The SMA levels correlated 
significantly with active (Figure 4B, Rho= 0.558, P=0.0005) and total TGF-β1 (Figure 4C, 





Figure 3F. Immunohistochemistry on Tu1-Tu4 samples, SMA = smooth muscle actin, myofibroblast and 
smooth muscle cell marker; Vim = vimentin, stromal cell marker; desmin, smooth muscle cell marker; pan-
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The pluripotent growth factor TGF-β1 is produced as a latent precursor and therefore 
activation is a crucial regulating event. We have previously shown the clinical relevance of 
high levels of active TGF-β1 levels in gastric cancer16, which we have now confirmed in a 
larger series of colorectal cancers and pre-malignant adenomatous polyps. Up-regulation of 
the latent TGF-β1 complex is already detectable early in the colorectal normal-adenoma-
carcinoma sequence, whereas substantial increase of TGF-β1 activity occurs merely in 
carcinomas, showing an increasing stepwise relation with differentiation grade and Dukes 
stage. Furthermore, only high active TGF-β1 levels were related to worse survival of the 
cancer patients. Although several studies have been performed on the expression of TGF-β1 
in colorectal carcinomas26,27, up to now only one study also examined total and active TGF-β1 
Figure 4. Smooth muscle actin (SMA) expression levels in colorectal (pre-)malignancies as determined by 
ELISA. A) The SMA concentration, representative for myofibroblast content is significantly increased in 
colorectal carcinomas (P=0.005), but not in adenomas. The box-plots represent median and quartiles. 
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levels28. They found that higher total TGF-β1 protein expression was associated with 
increasing tumour stage, but did not find a significant difference in active TGF-β1 levels 
between normal and tumour samples. The discrepancy with our study could be due to 
sensitivity differences between the different assays used. Although on average their levels of 
total TGF-β1 were comparable with the results from our study, active TGF-β levels in normal 
tissue, requiring extremely sensitivity, are probably better detectable using a mild detergent-
containing lysis buffer, as in our studies. 
Myofibroblasts of normal colon, adenoma and carcinoma differ in the expression of 395 
genes6. Although the origin of myofibroblasts is probably heterogeneous, TGF-β1 mediated 
trans-differentiation of resident fibroblasts seems to be a major source of myofibroblast 
aggregation in cancer12. Tumour-associated myofibroblasts promote the progression of 
carcinomas by modulation of invasion, angiogenesis and the immune-response6, 7 and the 
recent association between the presence of tumour stromal cells with poor survival of colon 
carcinoma patients is in part due to myofibroblasts29.   
Various studies have assessed the presence and number of myofibroblasts in colorectal (pre-) 
malignancies, mainly based on immunohistochemical staining of SMA20,30,31. We have 
developed an ELISA capable of detecting SMA-levels in homogenates of colorectal tissues. 
We found that the method of tissue homogenization is crucial for measuring SMA levels. 
Conventional Triton X-100 extracts obtained according to the protocol recently described32, 
showed low, hardly detectable SMA levels, because this technique is not stringent enough to 
extract the actin filaments24. However when resulting membrane fractions were boiled and 
treated with strong detergent and β-mercaptoethanol (to prevent clustering of the SMA 
filaments) this resulted in detection of levels of SMA, comparable to homogenation using a 
Turrax. Regardless of the two homogenization methods, a significant increase in SMA was 
observed in colorectal carcinomas compared to adjacent mucosa. Immunohistochemistry 
revealed the expression of SMA being present in myofibroblasts in different cancers. Desmin 
staining, normally restricted to smooth muscle cells, revealed also few desmin positive 
myofibroblasts, which has been described recently33 and could indicate a minor additional 
source of myofibroblasts. SMA was also detectable in normal colorectal tissue probably 
because of the high expression of SMA in the muscularis mucosa. Interestingly, adenomas 
contained lower SMA levels than normal tissue, which could be explained by the fact that the 
majority of the cells is of epithelial origin and the relative absence of muscularis mucosa in 
these samples. In addition, SMA expression has also been shown to be dependent on the 
histological type of the adenoma20. The low levels of SMA in adenomas suggest that the up-
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regulated levels of total TGF-β1 should be mainly of pre-malignant epithelial origin. The 
relative inactivity of this adenomatous TGF-β1 is probably due to the absence of an efficient 
activation mechanism and could result in suppression of malignant outgrowth of the tumour. 
Subsequent, over-activation of TGF-β1 in the adenomas will induce myofibroblast formation 
and in turn increased TGF-β1 expression which further validates tumour-associated 
myofibroblasts as therapeutic targets34,35. 
Besides induction of SMA in myofibroblasts TGF-β1 is also a regulator of extracellular 
matrix remodelling-associated genes. Colorectal tissue TGF-β1 levels correlated indeed 
significantly with the expression of urokinase and PAI-1 levels, two well-known  TGF-β1 
target genes, but also with PAI-2 and MMP-2. MMP-9 correlated with total but not with 
active TGF-β1, whereas the control proteinase tissue-type plasminogen activator did not 
correlate with TGF-β1 at all. PAI-1, urokinase and MMP-2 have been found in colorectal 
tumour-associated myofibroblasts as well as epithelial cells31,36,37. Recent studies have 
indicated that over-expression and efficient localized activation of both these proteolytic 
cascade systems are especially found at the interface between tumour cells and stromal cells38-
40. Interestingly, plasminogen activation as well as MMP-activity have both been associated 
with TGF-β1 activation in vitro41,42. 
In conclusion, we have shown that total and active TGF-β1 levels are clearly related to the 
normal-adenoma-carcinoma sequence and active TGF-β1 is more indicative of malignant 
progression, tumour stage and survival of the patients than total TGF-β1. Furthermore, the 
correlation between active TGF-β1 levels and smooth muscle actin expression might indicate 
a prominent role for TGF-β1 in myofibroblast trans-differentiation. 
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Abstract 
In colonic cancer myofibroblasts are present in high abundance. However, their origin and 
function remains unknown. We observed that the TGF-β/Smad signalling pathway is strongly 
activated in cancer-associated myofibroblasts (CAFs). Since TGF-β1 can induce trans-
differentiation of myofibroblasts in vitro, we analysed how TGF-β influences the colon 
tumour-microenvironment. Both HCT116 colon cancer cells and CAFs responded to 
exogenous TGF-β with strongly increased expression of plasminogen activator inhibitor-1 
and matrix metalloproteinases (MMPs). Moreover, we observed an 18-fold induction of TGF-
β1 production in TGF-β stimulated CAFs, indicating an autocrine feedback loop. Analysis of 
the TGF-β activation mechanism revealed that neither CAFs, nor cancer cells were able to 
activate exogenous small latent TGF-β1 complexes. However, culture of CAFs with HCT116 
derived medium, containing high amounts large latent TGF-β1, strongly increased TGF-β 
signalling and smooth muscle actin expression, indicating release from latent complexes and 
subsequent myofibroblast trans-differentiation. Experiments using various protease inhibitors 
suggested that this co-culture induced TGF-β activation was not dependent on proteolytic 
activity. 
In summary, we showed that the interplay between colonic cancer cells and CAFs enhanced 
TGF-β activation and subsequent myofibroblast trans-differentiation. This in turn led to 
cumulative production of TGF-β and proteinases within the tumour-microenvironment, 
creating a cancer-promoting feedback loop. 
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Introduction 
The interaction between carcinoma cells and fibroblasts within the tumour-microenvironment 
contributes to cancer initiation, progression and eventually metastasis in many cancer types1-4. 
Cancer-associated myofibroblasts are a heterogeneous group of fibroblasts expressing 
vimentin, fibroblast-activating protein (FAP) and α-smooth-muscle actin (SMA)5-9. Compared 
to normal mucosa the number of myofibroblasts is strongly increased in colorectal cancer8,10, 
where they influence the immune response and show increased synthesis of chemokines, 
cytokines, proteolytic enzymes and several components of the extracellular matrix (ECM)9,11. 
The origin of this distinct cell-population has not fully been clarified yet9, but based on 
primarily in vitro studies, the most commonly accepted hypothesis is that cancer-associated 
myofibroblasts are generated by Transforming Growth Factor-β (TGF-β) induced trans-
differentiation of resident fibroblasts1,12. 
Next to its contribution to the hyperactivation of resident fibroblasts, TGF-β is involved in 
carcinogenesis via tumour angiogenesis, increased production of ECM and proteolytic 
enzymes and immune suppression13-15. TGF-β is synthesized as a latent precursor consisting 
of the TGF-β homodimer non-covalently linked to the Latency Associated Protein (LAP) 
forming the small latent complex (SLC) and the latent TGF-β binding molecule (LTBP), 
which connects the complex to the ECM as the large latent complex (LLC)16. Removal of 
both LAP and LTBP is the crucial regulation mechanism for TGF-β bio-activity. Activation 
can occur through proteolytic processing  (e.g. plasmin17 and matrix metalloproteinases 
(MMPs)18-21) or non-proteolytically via conformational changes (e.g. integrins22). The 
activating mechanism seems to be strongly dependent on the cell/tissue type or the 
experimental conditions. Active TGF-β is able to bind to the widely expressed TGF-β type II 
Receptor (TβRII), which subsequently recruits and transphosphorylates the TGF-β type I 
receptor (TβRI), activin receptor-like kinase (ALK)-5. This results in signal transduction via 
phosphorylation of the Smad2/Smad3 complex, which recruits Smad4 and translocates to the 
nucleus where transcription is initiated. 
In this study we evaluated whether the enhanced numbers of myofibroblasts in colonic cancer 
could be derived from epithelial-cell-mesenchymal cell interaction involving TGF-β1 
activation. First SMA expression and TGF-β1 activity were immunohistochemically studied 
in human colonic cancer specimens. Next we assessed TGF-β1 response of both tumour cells 
and cancer-associated fibroblasts (CAFs) for the expression of target genes and proteases 
implicated in TGF-β activation. Co-culture experiments revealed that the interaction between 
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tumour cells and CAFs led to TGF-β1 activation and subsequent differentiation of fibroblasts 
into myofibroblasts. In turn, these myofibroblasts showed strongly increased expression of 
proteases and TGF-β1 creating a cancer-progressing feedback loop. 
 
Materials and methods 
Patient material 
Tissue specimens from patients undergoing surgical resection for colonic carcinoma at the 
Department of Oncologic Surgery, Leiden University Medical Centre, were collected. Tissue 
was fixated, dehydrated through graded alcohol and xylene and embedded in paraffin. 
Furthermore tissues from the same patients were used for isolation of primary cancer 
associated fibroblasts (CAFs). Human samples were used according to the guidelines of the 
Medical Ethics Committee of the Leiden University Medical Centre. 
 
Immunohistochemistry 
Immunohistochemical staining was performed as described before23. In short, sequential 
sections were deparaffinized, rehydrated and endogenous peroxidase activity was quenched 
using 0.3% hydrogen peroxide in methanol. Antigen retrieval was performed by boiling in 
0.01 M sodium citrate, pH 6.0 for 10 minutes followed by overnight incubation at room 
temperature (RT) with primary antibodies described in table 1. Sections were incubated with 
appropriate biotinylated secondary antibodies, streptavidin biotin complex (all Dako, 
Denmark) and staining was visualized using diaminobenzidine and H2O2. Representative 
photomicrographs were taken with a Nikon Eclipse E800 microscope equipped with a Nikon 
DXM1200 digital camera. 
 
Table 1 Antibodies used for immunohistochemistry. 
Antibody Clone  Manufacturer Dilution Antigen retrieval 
Pan-
Cytokeratin 
C11 Santa Cruz,  USA  1:1000 Citrate1 
Vimentin V9 Santa Cruz 1:400 paraffin 
1:1000 cytospins 
Citrate1 





pSmad2 Rabbit polyclonal Provided by P. ten Dijke59  1:500 Citrate1 
TGF-β TB21 Anogen 1:1000 Citrate1 
1 Boiling in 0.01 M Sodium Citrate buffer pH 6.0, 10 minutes 
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Cell culture, isolation of fibroblasts and preparation of conditioned media (CM) 
Colon carcinoma cell lines HT29, HCT116, LS180, Lovo, SW480, SW948, and CaCo-2 were 
cultured in DMEM/F12 + GlutaMAX-1 (Invitrogen, the Netherlands), 10 mM HEPES, 50 
μg/ml gentamycin, 100 U/ml penicillin and 100 μg/ml streptomycin (all Invitrogen), 
supplemented with 10% heat inactivated Fetal Calf Serum (FCS, Perbio Science, Belgium) or 
20% in case of CaCo-2. Human cancer-associated fibroblasts were isolated from the non-
necrotic part of the tumour.  The tissue was washed with PBS, cut into 5 mm pieces and 
incubated in 75 cm2 tissue culture flasks (Corning, the Netherlands). After 7-10 days 
fibroblast-like cell outgrowth was observed. The fibroblast origin of these cells was 
confirmed by positive staining for vimentin and negative staining for pan-cytokeratin. The 
cells were maintained in complete DMEM/F12 containing 10% FCS and used at passage 5-
11. 
Conditioned media (CM) from colon cancer cell lines and cancer-associated fibroblasts were 
prepared by seeding the cells in culture flasks and growing them to sub-confluence. Then 
medium was changed to serum free (SF)-DMEM/F12, containing HEPES and antibiotics as 
described above, and incubated for 4 days. CM used for stimulation was diluted 2 fold with 
fresh SF-DMEM/F12. To obtain myofibroblast CM, fibroblasts were stimulated with 5 ng/ml 
TGF-β1 (recombinant human, Peprotech, United Kingdom) for 24h. After three washes with 
SF-DMEM/F12, cells were incubated for 4 days with SF-DMEM/F12. Medium was analysed 
for MMP-2 and MMP-9 levels by zymography as described before24 and for TGF-β1 levels 
by ELISA as described below.  
 
MTS proliferation assay 
HT29 and HCT116 colon cancer cells were seeded in 96-well plates (Greiner Bio-one, 2,000 
or 10,000 cells/well) and allowed to attach overnight. Cells were stimulated with 5 ng/ml 
TGF-β1  for 6h or 72h and subsequently the medium was changed to 100 μl complete DMEM 
+ 20 μl MTS substrate (Promega, USA). The metabolic activity of the cells was analyzed by 
absorbance change at 490 nm after 2h. 
 
TGF-β response assay 
TGF-β response in tumour cells was determined using a (CAGA)12-MLP-Luciferase promoter 
reporter construct25. This construct contains 12 repeats of the Smad3/4 binding element 
derived from the PAI-1 promoter and was shown to be highly specific and sensitive to TGF-β. 
Tumour cells were seeded in 24 well plates (Corning) and allowed to attach overnight. 
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Subconfluent cells were transfected using Lipofectamin 2000 (Invitrogen) according to the 
manufacturer’s protocol. 0.1 µg β-galactosidase plasmid was co-transfected to correct for 
transfection efficiency. After 6 hours medium was changed to complete DMEM/F12 and the 
cells were incubated for 24h and serum starved overnight. Cells were stimulated with 0-5 
ng/ml TGF-β1 or under indicated conditions. After stimulation the cells were washed, lysed 
and luciferase activity was determined according to the manufacturer’s protocol (Promega, 
USA). β-galactosidase activity in the lysates was determined using β-gal substrate (0.2M 
H2PO4, 2 mM MgCl2, 4 mM ONPG, 0.25% β-mercaptoethanol,) and measuring absorbance 
change at 405 nm. For all samples the luciferase count was corrected for β-galactosidase 
activity and the relative increase in luciferase activity was calculated versus controls. 
Cancer-associated fibroblasts were infected using an adenoviral Ad-(CAGA)9-MLP-Luc 
promoter reporter construct26. Cells (18000/well) were infected with 1E+6 pfu virus. After 
infection medium was changed to complete DMEM/F12 for 24 hours and the fibroblasts were 
serum starved overnight, stimulated, lysed and the luciferase activity was determined as 
described for the colonic cells.  
 
Western blotting 
The expression of TGF-β signalling molecule Smad4 was analyzed by western blotting. Cell 
lysates of all colon cancer cell lines were prepared using a 50 mM Tris/HCl buffer, pH 7.6 
containing 1% Triton X-100 and sonification for 30 seconds. Protein concentrations were 
determined using the BCA assay (Pierce, USA). Equal protein amounts were separated on 
10% SDS-PAGE under reducing conditions. Proteins were transferred to a nitrocellulose 
membrane (Whattman, Germany) and aspecific binding was blocked with 2.5% milk powder 
(Biorad laboratories, USA) in PBS containing 0.05% Tween-20 (PBST, Merck, Germany) for 
2 hours at RT. Blots were incubated overnight with mouse monoclonal anti-Smad4 antibodies 
(BD Biosciences, Belgium) in 0.5% bovine serum albumin (BSA)/PBST. Detection was 
performed by incubation with goat-anti-mouse HRP labelled secondary antibodies (Dako) and 
chemoluminescence by Super Signal West according to the manufacturers’ protocol (Pico 
Chemoluminescent substrate, Pierce). Blots were stripped using restore stripping buffer 
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RNA isolation and real-time PCR analysis 
Expression of TGF-β target genes and MMPs were analyzed in HT29, HCT116, SW948 and 
CaCo-2 cells. Cells were grown to subconfluence, harvested and RNA was isolated using 
RNeasy minipreps according to the manufacturers’ instructions (Qiagen, USA). RNA 
concentration and purity was determined by A260/A280. cDNA synthesis was performed 
from 1 μg RNA using random primers. cDNA samples were subjected to 40 cycles Real-Time 
PCR analysis using primers as previously described27,28, except for MMP-7, MMP-13 and 
MMP-28 primer sets which were purchased from Applied Biosystems, the Netherlands. All 
values were normalized for cDNA content by GAPDH expression. To study TGF-β mediated 
upregulation of these genes HT29, HCT116 and cancer- associated fibroblasts were grown to 
subconfluence and stimulated with 5 ng/ml TGF-β1 for 24 hours. RNA was isolated as 
described above. TGF-β does not influence GAPDH expression29. 
  
TGF-β1 ELISA 
TGF-β levels in cell culture supernatants were determined by an ELISA for active TGF-β1 
(R&D Systems). Total TGF-β levels were determined in parallel after acid activation of the 
latent TGF-β1 in the same samples as described before23. 
 
HT29 invasion assay 
HT29 spheroids were grown by the liquid overlay technique as described before30. Spheroids 
were collected and 10 spheroids were embedded in collagen gels in 48-well plates (Corning), 
consisting of 10% DMEM/F12 with 0-10 ng/ml TGF-β1 and 1 mg/ml collagen type 1 
(Vitrogen, Nutacon, USA).  Spheroids were analyzed at 4-14 days for invasiveness and the 
formation of distant metastasis like cell clusters. Representative photomicrographs were taken 
using a Zeiss Axiovert microscope using the 10x objective. 
 
TGF-β1 activation experiments 
To analyze TGF-β1 activation by tumour cells and cancer-associated fibroblasts these cells 
were transfected as described above. Cells were stimulated with 10 ng/ml rh-small latent 
TGF-β1 complex (R&D systems) or CM from tumour cells or cancer-associated fibroblasts. 
To examine the contribution of proteolytic enzymes in TGF-β1 activation, fibroblast were 
stimulated with HCT116 CM in the presence or absence of several inhibitors: 10 μM ALK-5 
inhibitor SB421543 (Sigma-Aldrich, Germany), 1 μM GM6001 (broad spectrum MMP 
inhibitor), 1 μM specific MMP-2/9 or specific MMP-13 inhibitor, 10 μM specific MMP-3 
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inhibitor (all Calbiochem, USA), 1 μM Marimastat (broad spectrum MMP inhibitor, kindly 
provided by British Biotech Pharmaceuticals, UK), 10 μg/ml aprotinin (serine protease 
inhibitor including plasmin), 20 μM E64 (cystein protease inhibitor) or 100 nM α-2 
macroglobulin (all Sigma-Aldrich). Combinations of inhibitors were also tested. Incubations 
were performed for 24h and luciferase activity was determined as described above. For 
fibroblast experiments parallel incubations were performed, medium was harvested for the 
TGF-β1 ELISA and cells were harvested by trypsinisation. Cytospin preparations were made 
and cells were analyzed for SMA content by immunohistochemistry. SMA content was 
scored in a double blinded manner by one individual.  
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Results  
Immunohistochemistry 
In normal mucosa vimentin positive cells included fibroblasts, endothelial cells and 
inflammatory cells, whereas epithelial cells stained for pan-cytokeratin (not shown). A single 
layer of vimentin positive pericryptal cells co-stained for SMA indicating the myofibroblast 
phenotype (approximately 5%, Figure 1A). Staining for total TGF-β was low in normal 
mucosa, but epithelial cells stained for pSmad2 in the nucleus, indicating TGF-β signalling.  
 
  
pSmad2 nuclear staining intensity varied from the bottom of the crypts, where proliferation 
takes place, to the top (Figure 1A) consistent with the anti-proliferative action of TGF-β in 
normal tissue. pSmad2 was barely detectable in fibroblasts or myofibroblasts. In colonic 
cancer total TGF-β staining was strongly enhanced in malignant epithelial cells and the 
tumour ECM. The majority of the fibroblasts (up to 90%) was of the SMA-positive 
myofibroblast phenotype and strongly showed nuclear pSmad2 accumulation (Figure 1A, 
Figure 1. Immunohistochemistry 
on CRC tissue samples. Normal 
colonic mucosa displays a single 
layer of SMA positive 
myofibroblasts along the crypt 
axis, which show no nuclear 
staining for pSmad2, in contrast 
to epithelial cells, which show a 
gradient in staining from bottom 
to top of the crypt. Total TGF-β is 
present in low levels in normal 
mucosa, whereas it is strongly 
increased in CRC (A). Strongly 
increased SMA expression and a 
shift from epithelial to 
mesenchymal nuclear 
 accumulation of pSmad2 occurs 
in CRC, although some samples, 
like CRC-46, still show nuclear 
accumulation of pSmad2 in 
malignant cells next to 
myofibroblasts (B). Full-colour 
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lower panel).  The upper panel in Figure 1B shows the reduced epithelial nuclear localization 
of pSmad2 which is observed in the majority of the CRCs, indicating a shift from primarily 
epithelial TGF-β signalling in normal tissue to mesenchymal signalling in adjacent tumours. 
In contrast, the lower panel in Figure 1B shows another colonic tumour in which, besides 
surrounding fibroblasts, also the malignant epithelial cells still displayed nuclear pSmad2 
localization.  
 
Characterization of (myo)fibroblasts   
To examine the mechanism of fibroblast trans-differentiation, we isolated fibroblasts from 
colonic cancer tissue. The number of SMA positive myofibroblasts was evaluated by 
immunohistochemistry on cytospin preparations and varied between 50 and 90%. All tumour-
derived fibroblasts showed a dose-dependent induction of TGF-β response (3-10 fold) as 










































































































































































































































Figure 2. TGF-β regulated expression of target genes in cancer-associated fibroblasts. 
Fibroblasts respond dose-dependently to exogenous TGF-β1 (A, n=3-7 independent experiments) and real-
time PCR analysis showed upregulation of various proteinases and especially TGF-β mRNA (B). Secretion of 
TGF-β is also strongly enhanced into the medium of TGF-β stimulated fibroblasts (C). MMP-2 and MMP-9 
protein secretion is increased in TGF-β stimulated fibroblasts versus their non stimulated counterparts (D). 
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Real-Time PCR analysis revealed high basal expression of collagen type-1 and plasminogen 
activator inhibitor (PAI)-1 in these cells, confirming the predominant myofibroblast 
phenotype, but also the expression of MMPs was generally high compared with colon cancer 
cells (Table 2). TGF-β1 treatment increased the expression of collagen-1, PAI-1, uPA and 
various MMPs and TIMPs (Figure 2B). Interestingly, the expression of TGF-β1 was induced 
18 fold under TGF-β1 stimulation, indicating a strong autocrine regulatory loop. The protein 
expression of a selection of the up-regulated genes was verified using various techniques. 
TGF-β stimulation of fibroblasts indeed led to a strong increase of total TGF-β1 protein levels 
combined with a low increase in TGF-β1 activity (Figure 2C). Zymogram analysis revealed 
strongly increased MMP-2 and MMP-9 levels in the medium of stimulated fibroblasts 
compared to non-stimulated cells (Figure 2D). 
 
Table 2. Expression MMPs and TGF-β target genes by colon cancer cell lines and cancer-associated fibroblasts. 
Target HT29 HCT116 SW948 CaCo-2 CAF 
MMP-2 ++ - (*) ++ + +++ 
MMP-3 + - (*) ++ +/- +++ 
MMP-7 +++ + + + ++ 
MMP-9 ++ + ++ + + 
MMP-13 + +/- ++ + +++ 
MMP-14 + + ++ ++ +++ 
MMP-15 ++ + + ++ - 
MMP-16 ++ ++ ++ ++ ++ 
MMP-17 - ++ ++ + ++ 
MMP-28 - - + - - 
TIMP-1 ++ ++ ++ +++ +++ 
TIMP-2 ++ ++ ++ ++ +++ 
TIMP-3 + + ++ ++ +++ 
uPA ++ + ++ +/- - 
PAI-1 ++ ++ ++ + +++ 
TGF-β1 +++ +++ +++ +++ +++ 
Collagen-1 - - - - +++ 
Expression of MMPs and 
TGF-β target genes was 
determined in non-stimulated 
cells.    
–  No expression (dCt >20), 
+/- very low (dCt 15-20), + 
moderate (dCt 10-15), ++ 
high (dCt 5-10, +++ very 
high (dCt <5). All dCt values 
are expressed versus GAPDH 
as housekeeping gene. 40 
cycles of Real-Time PCR 
were used. CAF = Cancer-
associated fibroblast, MMP 
= Matrix Metalloproteinase, 
TIMP = Tissue Inhibitor of 
Matrix Metalloproteinases, 
uPA = urokinase type 
Plasminogen Activator, PAI-
1 = Plasminogen Activator 
Inhibitor. (*) = expressed 
upon TGF-β stimulation. 
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Figure 3. TGF-β response of colonic tumour cells. The majority of the cell lines is not responsive to 
exogenously added TGF-β (A, represented by CaCo-2, n=3 independent experiments,), whereas HCT116 cells 
dose-dependently respond to TGF-β (B). Proliferation is not inhibited by TGF-β in HT29 and HCT116 cells 
as determined by MTS proliferation assay after 72 hours stimulation (C). Smad4 western blot analysis 
revealed that the most of the non-responsive cell lines do not express Smad4 protein (D). Data represent 3-7 
independent experiments performed in triplicate (mean ± SEM) 
Characterization of colonic cancer cell lines 
To evaluate the variation in TGF-β1 response in colonic cancer cells we used a TGF-β 
promoter reporter construct in a panel of colon carcinoma cell lines. LS180, LOVO, SW480, 
SW948 and CaCo-2 cells showed no induction of luciferase activity after TGF-β treatment as 
shown by a representative graph in figure 3A.  
 
HT29 cells were partly responsive; only stimulation with concentrations of more than 5 ng/ml 
TGF-β1 increased luciferase activity (not shown). In contrast HCT116 cells showed dose-
dependent induction of luciferase activity up to 5-fold when treated with TGF-β1 (Figure 3B). 
Addition of ALK-5 inhibitor abolished the TGF-β1 induced response completely. Cell-
proliferation was not inhibited by 6h or even 72 hours of TGF-β1 treatment as shown by a 
HCT116
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MTS proliferation assay in Figure 3C. Analysis of Smad4 protein, important in downstream 
TGF-β signalling, revealed no detectable expression in SW480, SW948 and HT29, whereas 
expression was observed in CaCo-2, LS180 and HCT116 cells (Figure 3D). Next we analyzed 
the basal expression levels of TGF-β1, PAI-1 and invasion related proteinases in HCT116, 
HT29, SW948 and CaCo-2 cells by Real-Time PCR. The data revealed high expression of 
TGF-β1 in all cell lines, intermediate levels of PAI-1, and variable expression of uPA and 
MMPs (Table 2). Collagen-1 was not expressed, as expected. To analyze TGF-β1 mediated 
regulation of expression of these genes, only partly responsive HT29 cells and responsive 
HCT116 cells were treated with 5 ng/ml active TGF-β1. Figure 4A shows that TGF-β 
stimulation of HT29 cells resulted in up-regulation of uPA and PAI-1, but expression of 
several MMPs and TIMPs was even stronger induced. TGF-β mRNA itself showed only a 2-
fold up-regulation. In HCT116 cells a similar pattern was observed (Figure 4B), but the 
induction of MMP-2, MMP-13, PAI-1 and uPA was much stronger. However, TGF-β1 was 
not up-regulated in HCT116 cells after TGF-β stimulation. Increased expression of 
proteinases in cancer is associated with invasiveness of tumour cells via the degradation of 
ECM and by the processing/release of cytokines and chemokines. Figure 4C illustrates the 
effect of 0-10 ng/ml TGF- β1 in an invasion assay using HT29 spheroids embedded in a 3-
dimensional collagen matrix. TGF-β1 treatment clearly induced migration of spheroids of the 
only partly responsive HT29 cells into the collagen matrix, eventually leading to distant 
metastasis-like cell clusters. Unfortunately the effect on high responding HCT116 cells could 
not be evaluated due to poor spheroid formation of these cells. 
 
Latent TGF-β1 activation 
Tumour cells secrete the majority of TGF-β as a latent complex, needing processing to 
become biologically active. Therefore we evaluated whether in vivo interactions within the 
tumour-microenvironment could enable activation of the latent TGF-β complex. TGF-β 
responsive HCT116 cells, transfected with the CAGA construct and incubated with 10 ng/ml 
small latent TGF-β complex (SLC), did not show increased luciferase activity, implying no 
activation of the latent complex (Figure 4D). Stimulation of HCT116 cells with CM from 
HT29, containing high levels (1-2 ng/ml) of large latent TGF-β complex (LLC) led to a minor 
increase in activity. HCT116 cells stimulated with cancer-associated fibroblast derived CM, 
resulted in a 4-fold increased luciferase activity (Figure 4D), indicating that the interaction of 
tumour cells with fibroblast-derived factors mediated activation of TGF-β1 and could 
therefore be responsible for fibroblast trans-differentiation in vivo.  
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TGF-β induced fibroblast stimulation 
Compared to treatment with recombinant TGF-β, incubation of fibroblasts with CM from 
HT29 revealed only a minor increase in luciferase activity (Figure 5A). Treatment with 
HCT116 CM containing high levels (2-3 ng/ml) of LLC, and only minor amounts of active 
TGF-β1 (25-80 pg/ml), however led to a 5-fold increase compared to control levels. Addition 











































































































































































































































































































































































































































Figure 4. Regulation of proteinases and TGF-β targets genes in tumour cells by TGF-β. Real-time PCR analysis 
revealed that HT29 (A) and HCT116 (B) cells show upregulation of proteinases and TGF-β target genes upon 
stimulation with 5 ng/ml TGF-β. 3-dimensionally cultured, collagen embedded HT29 spheroids show increased 
TGF-β1-induced invasive properties and the formation of distant metastasis like cell clusters (C). Experiments 
using HCT116 cells revealed that these cells are not capable of activating recombinant SLC or HT29 derived 
LLC. However, strongly increased signalling is observed when combined with cancer associated fibroblast CM 
(D, 3-7 experiments, mean + SEM). 
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TGF-β mediated (Figure 5A). Analysis of the fibroblast medium after incubation with 
HCT116 showed enhanced active TGF-β1 levels (figure 5B). Furthermore, fibroblasts treated 
with HCT116 CM showed increased SMA expression until 95% comparable to addition of 5 
ng/ml TGF-β1, whereas parallel incubations with SLC or HT29 CM showed no change in 
SMA expression (Figure 5C). These data indicated that the interaction of HCT116 medium 
with fibroblasts lead to increased activation of TGF-β1 complex and subsequent 



































































































































































































































































































Figure 5. Myofibroblast generation in CRC. Co-culture of fibroblasts with HCT116 medium leads to strongly 
increased TGF-β signalling (A), increased levels active TGF-β in the medium after stimulation (B) and trans-
differentiation into myofibroblasts as shown by increased SMA levels on cytospins (C). Induction of TGF-β 
response cannot be inhibited by addition of separate proteinases inhibitors or cocktails, but is inhibited by ALK-
5 inhibitor or neutralising TGF-β antibody (D). Data represent 3-7 experiments, mean + SEM. 
Chapter 5 
- 98 -  
Because several proteolytic enzymes have been associated with the release of TGF-β in vitro, 
we analyzed the effect of various protease inhibitors on the HCT116 CM induced activation 
of fibroblasts. None of the used inhibitors, i.e. Aprotinin (plasmin and serine protease 
inhibitor), GM6001 (broad range MMP-inhibitor), E64 (broad range cystein protease 
inhibitor), specific inhibitors of MMP-2/9, MMP-3 and MMP-13 and α2-macroglobulin 
(BMP-1 and MMP inhibitor), were able to inhibit the HCT116 induced response (Figure 5D). 
To exclude the possible necessity of mutual activating proteolytic cascades, different cocktails 
of inhibitors were tested, also resulting in no inhibiting effect, whereas the controls ALK-5 
inhibitor and neutralizing TGF-β antibody inhibited the signal by more than 90 %. 
 
Discussion 
Although most cancers derive from epithelial cells, tumour stroma is thought to be a key 
player in the initiation, and progression of carcinomas, clearly illustrated by its prognostic 
relevance for the survival of colorectal cancer patients31,32. Within the tumour-
microenvironment especially cancer-associated myofibroblasts are associated with auto- and 
paracrine signalling1,9,33,34. Myofibroblast have been shown to be capable of influencing 
epithelial cell proliferation and enhance their invasive and metastatic potential35. Interactions 
between cancer cells and myofibroblasts can occur through direct cell-cell contact via for 
instance extracellular matrix metalloproteinases inducer (EMMPRIN), a potent inducer of the 
myofibroblast phenotype36, but  the majority of interactions is mediated by soluble factors. 
Important fibroblast-derived soluble factors influencing the epithelial cells are scatter 
factor/hepatocyte growth factor (SF/HGF), insulin like growth factor and TGF- β133. TGF-β1 
has also been shown to be a key inducer of myofibroblast trans-differentiation in vitro. 
Several studies suggested that the majority of the cancer-associated myofibroblasts in vivo are 
derived from TGF-β1 mediated conversion of resident fibroblasts34,37,38. In our in vitro 
experiments colonic fibroblasts responded indeed strongly to active TGF-β1, showing up-
regulation of SMA, PAI-1, collagen-1, MMPs and in particular TGF-β1, concomitant with 
trans-differentiation into myofibroblasts. 
Our immunohistochemistry data showed a clear shift in TGF-β signalling in colonic 
fibroblasts. Normal mucosa fibroblasts and SMA positive myofibroblasts showed hardly 
nuclear staining for pSmad2, indicating low TGF-β signalling in the normal stroma. In 
colonic cancers, however, the enhanced population of myofibroblasts showed strong nuclear 
accumulation of pSmad2, indicating TGF-β signalling in these cells, probably by increased 
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availability of active TGF-β1 in the tumour-microenvironment. Up-regulation of growth 
factors is a common phenomenon in many cancer types, but because most of these factors are 
secreted as inactive precursors, the subsequent activation seems to be even more crucial for 
the regulation of their bio-activity than over-expression23,39. For TGF-β1 we have recently 
shown that although the protein levels are already up-regulated in pre-malignant colorectal 
adenomas, increased TGF-β activity was only observed in carcinomas (Hawinkels et al, 
submitted), suggesting that over-activation and not over-expression is characteristic of 
malignant progression. In the present study we showed that cancer-associated fibroblasts were 
not efficient in releasing TGF-β1 from the SLC or HT29-derived LLC. However, combining 
fibroblasts with HCT116 CM led to activation of TGF-β1 levels resulting in enhanced TGF-β 
response, and subsequently leading to myofibroblast trans-differentiation. Although previous 
studies showed that the co-culture of dermal fibroblasts with keratinocytes increased 
myofibroblast levels38 and that breast cancer cells in co-culture with fibroblasts can also 
induce the myofibroblast phenotype via direct cell-cell contact40, our data indicate that TGF-
β1 could also be efficiently activated by soluble factors secreted by colonic cancer cells in 
combination with cancer-associated fibroblasts.  
Proteolytic cleavage or release by proteinases is often implicated in the processing of latent 
growth factors within the tumour-microenvironment24. Especially plasminogen activators and 
MMPs seem to be important in the regulation of growth factor bio-activity 41. Several in vitro 
studies described that latent forms of TGF-β can be proteolytically activated via MMP-142, 
MMP-243, MMP-320,44, MMP-921, MMP-1445, MMP-2846, BMP-118 and plasmin17, 47. Because 
in vivo many of these proteinases are produced as inactive zymogens, proteolytic activation 
cascades involving several cell types are often required for the local presence of active 
enzymes. For instance the activation mechanism of pro-MMP-2 via respectively EMMPRIN, 
MMP-14 and TIMP-2 led to active MMP-2 solely at the interface between cancer cells and 
myofibroblasts, despite the presence of pro-MMP-2 throughout the tumours48,49. As a 
consequence, the activation of latent TGF-β activation by one specific MMP could only be 
efficient if the for this MMP specific activating (e.g. other proteinases), docking (e.g. MMP-
14) and inhibiting proteins (e.g. TIMPs) are locally balanced. Our analysis using various 
proteinase inhibitors revealed that in our model, the proteinases secreted by the tumour cells 
in combination with the fibroblasts were not sufficient to generate TGF-β activation. The 
HCT116 medium contained minor amounts of active TGF-β, which might be generated via 
proteolytic processing of latent TGF-β, presumably at the tumour cell surface. Other factors 
secreted by tumour cells might also influence the effects of TGF-β on myofibroblast 
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differentiation, like has been shown for interleukin-1, which can inhibit TGF-β induced 
myofibroblast differentiation38. However, these soluble factors do not seem to be major 
contributors to myofibroblast trans-differentiation in our experiments, because 90% of the 
HCT116 CM induced response could be inhibited by a neutralising TGF-β antibody or an 
ALK-5 inhibitor. Besides proteolytic release several non-proteolytic mechanisms of TGF-β 
activation have been described, mainly involving release from the SLC, rather than the LLC, 
e.g. thrombospondin150,51 and αvβ6 integrin22). In addition, Wipff et al. showed that 
myofibroblasts can activate LLC TGF-β by mechanical contraction involving myofibroblast 
αvβ5 integrin releasing the active TGF-β molecule from the LLC52. In our model it might be 
that the minor amounts of active TGF-β1 in the HCT116 CM mediate the first trans-
differentiation into myofibroblasts, leading to the subsequent non-proteolytic activation of 
more TGF-β1 via binding of tumour cell- or fibroblast-derived LLC to myofibroblast αvβ5 
integrin. The small amount of active TGF-β in the HCT116 CM, which would not be 
sufficient to generate the high induction of response in the CAFs, might trigger this process 
and explain the difference observed between HT29 CM and HCT116, which both contain 
large amounts LLC, but differ in the amount of active of TGF-β1. 
We showed that TGF-β activation did not only lead to production of increased levels of TGF-
β and proteinases in fibroblasts, but also to increased production of MMPs in tumour cells, 
reflecting a double paracrine mechanism, efficiently enhancing itself, once started. Many 
studies have indicated that TGF-β plays a tumour-suppressive role in normal tissue and pre-
malignant cancer stages, as it inhibits epithelial cell proliferation. Only in later stages 
epithelial cells become refractory to growth inhibitory properties13,15,53,54, apparently leading 
to the presence of higher tumour-cell derived active TGF-β levels, and culminating in the 
overproduction of TGF-β by myofibroblasts. Immunohistochemistry on colorectal cancer 
specimen indeed revealed decreased nuclear accumulation of pSmad2 in tumour epithelial 
cells in the majority of the tumours, reflecting decreased TGF-β responsiveness. This was 
confirmed in vitro, where we show that some colon cancer cell lines are not TGF-β1 
responsive probably by mutations in the TGF-β receptors, Smad4 or other mutations in the 
signalling pathway as have been reported in colorectal cancer55,56. Although HT29 cells do 
not express Smad4 protein these cells are still partly TGF-β responsive, as has been noticed 
before57, indicating the contribution of other, non-Smad dependent signalling pathways. 
Apparently these pathways also lead to invasive processes as we have shown for HT29 
spheroids embedded in a collagen matrix. Moreover, over-production of TGF-β by these 
cancer cells could still contribute to the tumour-promoting effect, via interaction with 
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surrounding fibroblasts, leading to activation of TGF-β and subsequent differentiation of 
fibroblasts. In turn myofibroblasts are able to express other tumour cell growth-promoting 
chemokines and cytokines like SF/HGF, Stromal Derived Factor or VEGF which can promote 
tumour angiogenesis. 
In conclusion we have shown that HT29 and HCT116 cells and cancer-associated fibroblasts 
respond to TGF-β1 by upregulation of MMP, TIMP and TGF-β expression. Both tumour cells 
and fibroblast themselves are not capable of activation of latent TGF-β whereas co-culture of 
conditioned media of these cells leads to increased TGF-β activation via a non-proteolytic 
mechanism and myofibroblast differentiation. We propose that tumour cells produce latent 
TGF-β, which is activated via 
interaction with surrounding normal 
fibroblasts via a non-proteolytic 
mechanism. In turn, fibroblasts are 
trans-differentiated into myofibroblasts, 
which increase  production of TGF-β, 
and invasion related proteases, resulting 
in a cancer progressing feedback loop 
(Figure 6). These data further 
emphasize the role of tumour-stroma 
interactions and myofibroblasts and 
validate further to explore the tumour 
















Figure 6. Proposed mode lfor tumour myofibroblast differentiation. Initially tumour cells secrete minor amounts 
of TGF-β, which initiates the trans-differentiation of myofibroblasts. The myofibroblasts are in turn capable of 
binding tumour cell derived-LLC and releasing active TGF-β via SMA mediated contractile properties in a non-
proteolytical manner. This results in more trans-differentiation, increased synthesis of latent TGF-β and 
proteinases by both the myofibroblasts and tumour cells, facilitating invasion. Together these interactions create 
a cancer enhancing feedback loop in the tumour microenvironment. 
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Abstract 
Angiogenesis is crucial for the progression of colorectal carcinomas in which bioavailability 
of Vascular Endothelial Growth Factor (VEGF) plays a major role.  VEGF bioavailability is 
regulated by proteolytic release or cleavage. In colorectal cancer patients we observed a 
significant correlation between circulating VEGF and tumour tissue Matrix 
Metalloproteinase-9 (MMP-9) levels but not with MMP-2. Therefore, we evaluated the role of 
MMP-9 in regulating VEGF bioavailability and subsequent angiogenesis in 3-dimensional 
human cell culture models. MMP-9 treatment released VEGF dose-dependently from HT29 
colon carcinoma spheroids, comparable to heparitinase, a known mediator of VEGF release. 
Conditioned medium from human neutrophils, containing high amounts of active MMP-9, 
released VEGF comparable to recombinant MMP-9, in contrast to myofibroblast medium. 
MMP-9 treated spheroids showed decreased extracellular levels of heparan sulphates, 
required for VEGF binding to the matrix, whereas the levels in the medium were increased. 
Western blot analysis revealed that VEGF165 is the major isoform released by MMP-9 
treatment. In vitro experiments indicated that MMP-9 is not capable to cleave VEGF165 into 
smaller isoforms, like plasmin does. These data suggested that MMP-9 mediates release rather 
than cleavage of larger VEGF isoforms. Medium from MMP-9 treated HT29 spheroids 
induced endothelial cell sprouting in an angiogenesis assay, comparable to the effect of 
recombinant VEGF165. Anti-VEGF antibody treatment resulted in a strongly reduced number 
of sprouts. In conclusion, we have shown that neutrophil derived MMP-9 is able to release 
biologically active VEGF165 from the ECM of colon cancer cells by cleavage of heparan 
sulphates. 
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Introduction 
Colorectal carcinomas (CRC) are characterized by enhanced VEGF expression and 
corresponding high microvascular densities, indicating increased angiogenic activity and 
leading to worse patient survival1,2. Therapy using anti-VEGF antibodies improves CRC 
patient survival, emphasizing VEGF as a major angiogenic factor3-6. VEGF expression is up-
regulated by hypoxia and various tumour-related cytokines including Transforming Growth 
Factor-β, Interleukin-1β, Platelet Derived Growth Factor and Epidermal Growth Factor7,8. At 
least six human VEGF isoforms are known, ranging in length from 121 to 206 amino acids, 
from which VEGF165 is the most predominant. Except for VEGF121 all isoforms contain a 
heparin-binding domain mediating adhesion to the extracellular matrix (ECM) by interaction 
with heparan sulphate proteoglycans (HSPGs)9. Binding of larger isoforms to the ECM 
provides a reservoir of biologically active VEGF. Consequently, the local release of soluble 
VEGF is a key factor in angiogenesis. Various proteinases have been studied as mediators of 
VEGF cleavage and/or release, including members of the matrix metalloproteinase (MMP) 
family like MMP-210,11, MMP-712, MMP-913 and MMP-1414,15. Most of the experiments 
showing the involvement of proteinases in VEGF-release were done using animal models and 
simple in vitro systems. Because interspecies differences have been described for several 
substrate/MMP combinations16, we investigated the role of the gelatinases MMP-2 and MMP-
9 in VEGF-bioavailability in human CRC. First, the concentration and localization of VEGF, 
MMP-2 and MMP-9 were determined in tissues and plasma of CRC patients. Next, we used a 
3-dimensional ECM-producing human colon cancer model system to evaluate the role of 
several MMPs in VEGF release. Recombinant MMPs and conditioned media from 
neutrophils and myofibroblasts, cell-types associated with the angiogenic switch, were 
evaluated for their MMP content and VEGF-releasing capacity. VEGF functionality was 
determined in a 3-dimensional human endothelial cell-sprouting assay, resembling in vivo 
angiogenesis. This study shows the importance of especially MMP-9 in the release of 
biologically active VEGF165 from the ECM, mainly by cleavage of HSPGs, leading to the 
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Materials and methods 
Patient material 
Pre-operative plasma and tissue specimens from 46 patients (29 ♂, 17 ♀) undergoing 
resection for primary CRC at the department of Oncologic Surgery, Leiden University 
Medical Centre, were collected as described before17. Tissues were homogenized in 
Tris/Tween-80 and the protein concentrations were determined as described previously18,19. 
For immunohistochemistry, tissue specimens were fixed in 4% paraformaldehyde, dehydrated 
in graded alcohol and xylene and embedded in paraffin. All human samples were used 




VEGF levels in tissue, plasma and cell culture supernatants were determined using an ELISA 
(DY293b, R&D Systems Europe, Abingdon, UK) in combination with a substrate reagent 
pack (DY999) according to the manufacturers’ instructions, detecting specifically human 
VEGF121 and VEGF165.   
 
MMP -2 and -9 ELISAs 
MMP-2 and MMP-9 levels were determined by ELISAs as described before20. In short, plates 
were coated with anti-MMP-2 or anti-MMP-9 as capture antibodies and incubated with 
appropriately diluted samples (o/n, 4°C). Polyclonal rabbit anti-MMP-2/biotin-labelled goat 
anti-rabbit-IgG and biotin-labelled polyclonal anti-MMP-9 antibodies were used for immune-
detection. Colour development was performed with streptavidin-peroxidase/tetramethyl 
benzidine/H202. The reaction was stopped with 1M H2SO4 and the absorption was measured 
at 450 nm. Sample concentrations were calculated in ng/mg protein. ρ-Aminophenyl-mercuric 
acetate (APMA) was used to activate pro-MMP-9 (in 0.25 mM in 50 mM Tris-HCl, pH7.6, 
1.5 mM NaCl, 0.5 mM CaCl2, 1 μM ZnCl2, 0.01% Brij35, 1.5 hours at 37º). MMP-9 
activation was monitored by zymography as before18.  
 
Immunohistochemistry 
Immunohistochemistry on 5 μm paraffin sections was performed as described before21.  
Sections were incubated overnight at room temperature with primary unlabelled antibodies 
(Table 1). Frozen 4 μm sections for HSPG staining were fixed in ice-cold acetone for 10 
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minutes and incubated with monoclonal mouse anti-HSPG antibodies (10E4 kindly provided 
by Prof G. David, Leuven22) overnight at 4ºC. Detection of primary antibodies was performed 
as before21. Human placenta was used as a positive control for all antibodies. Negative 
controls were included by omitting the primary antibodies. Representative photomicrographs 
were taken with a Leica DMLB microscope and DC500 camera. 
Table 1. Antibodies used for immunohistochemistry 
Antibody Clone Dilution Supplier Antigen retrieval 
CD31 JC70A 1:400 Dako, Glostrup, Denmark Citrate1 
CD34 B1-C35 1:1600 Zymed, San fransisco, USA Citrate 









  1:1000  Citrate 





MMP-2 rabbit polyclonal 1:250 
TNO, Leiden, the 
Netherlands 
Citrate 
MMP-9 rabbit polyclonal 1:400 
TNO, Leiden, the 
Netherlands 
Citrate 
HSPGs 10E4 1:800 Prof. G. David, Leuven Frozen sections 
Laminin rabbit polyclonal 1:800 Abcam, Cambridge, UK Frozen sections 
CD105 SN6h 1:1000 Dako, Glostrup, Denmark None2 
1 10 minutes boiling in 0.01 M citrate buffer, pH 6.0 
2 Catalysed signal amplification system used according to manufacturers’ protocol (Dako) 
 
Cell culture and preparation of spheroids 
HT29 colon carcinoma and fibroblast spheroids were prepared as described before (2,500 
cells/well)23 and collected after 48 hour of incubation. For immunohistochemistry the 
spheroids were fixed in 4% formaldehyde overnight at 4°C, dehydrated and embedded in 
paraffin. Human umbilical vein endothelial cells (HUVECs) were isolated according to Jaffe 
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and colleagues24 Cell culture and spheroid generation were performed as described before25.  
After 24 hours the spheroids were collected for the collagen sprouting assay.  
 
Treatment of HT29 spheroids with MMPs and heparitinase 
HT29 spheroids were incubated in 48 well plates (8-10 per well), coated with 0.6% agarose, 
in 100 µl serum free (SF)-DMEM/F12 medium containing 0-128 ng/ml activated recombinant 
human (rh) MMP-2 (kindly provided by TNO, Quality of life BioSciences), rh-MMP-7 
(R&D-systems), rh-MMP-8 (Chemicon Europe, Chandlers Ford, UK) or rh-MMP-9 (Invitek, 
Berlin, Germany), 128 ng/ml MMP-9 with 1 µg/ml Marimastat, a broad range MMP-
inhibitor, kindly supplied by British Biotech Pharmaceuticals, or 5 mU heparitinase 
(Seikagaku Corporation, Tokyo, Japan). Pro-MMPs were activated as described above. After 
24 hours incubation at 37°C, conditioned media (CM) were collected and applied to the 
collagen sprouting assay. The VEGF levels were determined by ELISA. VEGF isoform 
determination was performed by incubating 200 HT29 spheroids in 100 μl MMP-9 containing 
SF-DMEM/F12 to obtain VEGF levels above western blot detection limit. HT29 spheroids 
were embedded in OCT and frozen in liquid nitrogen for HSPG staining.  
 
Western blots for VEGF and HSPGs 
Samples were analysed on 10-15% SDS-PAGE under reducing and non-reducing conditions. 
Proteins were transferred to a nitrocellulose membrane (Whatman, Dassel, Germany) 
overnight. After each step blots were washed 3 times with PBS containing 0.05% Tween-20 
(PBST, Merck). Non-specific binding was blocked with 0.2 % gelatin in PBST for 30 
minutes. VEGF was detected by incubation with polyclonal rabbit-anti-human VEGF 
antibody (Santa Cruz) recognizing VEGF isoforms 121, 165 and 189, followed by 
biotinylated goat-anti-rabbit antibodies and streptavidin-HRP (both Dako). HSPGs was 
detected with mouse monoclonal antibody 3G10 recognizing HSPG stubs (cleaved heparan 
sulphates) followed by goat anti-mouse HRP22. Detection was performed using Super Signal 
West according to the manufacturers’ protocol (Pico Chemoluminescent substrate, Pierce, 
Rockford, IL, USA). 
 
Collagen sprouting assay 
HUVEC spheroids were embedded in 96 well plates in type I collagen matrix consisting of 
basic M199 medium supplemented with 20% FCS and 1 mg/ml collagen (Type I, calf skin, 
Vitrogen, Palo Alto, USA). After 1 hour of polymerisation, 75 µl of the medium from the 
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treated HT29 spheroids was applied. After overnight incubation sprout-formation was 
determined by counting the number and average length per spheroid (double blind by 2 
individuals). Complete M199 medium with or without 100 ng/ml recombinant human (rh)-
VEGF165, (Calbiochem, La Jolla, CA, USA), and active MMP-9 which was not incubated 
with HT29 spheroids were included as controls. To confirm the role of VEGF, MMP-9 treated 
HT29 spheroid CM was supplemented with anti-VEGF antibody (Bevacizumab/Avastin), 
kindly provided by Dr. I.M. Teepe-Twiss).  
 
Preparation of neutrophil and myofibroblast CM 
Neutrophils were isolated from 80 ml whole human blood using a Ficoll gradient. Remaining 
erythrocytes were lysed with 160 mM NH4Cl, 10 mM KHCO3, pH 7.4. Neutrophils 
(6x106/ml) were incubated in SF-RPMI 1640 medium (Invitrogen) for 24 hours under argon 
to induce hypoxia, resulting in the release of MMP-9. 
Human CRC fibroblasts were isolated by outgrowth of the cells from resection specimens. 
Fibroblast origin was confirmed by morphology, vimentin staining (>95% positive) and ~50% 
α-smooth muscle actin (SMA) staining. Fibroblasts were maintained in 10% DMEM/F12 and 
used at passage 5-11. Myofibroblasts were generated by stimulation with 5 ng/ml TGF-β1 
(Peprotech, United Kingdom) overnight. Differentiation into myofibroblasts was confirmed 
by SMA-staining. Medium was changed to SF-DMEM/F12 and collected after 24 hour 
incubation. All CM were analyzed for MMP-2 and -9 content and activity by zymography. 
 
Proteolytic cleavage VEGF165 
To analyze the capacity of MMP-9 to cleave VEGF165 in vitro 1 μg rh-VEGF165 (Calbiochem) 
was incubated in MMP-9 activation buffer with/without 1280 ng/ml active MMP-9 or with 
0.1 U/ml human plasmin (Sigma-Aldrich) in PBS. After incubations of 30 minutes, 4h and 
overnight samples were analysed by western blot.  
 
Statistical analysis 
Statistical analyses were performed using SPSS Statistical Package 11.0 (SPSS Inc., Chicago, 
USA). Differences between normal and tumour levels were calculated using the Wilcoxon 
signed rank test. Sprout formation data are presented as mean ± standard deviation and extent 
of endothelial cell sprout formation was analysed using the Student’s t-test. For the 
correlation between tissue and serum levels Pearson’s correlation analysis was used. P≤0.05 
was considered significant. 
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Results 
 
VEGF and MMP-2 and -9 levels in CRC and in the circulation 
Figure 1 shows the concentrations of VEGF and MMP-9 in CRC and corresponding mucosa. 
VEGF and MMP-9 levels were significantly enhanced in tumours (both P<0.0001, n=46 
pairs) and were mutually correlated (R=0.405, P<0.0005, n=92). Tissue MMP-2 levels were 
not enhanced in CRC compared to normal mucosa (18.4 versus 18.3 ng/mg protein, n=46 
pairs) and did not correlate with the tumour VEGF concentration. Tumour levels of MMP-2 
and MMP-9 correlated weakly with each other (R=0.250, P=0.019), but only MMP-9 level 
correlated significantly with the circulating VEGF concentration (MMP-9: R=0.379, P=0.009; 
MMP-2: R=-0.052, P=0.729, n=46). Circulating VEGF was not correlated with tumour 




To examine the association of tumour MMP-9 and VEGF release, we performed 
immunostaining in consecutive sections. In normal colon tissue, weak VEGF staining was 
detected in epithelial cells (Figure 2A). MMP-9 was detected in some endothelial cells of 
small blood vessels and in infiltrating leukocytes, although the frequency of these cells was 
low (Figure 2D). In CRC, high VEGF expression was detected exclusively in epithelial cells 
and endothelial cells (Figure 2B). MMP-9 was observed in SMA-positive myofibroblasts 
(Figure 2E), infiltrating leukocytes, especially neutrophils (insert Figure 2E), and weakly in 
some tumour cells. All endothelial cells stained for CD31, whereas markers for newly formed 
blood vessels (CD34 and CD105) were restricted to small blood vessels in the submucosal 
Figure 1. Protein levels of VEGF and MMP-9 in tissues from 46 colorectal cancer patients. In cancer 
samples VEGF (A) and MMP-9 (B) levels are significantly (P<0.0001) increased compared to 
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area in normal mucosa, but were rarely observed in the proximity of epithelial cells (Figure 
2I). Strongly increased numbers of CD34 and CD105 positive vessels were present in CRC, 
mainly localized in between tumour cells (Figure 2J). 
 
Characterization of HT29, fibroblasts and HUVEC spheroids 
To validate the resemblance of the cell culture models with human CRC tissue, HT29, 
fibroblasts and HUVEC spheroids were stained for VEGF, MMPs, cell-markers and ECM 
molecules. Strong expression of VEGF in HT29 spheroids was observed (Figure 2C), whereas 
Figure 2. Immunohistochemical staining of normal and tumour colon tissues and 3-dimensional cell culture 
models showing the resemblance between patients derived tissue and in vitro cell culture models. VEGF 
expression was very low in normal colon tissue (A) and strongly increased in colon tumour cells (B, 
arrowheads). HT29 colon cancer spheroids strongly express VEGF (C). MMP-9 was hardly detectable in 
normal colon tissue (D) and strongly expressed in stromal cells in colorectal cancer (E), especially in 
neutrophils (enlarged insert, 630x). HT29 spheroids were negative for MMP-9 (F), and produced VEGF 
binding HSPGs (G, left) and the ECM molecule laminin (G, right).  Fibroblast spheroids (H) were positive for 
vimentin (VIM) and for SMA. MMP-9 was expressed, but MMP-2 was more abundant. CD34 showed minor 
staining in normal colon except for the submucosal area (I, insert). In tumours many neo-angiogenic CD34 
positive vessels are present in the proximity of tumour cells (J, insert, 630x).  HUVEC spheroids were positive 
for CD31 (K) while sprouting endothelial cells showed additional positivity for the angiogenesis marker 
CD105 (L). Full-colour illustration at page 206. 
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virtually no MMP-9 (Figure 2F) or MMP-2 (not shown) expression was present, consistent 
with the findings in vivo. HT29 spheroids contained functional ECM components, including 
HSPGs (Figure 2G, left) and laminin (right). Fibroblast spheroids showed strong vimentin 
expression, and were positive for SMA. MMP-9 was expressed, but MMP-2 expression was 
more abundant. (Figure 2H) HUVEC spheroids stained for CD31 (Figure 2K) and sprouting 
HUVECs additionally showed positive staining for CD105 (Figure 2L).  
 
MMP mediated VEGF release from HT29 spheroids 
To assess whether MMPs were capable of releasing VEGF from colorectal cancer ECM, 
HT29 spheroids were treated 24 hours with active rh-MMP-2, -7, -8, or -9. Medium from 
untreated HT29 spheroids contained low levels of VEGF, which was dose dependently 3-fold 
increased by treatment with 32-128 ng/ml MMP-9 (Figure 3A).  
Treatment with MMP-7 or low concentrations of MMP-2 or MMP-8 did not influence VEGF 
release. Treatment with high concentrations of MMP-2 or MMP-8 led to maximal 2-fold 
VEGF increase. Addition of MMP inhibitor Marimastat reduced MMP-9-mediated VEGF 
release to basal levels (Figure 3A). Control media containing APMA did not affect VEGF 
release (not shown). Treatment of HT29 spheroids with neutrophil-derived CM, containing 
high amounts of active MMP-9 (zymogram Figure 3B), resulted in release of VEGF levels 
comparable to treatment with 128 ng/ml rh-MMP-9 (Figure 3C). Marimastat inhibited the 
release significantly.  
Treatment of the spheroids with myofibroblast CM, containing high amounts of MMP-2 and 
minor amounts of MMP-9 (zymogram Figure 3B), resulted only in a mild increase in VEGF, 
comparable to 128 ng/ml MMP-2 treatment, which was completely inhibited by Marimastat. 
The MMP-9-mediated VEGF release was comparable to the effect of heparitinase (Figure 










MMP-9 mediated VEGF release  










HSPG immunostaining on spheroids treated with MMP-9 or heparitinase showed a similar 
decrease in the extracellular localization of HSPG (Figure 4A), suggesting cleavage of 
HSPGs by MMP-9. To evaluate the effect of MMP-9 on HSPGs, 200 HT29 spheroids were 
treated with/without 128 ng/ml MMP-9 and the medium was subsequently immunoblotted 





































































































































































Figure 3. A) VEGF release (mean±SEM) from colon carcinoma spheroids after treatment with various MMPs 
and heparitinase as control.  HT29 colon carcinoma spheroids were treated for 24 hours with 0, 32 or 128 ng/ml 
active MMP-2, -7, -8 or -9. Treatment with MMP-9 resulted in the highest dose-dependent release of VEGF, 
completely inhibitable by addition of MMP inhibitor Marimastat (Mst, 1 μg/ml). The experiments were 
performed 3-6 times, except where no error bars are indicated (result of 3 pooled experiments). B) Gelatin 
zymogram showing respectively pro-MMP-9, APMA activated MMP-9 and conditioned medium (CM) from 
neutrophils and myofibroblasts. Neutrophil CM contained high levels of MMP-9, whereas myofibroblast 
released high levels of MMP-2 and low but detectable levels of MMP-9. C) VEGF release from HT29 spheroids 
treated for 24 hours with neutrophil and myofibroblast conditioned medium. The experiments were performed 3 
times.  MST: addition of  1 μg/ml Marimastat; CM: conditioned medium. 
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(Figure 4B). MMP-9 treatment resulted in stronger and additional bands compared with the 












To examine whether MMP-9 cleaves VEGF165 to smaller isoforms or that alternatively intact 
VEGF165 is released, we incubated rh-VEGF165 with 1280 ng/ml MMP-9 or plasmin, known 
to cleave VEGF165 9. As shown in Figure 5A plasmin cleaves VEGF165 resulting in a 17 kDa 
fragment after 4h. In contrast MMP-9 is not capable of cleaving VEGF165 after 4h or even 
overnight incubation, indicating that MMP-9 mediates VEGF release rather than inducing 
cleavage. Western blot analysis of HT29 spheroid CM showed that VEGF165 is the major 









Figure 4. A) Immunohistochemical staining for HSPGs with monoclonal antibody 10E4 of HT29 spheroids 
after treatment with MMP-9 or heparitinase resulting in decreased extracellular localization of HSPGs 
(magnification 630x). B) Western blot of medium from HT29 spheroids treated with MMP-9 and 
subsequently stained with monoclonal antibody 3G10, specifically recognizing epitopes on HSPGs after 
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HT29 spheroid-derived VEGF mediates endothelial cell sprouting 
To determine if the released VEGF was capable of inducing endothelial sprouting we used a 
3-dimensional angiogenesis model. Stimulation of HUVEC spheroids with untreated HT29 
spheroid CM resulted in minimal endothelial sprout-formation, reflecting the low VEGF 
levels as determined by ELISA (Figure 6A) and comparable to the medium control (Figure 
6B). In contrast, when HUVEC spheroids were incubated with medium from HT29 spheroids 
treated with 128 ng/ml MMP-9 extensive sprout formation was observed (Figure 6C), 
comparable to stimulation with 100 ng/ml rh-VEGF (Figure 6D). Analysis of the sprouts 
showed a significant increase in both length and number after stimulation with MMP-9-
treated HT29 spheroid CM (Figure 7A/B). Medium from HT29 spheroids treated with MMP-
9 in the presence of Marimastat did not result in endothelial cell sprouting (Figure 6E). Active 
















Figure 5. A) Western blot analysis (reduced gel) showing treatment of human recombinant VEGF165 by MMP-
9 and plasmin. Plasmin cleaves VEGF165 to VEGF121 whereas MMP-9 has no effect. Control: rh-VEGF165; 
MMP-9: addition of 1280 ng/ml rh-MMP-9, 4h; Plasmin: addition of 0.1 mU human plasmin, 30 min).  
B) Western blot analysis (unreduced gel) showing that after MMP-9 treatment of HT-29 spheroids VEGF165 is 
the major isoform observed in the medium. 
VEGF: 20 ng rh-VEGF165; HT29/MMP-9: medium from HT29 spheroids treated with 128 ng/ml MMP-9; 
HT29: spheroid medium without treatment 
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The contribution of VEGF in the angiogenesis assay was determined by pre-incubation with 
the neutralizing VEGF antibody Bevacizumab. Bevacizumab efficiently inhibited endothelial 
cell sprouting by rh-VEGF (Figures 6G and 7A/B). When incubated with MMP-9-treated 
HT29 spheroid CM, Bevacizumab inhibited the number of endothelial sprouts formed 
significantly (Figures 6H and 7A), whereas the reduction of the length of the residual sprouts 















Figure 6. Sprout formation by MMP-9-released VEGF in a 3-dimensional angiogenesis model. Medium from 
untreated HT29 spheroids did not induce sprout formation in HUVEC cells (A), compareble to the medium control 
(B). The medium from MMP-9 treated HT29 spheroids strongly induced HUVEC sprout formation (C) comparable 
to rh-VEGF165 (D). Treatment of HT29 spheroids with MMP-9 in the presence of Marimastat (Mst) resulted in 
strongly reduced sprout formation in HUVEC cells (E). Active MMP-9 itself was unable to induce HUVEC sprout 
formation (F).  Sprout formation induced by VEGF165 was strongly reduced by addition of Bevacizumab (G). 
Bevacizumab reduced the number of sprouts induced by MMP-9 treated HT29 spheroid medium, whereas sprout 
length was reduced to a lesser extent (H). 
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Discussion 
The ability of VEGF to induce angiogenesis depends on the presence of active, mobile 
isoforms within the microenvironment. After production and release from the cells, VEGF 
bioavailability is regulated via cleavage and/or release by proteolytic activity in combination 
with the acidic pH present in the tumour-microenvironment26. Heparanases27,28, plasmin9,29, 
urokinase30,31, phoshatidyl-inositol phosholipase C9, and MMPs11-15 have been shown to 
cleave larger VEGF isoforms into smaller fragments or, alternatively, mediate release of 
VEGF by remodelling of the ECM. In our study, significantly increased and correlating 
VEGF and MMP-9 tumour levels were accompanied by a significant correlation of tumour 
MMP-9 and pre-operative circulating levels of VEGF, a factor associated with poor outcome 
in CRC-patients32. Tumour tissue MMP-2 did not correlate with circulating VEGF. These 
data suggested a prominent role for MMP-9 in the release and bioavailability of VEGF in 
CRC in vivo. MMP-9 has been shown to mediate VEGF release in mouse pancreatic cancer, 
whereas MMP-2 and urokinase had no effect13. Studies with human ovarian tumours 







































































































Figure 7. Quantification of number and length of sprouts induced by VEGF. The number of sprouts is significantly 
induced by VEGF, and is inhibited by Bevacizumab (Bmab).  MMP-9 treated HT29 spheroid medium showed, like 
VEGF, significant induction of sprout formation, which is reduced to control level by addition of Bmab. The 
average sprout length was increased by VEGF which was found to be inhibited by Bmab. A comparable induction 
was observed by MMP-9 treated HT29 spheroids medium, but surprisingly the length of the sprouts could not 
completely be inhibited by the addition of Bmab. 
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ascites11,33. Those studies however did not distinguish whether VEGF was released via 
cleavage of larger VEGF isoforms or by ECM remodelling, leaving VEGF intact. 
To elucidate the role of MMP-9 on VEGF release and angiogenesis in human CRC, we used 
3-dimensional human cell-models, comparable to human tumour xenografts in mice34, but 
avoiding inter-species complications. Our data show that MMP-9 induced VEGF release was 
comparable to the effect of the HSPG degrading enzyme heparitinase. In comparison, MMP-2 
and MMP-8 were also capable of VEGF release, albeit less potent. Staining of MMP-9-
treated spheroids showed a decrease in the extracellular localization of HSPGs, suggesting 
that MMP-9 cleaved HSPGs rather than VEGF itself, similar to what was found previously 
for VEGF bound to connective tissue growth factor35. Western blotting of medium from 
HT29 spheroids with monoclonal antibody 3G10 confirmed MMP-9 mediated cleavage of 
HSPGs. 
Our in vitro data showed that in contrast to plasmin, human MMP-9, even after overnight 
incubation, did not cleave human VEGF165 into a 17 kDa VEGF121 fragment, as previously 
described for mouse VEGF36, suggesting that in an) entirely human setting intact VEGF165 
release by MMP-9 is more probable than cleavage. Western blot analysis confirmed that the 
major isoform released from the HT29 spheroids is VEGF165 rather than VEGF121. 
Additionally, sequence alignment of mouse versus human VEGF165 revealed a low homology 
in the expected cleavage sequence, presumably resulting in a different proteolytic 
sensitivity37.  
Immunohistochemistry on human CRC showed expression of VEGF primarily in tumour 
cells, whereas MMP-9 expression was mainly detected in stromal cells including neutrophils, 
endothelial cells, myofibroblasts, and incidental macrophages. In vitro myofibroblasts 
secreted mainly MMP-2 and low levels of MMP-9. Treatment with myofibroblast CM lead to 
increased VEGF release, probably induced by a combination of MMP-9 and MMP-2, but 
never reached the level of neutrophil CM. Tumour-infiltrating neutrophils have previously 
been shown to mediate the initial angiogenic switch in a model of multistage carcinogenesis38. 
In neutrophils, MMP-9 is located in granules and is not used for ECM-degradation during 
migration to the tumour, but is released upon signals from the tumour into the 
microenvironment without accompanying TIMP, resulting in high catalytic MMP-9 
activity39,40. Therefore, extravasated neutrophils are good candidates to initiate rapid changes 
in the hypoxic microenvironment compared to other MMP-9 positive stromal cells. Besides 
MMP-9 neutrophils contain a range of other proteinases, which might contribute to VEGF-
release or degradation. Previously we showed in gastric carcinoma homogenates that the level 
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of MMP-9 correlated significantly with myeloperoxidase, a specific neutrophil marker41, 
suggesting that neutrophils are a major source of MMP-9. MMP-9 levels were also highly 
correlated with MMP-8, also called neutrophil collagenase. Although MMP-8 was less 
efficient than MMP-9 in this study, it could still be involved in VEGF release. Because MMP-
8 resides in other granula in neutrophils than MMP-9 the time and/or the location of release of 
these proteinases presumably differs. Due to these variations in localization and activity levels 
within the tumours, even proteinases with lower efficiencies than MMP-9, including other 
MMPs could be involved in VEGF release in situ10-12,14,15. Our data using broad range MMP 
inhibitor Marimastat support this notion.  
The involvement of MMP-9 in VEGF-mediated endothelial cell sprouting was confirmed by 
the use of the VEGF inhibitor Bevacizumab, resulting in inhibition of the number and to a 
less extend the length of endothelial sprouts. Variation in sprouting phenotype was previously 
associated to different VEGF165 
concentrations42. In our model it is more 
likely caused by other angiogenic factors 
present in the MMP-9-treated spheroid CM. 
These factors, like bFGF or TGF-β, are 
capable of stimulating endothelial sprout-
outgrowth after sprouting has been initiated. 
Our data support the involvement of VEGF 
particularly in the onset of the angiogenic 
switch. Summarized in figure 8, we propose 
that in small, not yet vascularised tumours 
hypoxia leads to increased epithelial cell 
VEGF production, which stays bound to the 
ECM. MMP-9 release from tumour 
infiltrating neutrophils in turn mediates 
release of VEGF from the ECM by HSPG 
cleavage. Then, soluble VEGF165 diffuses to endothelial cells, initiating the angiogenic 
switch. Our study also indicates the value of human model systems, to confirm or supplement 








Figure 8. Proposed model for the role of neutrophil-
derived MMP-9 in HSPG cleavage initiating the 
angiogenic switch by releasing VEGF in colorectal 
carcinomas. 
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Abstract 
Over-expression of matrilysin (MMP-7) is predominantly associated with epithelial 
(pre)malignant cells. In the present study MMP-7 expression is also found in endothelial cells 
in various human cancer types. Endothelial MMP-7 was associated with CD34 and/or CD105 
expression. These immunohistochemical data were confirmed by RT-PCR on VEGF-
stimulated endothelial cells. In addition, MMP-7 was also identified in sprouting endothelial 
cells in vitro. The potential clinical relevance of endothelial MMP-7 was assessed for cervical 
cancer patients by evaluating the association with overall survival. In contrast to MMP-7 in 
malignant epithelial cells, MMP-7 expression in endothelial cells showed a significant 
association with poor survival (LR 5.12, P=0.02, n=30). Our data suggest that MMP-7 is 
involved in tumour angiogenesis, thereby contributing to malignant growth and hence 
associated with decreased survival. 
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Introduction 
Matrilysin (matrix metalloproteinase 7, MMP-7) has long been regarded as the MMP 
exclusively produced by epithelial cells. Up-regulation of epithelial MMP-7 in early stage 
tumours is a consequence of mutations in the Wnt-signaling pathway1. In later tumour stages, 
hypoxia contributes to the induction of MMP-7 expression2. Only few non-epithelial cell 
types have been described to express MMP-7 in vivo. The first indication for MMP-7 
production by endothelial cells in tumour tissue came from Nagashima et al.3, but this 
important finding has never been confirmed. We evaluated the presence and the role of MMP-
7 in endothelial cells in cancer. First, we investigated MMP-7 expression in endothelial cells 
within various tumour types in relation to co-expression with pan-endothelial marker CD34 
and proliferating endothelium associated marker CD1054. Secondly, using real time RT-PCR, 
we determined whether VEGF, the classical initiator of angiogenesis, was able to induce 
MMP-7 expression in sprouting endothelial cells in vitro. In addition, we determined the 
effect of an MMP inhibitor on sprouting endothelial cells, in which MMP-7, either directly or 
indirectly, could be involved. Finally, to evaluate a potential clinical implication, we assessed 
the association between MMP-7 expression in tumour endothelial cells and survival of 




A total of 254 patients with untreated primary cervical carcinoma underwent a radical 
hysterectomy type III with lymphadenectomy between 1985 and 1995. Tissue samples were 
fixed in 10% formalin and embedded in paraffin. Samples from 30 patients were included in 
this study: Mean age 45 years (range 29-72); FIGO stage: (20), IIA (8), IIB/IIIB (2); lymph 
node metastases: No (16), Yes (14);distant metastases: No (13), Yes (17); tumour size: <40 
mm (16), ≥40 mm (12); infiltration depth <15 mm (15), ≥15 mm (9); vascular space 
involvement: No (10), Yes (20); parametrial invasion: No (20), Yes (10); HPV status: 16/18 
(19), other types (6); Tumour classification: squamous cell carcinoma (25), adenocarcinoma 
(1), adenosquamous carcinoma (4). In addition, formalin-fixed, paraffin-embedded tissue 
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Cells, chemicals and antibodies 
Human umbilical vein endothelial cells (HUVEC) were isolated5. Cells from passage 3 to 6 
were grown in M199 medium (InVitrogen) containing 20% heat inactivated Fetal Calf Serum 
(Perbio), 0.05 mg/ml heparin, 2 mM Glutamine, 100 U/ml Penicillin, 100 µg/ml Streptomycin 
(InVitrogen) and 12.5 μg/ml Endothelial Cell Growth Supplement (Sigma-Aldrich) in 
fibronectin coated culture flasks (0.05 mg/ml). Human recombinant VEGF165 was from 
Calbiochem. Antibodies: MMP-7 (clone 111433, IgG2B mouse monoclonal detecting pro and 




Paraffin sections were stained as previously described6. Deparaffinized and rehydrated 4μm 
sections were quenched for endogenous peroxidase with 0.3% H2O2 in methanol before 
incubation with primary antibodies (o/n) diluted in phosphate-buffered saline (PBS), 1% 
bovine serum albumin (BSA). Biotinylated rabbit anti-mouse immunoglobulins followed by 
horseradish peroxidase (HRP)-streptavidin complex (both Dako) were applied for 30 min 
each. Immune complexes were visualized using 0.05% diaminobenzidine (DAB, Sigma), 
containing 0.0038% H2O2 in 0.05 M Tris-HCl buffer (pH 7.6) resulting in brown precipitate 
or alternatively Nova Red (Vector Laboratories, Burlingame, CA) resulting in red staining, 
and  counterstained with Mayer’s hematoxylin. Citrate antigen retrieval was used when 
indicated by the manufacturer. Appropriate tissue sections were included as positive controls 
and incubation with PBS-BSA without primary antibodies served as negative controls. MMP-
7 staining in tumour and endothelial cells was independently scored by 2 individuals (C.S. 
and K.Z.), integrating the percentage of cells stained and the intensity of staining in a total 
score ranging from 0 to 8 6. A score from 0-4 was considered Low and 5-8 as High. 
 
RNA isolation and real- time RT-PCR 
Total RNA was isolated from HUVECs cultured on fibronectin, gelatin or collagen I coated 6 
well plates with or without 100 ng VEGF per well, using the RNeasy Mini kit (Qiagen). 
Reverse transcriptase PCR was carried out in 1 µg RNA using random primers and a cDNA 
synthesis kit (Promega). MMP-7 expression was quantified using real-time quantitative PCR 
according to the TaqMan method (Applied Biosystems, Hs 00159163m1, Perkin-Elmer) with 
GAPDH as endogenous housekeeping gene7. Double-stranded MMP-7 cDNA was used as 
positive control. 
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Sprouting assay 
Endothelial spheroids were prepared from HUVEC8,9 in complete M199 medium containing 
0.1% carboxymethylcellulose (Sigma-Aldrich) and 20% FCS, and seeded into non-adherent 
round bottom 96 well plates. After 24 h the spheroids were embedded in 1 mg/ml collagen 
matrix (Vitrogen 100, Nutacon) containing 20% FCS and treated with or without 100 ng/ml 
VEGF in complete M199 medium. Sprout-formation started after 3 hrs. Following overnight 
incubation, the spheroids containing collagen matrix was fixed in formalin and embedded in 
paraffin for immunohistochemical analysis. 
 
MMP-7 activity assay 
MMP-7 activity in cell culture media was determined using a recently developed 
immunocapture-based activity assay10. 
 
Immunoblot 
Samples were analyzed on 15% SDS-PAGE under non-reducing conditions. Proteins were 
transferred to a nitrocellulose membrane (Whatman, Dassel, Germany). Blots were washed 
with PBS containing 0.05% Tween-20 (PBST, Merck) 3 times for 5 minutes. Non-specific 
binding was blocked with 0.2 % gelatin in PBST for 30 minutes at room temperature. MMP 
was detected by incubation with anti-MMP-7 antibody (IgG2B mouse monoclonal antibody, 
R&D), followed by biotinylated goat-anti-mouse antibodies and Streptavidin-HRP (both 
Dako). Coloration was performed using DAB. 
 
Statistical analysis 
Spearman correlations between parameters, survival curves, Log-Rank analyses and 
multivariate Cox analyses were performed using the SPSS 10.0 software package (SPSS Inc). 
P values ≤0.05 were considered significant. 
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Results 
Representative stainings of MMP-7 in endothelial cells in respectively stomach, colon, breast, 
cervix, and prostate cancer tissue is shown in Figure 1A-E. The unexpected staining of MMP-
7 in endothelial cells was confirmed using 3 other anti- MMP-7 antibodies with similar results 
(rabbit polyclonal RP1MMP-7 from Triple Point, rabbit polyclonal from Abgent and goat 
polyclonal from R&D, data not shown). The presence of MMP-7 expression in endothelial 
cells was associated with co-staining for CD34 and CD105 in sequential sections from the 
same tissue, suggesting that these cells were of neo-angiogenic origin (Figure 1). MMP-7 
expression in endothelial cells was in general less intense than expression in epithelial cells. 
MMP-7 staining in endothelial cells did not correlate with the expression in epithelial cells in 
the same sections (R=0.069, P=0.716, n=50). 
 
MMP-7 expression is not expected to be present in endothelial cells. Therefore, we first 
demonstrated that endothelial cells are indeed able to express MMP-7 by evaluating MMP-7 
mRNA levels in HUVEC. Unstimulated HUVEC, cultured on fibronectin, did not express 
detectable quantities of MMP-7 mRNA (> 40 cycles of RT-PCR). However, when grown on 
gelatin or collagen type I, HUVEC did express MMP-7 mRNA, and VEGF stimulation up-
Figure 1. Immunohistochemical staining of endothelial cells for MMP-7, indicated by arrows in gastric 
cancer (A), colonic cancer (B), breast cancer (C), cervical cancer (D), prostate cancer (E), and in in vitro 
sprouting HUVEC cells (F). Inserts I and II indicate respectively CD34 and CD105 staining in sequential 
section from the same tissue. The inserts in (F) show VEGF-induced endothelial cell sprouting in control 
and marimastat-treated HUVEC spheroids. Arrowheads indicate epithelial cell staining. Bars correspond 
with 100 μm in (A-E) and with 300 μm in (F). Full-colour illustration at page 207. 
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regulated MMP-7 mRNA expression more than 3-fold after 16 hrs (comparative Ct method: 
dCt 11.84 versus 10.43 respectively). Longer periods of VEGF stimulation resulted in 
decreasing levels of MMP-7 mRNA. Increased mRNA levels were reflected by the MMP-7 
level in the conditioned medium. Serum-free medium from VEGF-stimulated HUVEC 
contained a similar level of MMP-7 as found in HT-29 colon cancer cell medium as 
quantified by a specific MMP-7 activity assay (24 versus 15 ng/ml respectively) and 
illustrated on the immunoblot in Figure 2 in medium and cell homogenates. 
  
Subsequently, we used a 3-dimensional in vitro endothelial cell sprouting model to confirm 
our immunohistochemical and cell culture data. Figure 1F shows the presence of MMP-7 in 
VEGF-treated sprouting HUVEC. As expected, these cells stained also for CD105. Without 
VEGF stimulation HUVEC did not form sprouts and also stained less intense for MMP-7 and 
CD105 (data not shown). Addition of 1μg/ml Marimastat, a broad-range MMP inhibitor, 
prevented VEGF-mediated sprout formation completely (insert Figure 1F), suggesting the 
involvement of MMP activity in tumour angiogenesis. 
We evaluated the relation of MMP-7 expression in endothelial cells as well as cancer cells 
from the 30 cervical cancer patients with the clinico-pathological parameters described in the 
Patients, materials and methods section. None of these parameters were significantly 
correlated with MMP-7, except for the expression in endothelial cells with survival (Low 
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Figure 2. Immunoblot staining MMP-7 in endothelial 
cells and culture medium. 
rec: recombinant active MMP-7; hom: homogenates 
of HUVEC grown on collagen type I and treated with 
100 ng/ml VEGF; med: serum-free culture medium of 
HUVEC treated with VEGF. Arrows indicate presence 
of active (18 kDa) and pro-form (28 kDa) of MMP-7. 
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MMP-7 expression in tumour cells of these patients was not correlated with survival (Log 
Rank 1.91, P=0.17, Fig. 3b). In multivariate analysis against all the clinico-pathological 
parameters all the univariate significant parameters, i.e. endothelial MMP-7 staining, FIGO 
stage, infiltration depth, and parametrial invasion lost their statistical significance due to the 




Previously, MMP-7 has been found in early adenoma epithelial cells, in malignant cells at the 
invasive front, and in colon-derived liver metastases11,12. MMP-7 staining was also 
demonstrated in colonic endothelial cells adjacent to MMP-7 positive malignant epithelial 
cells, without detectable MMP-7 mRNA levels in endothelial cells3. Our results show the 
presence of MMP-7 in angiogenic endothelial cells in various cancer types. Endothelial 
MMP-7 expression was not dependent on the proximity of malignant MMP-7 expressing 
epithelial cells, suggesting an endogenous endothelial origin. RT-PCR data indicated that 
endothelial cells under angiogenic conditions are indeed able to express MMP-7. Moreover, 
Figure 3. Kaplan-Meier survival curves for cervical cancer patients stratified for Low (score 0-4) and High 
(score 5-8) MMP-7 immunohistochemical staining. A) MMP-7 in endothelial cells (LR 5.12, P=0.02). B) 
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we have shown that under conditions closely resembling the in vivo neo-angiogenic process, 
MMP-7 up-regulation in endothelial cells coincides with sprout formation. Addition of 
Marimastat, a broad-range MMP inhibitor, prevented sprout formation completely without 
affecting cell viability. This suggests that endothelial cell-derived MMPs are involved in neo-
angiogenesis. From all MMPs, especially MMP-7 could be of key importance in cancer, 
because it acts locally due to its cell membrane-adhering properties, secondly because it is 
able to activate other pro-MMPs like MMP-2, -8 and -9, and thirdly because of its capacity to 
release/cleave other important bioactive molecules13. The importance of MMP-7 in 
angiogenesis was underlined by the clinical data from our study, showing an association 
between endothelial MMP-7 expression and decreased survival in cervical cancer patients. 
Multivariate analysis did not reveal endothelial MMP-7 staining as a independent prognostic 
marker against clinico-pathological parameters, but this was probably due to the strength of 
one of these parameters in this small population: 17 of the 18 deceased patients had a distant 
metastasis. Support for endothelial MMP-7 as a prognostic indicator was recently provided by 
a study in 156 renal cell cancer patients14. 
In conclusion, MMP-7 expression was demonstrated in endothelial cells of various tumours 
and was associated with decreased survival in a cohort of cervical carcinoma patients. 
Considering the role of MMP-7 as local activator of proteinases and other biologically active 
proteins, specific inhibition of MMP-7 could contribute to inhibition of angiogenesis and anti-
cancer therapy in general. 
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Abstract 
Up-regulation of matrilysin (matrix metalloproteinase-7), a target gene of the APC-Wnt 
pathway, has been found in epithelial cells of colonic tumours, where it is involved in the 
degradation of extra-cellular matrix and the activation/shedding of cytokines, growth factors, 
and adhesion molecules. Because the proteolytic effect of matrilysin depends on the co-
expression of activators, measurement of matrilysin activity should in principle be more 
relevant for clinical purposes than the detection of mRNA or protein. We developed an 
immunocapture bioactivity assay (BIA) that simultaneously detects the total amount as well 
as the activity of matrilysin in biological samples, including tissue homogenates. The BIA 
was validated for gastric cancer homogenates using an established commercial ELISA and 
immunoblotting. The matrilysin BIA was used for a pilot study on homogenates from human 
colonic adenomas and carcinomas. Both active as well as total matrilysin levels were 
enhanced in neoplastic tissues compared to normal mucosa. However, samples from 
adenomatous origin showed more pronounced differences between active and total matrilysin 
levels than carcinoma samples. Low matrilysin activity accompanied by an enhanced total 
level indicates an incomplete activation mechanism, which reflects the multi step nature of 
colon carcinogenesis. Therefore, the simultaneous detection of total and active matrilysin 
levels could be of clinical relevance.  
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Introduction 
Matrilysin (matrix metalloproteinase-7, MMP-7) is the smallest member of the MMP family. 
It is secreted as a 28 kDa inactive pro-enzyme and activated by cleavage to a 19 kDa form1. In 
contrast to other secreted MMPs, production of matrilysin has been shown mainly in 
epithelial cells. Targets of matrilysin include collagen, osteopontin, pro-TNF-α, β-integrin, α-
defensins, E-cadherin, and Fas-Ligand2. The nature of its substrates, combined with the 
enhanced expression by malignant epithelial cells suggests an important role for matrilysin 
during carcinogenesis. Knock-out studies confirm that intestinal tumourigenesis is suppressed 
in mice lacking matrilysin3. Matrilysin is a target of the APC-Wnt pathway, often affected in 
early stages of colorectal carcinogenesis. Immunohistochemical studies have indeed shown 
the enhanced presence of matrilysin in early stage colorectal neoplasia4, but also a correlation 
of matrilysin with Dukes classification and metastasis5. The clinical potential of matrilysin 
has recently been emphasized by different studies reporting the predictive value of enhanced 
matrilysin mRNA levels for the presence of metastasis and survival of patients with colonic or 
rectal cancer6,7. If matrilysin mRNA levels are already clinically relevant, than protein levels, 
especially of the active form, should be even more informative. The primary aim of our study 
was to measure matrilysin protein levels in homogenates derived from human gastrointestinal 
cancer tissues. For this purpose we developed a simple 96-well immunocapture bioactivity 
assay (BIA) for determining the activity of matrilysin in tissue homogenates. The BIA is 
based on a well established substrate consisting of modified pro-urokinase, in which the 
activation sequence was replaced by an amino acid sequence which is specifically recognized 
by MMPs8. The BIA uses specific antibodies to capture matrilysin and a chromogenic peptide 
substrate for urokinase for detection. In principle the BIA detects the amount of matrilysin 
that is present in the activated form. Activation of pro-matrilysin using APMA (4-
aminophenylmercuric acetate) in parallel incubations should express the total amount of 
matrilysin in the sample. 
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Patients, materials and methods 
Fresh tissue specimens from patients who underwent resection for gastric or colonic neoplasia 
at the department of Oncologic Surgery of the Leiden University Medical Centre were 
collected. Normal colonic tissue samples were taken at least 5 cm from the carcinomas 
(n=15). Representative parts of the whole carcinomas and adenomatous polyps (n=15) were 
selected. Samples were snap-frozen and stored at -70ºC until extraction. Homogenization of 
tissue specimens and determination of protein concentrations were performed as described 
previously9. Plasma from citrated blood and early morning urine were collected from patients 
with colorectal carcinoma before surgical therapy (6♂/2♀, age 40-70 years). The study was 
performed according to the instructions and guidelines of the LUMC medical ethics 
committee. Anti-matrilysin antibodies were mouse monoclonal and goat polyclonal (both 
from R&D Systems Europe, Abingdon, UK) and rabbit polyclonal (Abgent, San Diego, 
USA). The commercially available ELISA for total human matrilysin (Quantikine, R&D 
Systems Europe) was carried out according to the manufacturer's instructions using 10 μl of 
tissue homogenate. The matrilysin specific immunocapture activity assay was adapted from a 
MMP-9 activity assay as described previously10. In short, 96-well plates (Maxisorb, Nunc) 
were coated with 100 μl matrilysin specific antibody for 2 hours at 37ºC, and blocked for 2 
hours with StabilCoat (Diarect AG, Freiburg, Germany). After washing (4x PBS containing 
0.05% (v/v) Tween-20), matrilysin from standard (human recombinant 0-32 ng/ml, R&D) or 
sample was allowed to bind for 16 hours at 4ºC in assay buffer (50 mM Tris-HCl pH7.6, 1.5 
mM NaCl, 0.5 mM CaCl2, 1 μM ZnCl2 and 0.01% (v/v) Brij-35). After activation of parallel 
incubations in assay buffer containing 1 mM APMA (Sigma-Aldrich), the plates were washed 
(4x) and incubated with assay buffer to which 7.5 μg/ml modified pro-urokinase8 and 0.96 
mM chromogenic substrate S-2444 (Chromogenix, Mölndal, Sweden) were added. Color 
development was recorded by measurement of OD450 using a Molecular Devices Microplate 
Reader during 7 hours. 
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Results and discussion 
Figure 1a shows standard curves of APMA-activated recombinant matrilysin detected after 
coating with various dilutions of 3 different catching antibodies. The mouse monoclonal 
antibody which performed well in immunohistochemistry and western blotting, did not 
capture detectable levels of matrilysin in the BIA, not even in an coating-antibody 
concentration of 10 µg/ml. The rabbit antibody worked better, but the highest levels of 
matrilysin were captured by the goat polyclonal antibody. The low cross-reactivity (<5%) of 
this particular antibody with rhMMP-1, -2, -3, -8, -9, -10, -12, and -13, as indicated by the 
manufacturer, was confirmed in the BIA by spiking with 32 ng/ml active MMP-2, -3, -9, -14 
(0-8% cross-reactivity). 
To validate the BIA we first measured the total matrilysin content of 11 tissue homogenates 
derived from gastric cancer patients using a commercial ELISA detecting total matrilysin 
(active and pro-form). The homogenates were selected for increasing matrilysin content 
(numbers 1-11 in Figure 1b) consisting of 3 normal tissue and 8 carcinoma samples. These 
levels were compared with the matrilysin data as found with the BIA in parallel 
determinations, i.e. with or without APMA activation. The total amount of matrilysin 
according to the BIA correlated significantly with the data obtained by ELISA (Pearson’s r = 
0.910; P<0.0001, n=11), but active matrilysin did not (Figure 1b, open versus closed circles 
respectively). Apparently, some gastric carcinoma samples contained relatively little active 
matrilysin compared to the total amount, whereas other samples contained almost exclusively 
active matrilysin. This phenomenon was confirmed using western blotting. The two most 
pronounced examples from the BIA (majority pro- versus majority active matrilysin) are 
depicted in the insert in Figure1b, showing the corresponding prominent bands in the 
respective homogenates. To validate the BIA further, we spiked all these samples with a fixed 
amount of active recombinant matrilysin, leading to a steady increase in all homogenates, 
except for the 2 highest samples (Figure 1b). The latter was due to the high endogenous 
matrilysin level within these samples. Repeated (3- to 5-fold) measurements of the same 
samples within and between different assays resulted in an intra-assay coefficient of variation 
of 3.2% and an inter-assay variation of 8.4%. Gastric cancer tissues showed markedly 
enhanced levels of active as well as total matrilysin compared to the normal mucosa (Figure 
1b), confirming our previous ELISA data on matrilysin in gastric cancer11,12. The matrilysin 
BIA was then used for homogenates from colonic tissue samples. Figure 1c shows the active 
and total fraction of matrilysin in respectively colonic mucosa, adenomas and carcinomas.  
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In general, matrilysin levels were strongly enhanced in neoplastic tissues of the colon. 
Especially in case of the pre-malignant adenomas, specific samples showed a dramatic 
difference between the total amount of matrilysin and the active form, indicating a large pool 
of pro-matrilysin and suggesting a (still) ineffective activation mechanism. Finally, the 
applicability of the assay was also determined for plasma and urine. Plasma from colorectal 
cancer patients (n=8) contained 31-46 ng/ml active and 40-75 ng/ml total matrilysin. In the 
urine from the same patients all matrilysin was present in the active form (27-208 ng/ml). 
High urinary levels of MMP-2 and MMP-9 have previously been shown to be associated with 
Figure 1. A) Standard curves for APMA-activated 
recombinant human matrilysin using a 96-wells format 
activity assay and different coating antibodies against 
matrilysin. B) Homogenates derived from normal gastric 
mucosa (numbered 1-3) and carcinoma tissue (4-11), 
selected for stepwise enhanced matrilysin levels as 
determined with an ELISA (horizontal axis), were 
compared with the matrilysin specific activity assay, 
which detects the total (○) and active (●) form of the 
enzyme in parallel (vertical axis). Horizontal stripes 
indicate the values measured with the activity assay 
using the same homogenates, but spiked with a fixed amount of recombinant matrilysin. The insert represents 
a western blot of samples 10 and 11 and APMA-activated recombinant human matrilysin (aMMP-7), using 
mouse anti-matrilysin. Molecular weight markers are indicated (MW). C) Active and total matrilysin levels in 
homogenates from normal and (pre) malignant colonic tissue according to the matrilysin activity assay. The 
group medians are indicated (-), to illustrate the relatively high differences between total and active 
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tumour stage and grade in urothelial carcinomas13,14. The fact that matrilysin is most likely 
derived from malignant epithelial cells, in contrast to MMP-2 and MMP-9, suggests a 
potential application for urinary matrilysin as tumour marker, which is presently under study. 
In conclusion, this study introduces an assay to determine total as well as active matrilysin 
and the applicability was validated for biological samples from patients with gastrointestinal 
(pre-)malignancies. The assay was constructed in the light of the recent publications 
suggesting a predictive value of matrilysin mRNA in colorectal cancer tissue for the presence 
of metastasis and the survival of the patients6,7. Measurement of matrilysin protein levels, 
especially of the active form, is expected to be at least as clinically relevant, because the 
oncogenic function of the proteinase should be directly correlated to the enzyme activity and 
only indirectly to the potential pool of enzyme (i.e. up-regulated mRNA and/or protein). Our 
preliminary results indicate indeed a discrepancy between total and active levels of matrilysin 
in particular neoplastic samples, illustrating regulatory processes in the effectiveness of the 
matrilysin activation mechanism. The clinical relevance of this phenomenon should still be 
verified however, using larger groups of patients. 
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Abstract  
In this report, we describe a novel phage display strategy for the identification of dedicated 
protease inhibiting peptides, based on degradation-aided enrichment of protease resistant 
phages. Phages were directly incubated with a range of phage-degrading proteases, after 
which non-degraded phages were used for the next selection round. For proteinase-K we 
identified after only four selection rounds a peptide (VLIMPVLLGIPLLC) that inhibits 
proteinase-K activity with an inhibition constant of 4 μM. In analogy, we identified a peptide 
capable of inhibiting substrate degradation by cathepsin-S (VWNCERITISRLIN), which 
showed functional inhibition of cathepsin-S induced sprouting of endothelial cells. We 
envision that the pursued strategy of degradation-aided selection of protease inhibitors 
(DASPI) represents an effective approach in the design of new protease inhibitors but also of 
new strategies to render gene and drug vectors protease resistant.  
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Introduction 
Proteases play essential roles in biological processes as non-specific mediators of protein 
degradation and in specific cleavage events. Especially imbalanced regulation of protease 
activity leading to basement membrane degradation and excessive release of bioactive 
molecules (e.g. growth factors, chemoattractants, angiogenic molecules) is of major 
importance in inflammatory disease and cancer progression1-5. Furthermore it also poses a 
major hurdle in drug and gene delivery protocols6.   
Therefore, design of selective protease inhibitors constitutes a major scientific and 
pharmaceutical challenge. Several approaches including combinatorial chemistry7,8, 
positional-scanning of synthetic libraries9 and oriented synthetic peptide libraries10 have been 
used to develop protease inhibitors. Furthermore combinatorial repertoire cloning and 
peptide/protein phage display have shown to hold great promise in the design of peptide 
ligands11-13 such as caspase inhibitors14 and DNaseII inhibitors15. Generally, identification of 
binding peptides/proteins is based on affinity-selection for a selective agent (antigens or cells) 
that is immobilized on a solid support16-18. A possible disadvantage of these selection 
procedures is their rather unbiased nature that generally favours the selection of binders rather 
than functional antagonists. 
In this study, we present a new selection strategy to identify functionally active protease 
inhibitors: degradation-aided selection of protease inhibitors (DASPI, Figure 1). In DASPI, 
phages are directly incubated with the target protease and selection pressure is based on the 
extent of phage degradation. We show the effectiveness of DASPI in the identification of 
peptide sequences inhibiting proteinase-K and cathepsin-S, which could further be chemically 
optimised.  
 
Materials and methods 
Materials  
Phagemid libraries pComb8, with a constrained 6 (CX6C) or 15 amino acid (CX15C) insert 
and pComb3 with a linear 6 (X6) or 15 amino acid (X15) insert were generous gifts from Prof. 
H. Pannekoek, Amsterdam Medical Center, Amsterdam, The Netherlands. MOPS was from 
Boehringer Mannheim, Mannheim, Germany. BSA was obtained from Sigma, St Louis, MO, 
USA. Phenyl Methyl Sulphonyl Fluoride (PMSF) and E64 cysteine protease inhibitor were 
supplied by Sigma-Aldrich, Steinheim, Germany. VCSM13 was from Stratagene, La Jolla, 
CA, USA.  Cathepsin-S (bovine spleen and human spleen), cathepsin B (human liver), calpain 
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I (human erythrocytes) and cathepsin inhibitor I were purchased from Calbiochem, San 
Diego, CA, USA. The specific cathepsin-S substrate (Z-Val-Val-Arg-AMC) was purchased 
from Bachem, Weil am Rhein, Germany. 
 
Determination of colony forming units (CFU)  
Escherichia coli (XL-1-blue) was grown at 37°C to mid-log phase (OD600 = 0.6-0.8) in Super 
Broth (SB) medium (30 g/l tryptone, 20 g/l yeast, 10 g/l MOPS) containing 20 μg/ml 
tetracycline (tet). M13-bacteriophage libraries containing an ampicilin (amp) resistance gene, 
were diluted in TBS and allowed to infect XL-1-blue (100 μl, 30 min, 37°C). Infected 
bacteria were plated on amp (100 μg/ml) containing LB agar, incubated overnight (o/n) at 
37°C and CFU were counted. 
 
Phage amplification 
The selected phage pool (10 μl) was incubated with 100 μl bacterial culture in the mid-log 
phase (30 min). Infected bacteria were plated on amp-containing agar plates and incubated o/n 
at 37°C. Colonies were dissolved in 10 ml SB/tet/amp medium and incubated for 30 min at 
37°C. 200 μl was transferred to 10 ml SB/tet/amp (30 min, 37°C) and helper phage VSCM13 
was added in a 20-fold excess (2 hours, 37°C). Kanamycin (125 μg/ml) was added and the 
culture was incubated o/n. Bacteria were centrifuged (5,000 rpm, 20 min) and  phage 
containing supernatant was precipitated by addition of  2.5 ml 20% PEG/23.4% NaCl and 2 
hour incubation on ice. Phages were centrifuged (10,000 rpm, 20 min) and the pellet was 
washed in TBS (30 min at 37°C).  
 
Phage selection 
Phage libraries (1010 CFU, 1 μl in TBS) were incubated with 100 μg/ml proteinase-K at 0°C. 
After 1 hour, proteolysis was quenched by addition of 50 μl of buffer containing 1% BSA, 10 
μM PMSF, 10 mM EDTA to inactivate proteinase-K. For bovine cathepsin-S selection, phage 
libraries (1010 CFU in TBS) were incubated with 20 pmol enzyme for 24 hours at 37°C in 100 
μl protease buffer (50 mM NaAc, 1 mM dithiothreitol (DTT), 1 mM EDTA, pH 5.5). 
Selection was stopped by adding 10 μl cathepsin inhibitor I (20 pmol in DMSO). Protease 
resistant phages were incubated with 100 μl E.coli XL-1 blue log culture (30 min, 37°C) and 
the suspension was incubated o/n at 37°C on LB/amp plates. Phages were titrated, amplified 
and purified as described12. For DNA sequencing, plasmid DNA was isolated from single 
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colonies using the Wizard Plus SV miniprep DNA purification System (Qiagen, Westburg, 
Belgium). DNA sequencing was conducted at the Leiden Genome Technology Centre 
(LGTC), Leiden, The Netherlands, using a standard M13 primer12.  
 
Evaluation of proteinase-K inhibition by SDS-PAGE  
Phages (109 CFU) were incubated with BSA (10 μg) and proteinase-K (50 μg) at 0°C (in PBS, 
100 μl). After 1 hour PMSF (1 mM, 5 μl) was added. Degradation of BSA was evaluated by 
SDS-PAGE (15%). Proteins were stained with Bio-Safe Coomassie brilliant blue G250 (Bio-
rad laboratories, Hercules, CA, USA).  
 
Peptide synthesis 
Peptide sequences (K1: VLIMPVLLGIPLLCY; K1-C: VLIMPVLLGIPLLY, S1: 
VWNCERITISRLIN; S2: c-LRNSPRKQADRIL-c) were synthesized according to standard 
Fmoc solid phase chemistry. The terminal tyrosine was added to allow (radio) labelling of the 
peptide. After cleavage from the resin and simultaneous deprotection in 94.5% trifluoroacetic 
acid, 2.5% ethane-dithiol, 2.5 % H20 and 0.5% tri-isopropylsilane,  the crude peptides were 
precipitated by diethylether and purified on a reverse phase C18 column (Alltech, Deerfield, 
IL, USA) using a  20-90 % acetonitril/water gradient. Peptide mass and purity (> 70% for all 
peptides) was verified by LC-Mass Spectrometry.  
 
Evaluation of protease inhibition  
For the proteinase-K degradation assay, 125I-BSA (1 μg), iodated according to McFarlane19, 
was incubated with proteinase-K (50 μg) in the presence or absence of K1 and K1-C peptide. 
Samples were incubated for 30 min at room temperature in triplicate. The reaction was 
quenched by addition of excess BSA (800 μg) and trichloroacetic acid (35% v/v; 200 μl) to 
precipitate BSA. After centrifugation the percentage degradation was calculated from the 
radioactivity in the supernatant (degraded BSA) relative to a control sample without peptide.   
The inhibitory capacity of the S1 and S2 peptides was assessed by a fluorometric assay. 
Human cathepsin-S (5nM) was incubated in 100 mM NaAc, 2 mM EDTA and 1 mM DTT in 
0.1% Brij 35, pH 5.5 in the presence or absence of peptide (0-70 μM; 0.25% DMSO/100 mM 
NaAc final concentration) for 15 min at RT. Cathepsin-S specific substrate (Z-Val-Val-Arg-
AMC; 10 μM in 1% ethanol/0.002% DMSO/100 mM NaAc) was added and the A360/480 
was monitored at 28°C during 60 minutes20. As a measure of residual enzymatic activity, the 
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slope in Relative Fluorescence Units/time (ΔRFU/min) was calculated for all individual 
samples. Percentage degradation was calculated relative to the control (in 0.25% DMSO/100 
mM NaAc).  
All IC50 values were determined by non linear regression analysis for a single site binding 
model (Graphpad-prism 4.0). 
 
Cell culture and spheroid formation 
HT29 colon carcinoma cells were grown in DMEM/F12 (Invitrogen) supplemented with 10% 
heat inactivated Fetal Calf Serum (FCS, Perbio Science, Belgium), 10 mM HEPES, 50 μg/ml 
gentamycin, 100 U/ml penicillin and 100 μg/ml streptomycin (all Invitrogen). HT29 
spheroids (2,500 cells/well) were generated by the agarose liquid overlay technique as 
described before21, collected after 48 hour and incubated in 500 ng/ml human spleen 
cathepsin-S containing serum free (SF) DMEM/F12 in an agarose coated 48 well plates (10 
spheroids/well in 100 μl). After 24 hour incubation conditioned medium (CM) was collected 
and applied to the HUVEC sprouting assay. Inhibition studies for the S1 peptide (stock 1 
mg/ml in SF DMEM/F12) and the cysteine protease inhibitor E64 (in PBS, stock 1 mg/ml) 
were performed by pre-incubating cathepsin-S with the peptide inhibitors for 15 minutes at 
room temperature before addition to the HT29 spheroids.  
Human umbilical vein endothelial cells (HUVEC) were isolated according to Jaffe et al.22. 
Cells (passage 6-9) were grown in fibronectin coated flasks (0.05 mg/ml) in M199 medium 
(Invitrogen) supplemented with 20% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin, 2 
mM glutamin (Invitrogen), 0.05 mg/ml heparin and 12.5 μg/ml endothelial growth factor 
supplement (Sigma-Aldrich). 
 
HUVEC sprouting assay 
HUVEC spheroids were prepared as described before23. In brief, HUVEC cells were 
suspended in complete M199 medium containing 0.1% carboxymethylcellulose (Sigma-
Aldrich) and seeded into 96 well U-shape suspension culture plates (Greiner Bio-one, The 
Netherlands, 750 cells/well). After 24 hour incubation HUVEC spheroids were embedded in 
33% collagen type I (1 mg/ml, Vitrogen 100, Nutacon, CA, USA). The HUVEC spheroids 
were treated with HT29 spheroid CM. Sprout formation was determined after overnight 
incubation and scored on a 0 (absent) - 5 (abundant) scale in a double blinded manner. 
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Experiments were performed in triplicate. Representative photomicrographs were made using 
a Zeiss Axiovert 200 microscope. 
 
Results 
Screening for protease inhibitors 
We developed a method to select potential protease inhibitors by the use of the phage 
degrading capacity of proteases. Excess of protease is used to create the highest possible 
selection pressure. Only phages displaying peptides capable of resisting protease treatment 
survive selection (Figure 1).  
 
We incubated proteinase-K or cathepsin-S with the pComb8 (CX15C) library and observed 
more than 99.9% of the phages being degraded by proteinase-K and 99.8% by cathepsin-S. 
Other proteases including cathepsin B and calpain, although less potent (respectively 99.7% 
and 99.6% phage degradation), still were capable of degrading phages and therefore creating 
selection pressure. 
For selection, all phage libraries were incubated with proteinase-K (proof of principle), or, 
therapeutically interesting, cathepsin-S. After proteolysis, non-degraded phages were isolated, 
amplified, and used as template for a subsequent selection round. After four selection rounds 







Figure 1. Concept of degradation-aided selection of 
protease inhibitors (DASPI).  The phage library 
displaying different peptides (step 1) is incubated 
with a protease (step 2) to degrade non-inhibiting 
phages. A protease inhibitor is added to the mixture 
(step 3) to stop the selection procedure by 
inactivating the protease. In step 4 and 5 the non-
degraded phages are recovered and phages are 
amplified. Amplified phages are then subjected to a 
second selection round and the procedure is 
repeated until sufficient enrichment is achieved. (B) 
Schematic presentation of the pComb3 phage 
library with displayed peptides (arrowhead). 
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In contrast, the pComb3 15-mer libraries showed that input-to-output ratios were increased by 
40,000-fold for proteinase-K (Figure 2A) and 3,500-fold for cathepsin-S (Figure 2B), 
reflecting a substantial enrichment of protease resistant phages.  
 
DNA sequence analysis revealed for proteinase-K, that 70% of the phage clones contained the 
VLIMPVLLGIPLLC (K1, table 1) sequence, suggesting that this sequence may be 
instrumental in proteinase-K resistance. Furthermore, two phage clones, K2 and K3 were 
identified with highly homologous peptide inserts (10 out of 15 amino acids, table 1).  
Selection of the pComb3 and pComb8 libraries for cathepsin-S resistant clones revealed two 
major peptide sequences (S1: VWNCERITISRLIN; 50% and S2: c-LRNSPRKQADRILN-c; 
60%; table 1).  
 
Table 1. Peptide sequences identified by DASPI  
Protease Library Enrichment** Peptide sequences Code Occurrence 
(%) 
Proteinase-K pComb3 (X15) 40,000 VLIMPVLLGIPLLC* K1 70% 
   VXNCERITISRILN* K2 10% 
   VXNCERITISQNSKL K3 10%  
   RSLNHASSFGYSVIM  10% 
Cathepsin-S pComb3 (X15) 3,500 VWNCERITISRLIN* S1 50% 
 pComb8 C(X15)C 200 c-LRNSPRKQADRILN*-c S2 60% 
**As compared to non-selected phage.* signifies a stopcodon, which is ignored and overran during 
















































































Figure 2. A) Selection for proteinase-K resistant phage clones in the pComb3 library resulted in a 40,000-fold 
enrichment of proteinase-K resistant phage after 4 selection rounds. B) Selection for cathepsin-S resistance 
resulted in a 3,500-fold enrichment of cathepsin-S-resistant phages in the 4th selection round, using the 
pComb3 library. All values are expressed as the ratio between output and input titer (%). 
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Proteinase-K inhibition by K1 
To examine if clones K1, K2, and K3 were more resistant to proteinase-K degradation than 
non-selected phages, individual clones were amplified and tested for their ability to interfere 
with proteinase-K degradation. Selected phage pools withstood proteinase-K degradation 
better than non-selected phages, which were completely degraded (Figure 3A). Besides being 
more resistant to proteinase-K degradation, the phages also conferred protection of BSA to 
proteinase-K degradation (Figure 3B).  
 
Next, we investigated whether synthetic peptides corresponding with the peptide sequence 
insert of the selected phage clones also could inhibit protease activity. VLIMPVLLGIPLLCY 
(K1), a truncated K1 mutant lacking the C-terminal cysteine (K1-C), VWNCERITISRLIN 
(S1) and c-LRNSPRKQADRIL-c (S2) were synthesized.  Both K1 and K1-C peptides were 
able to inhibit 125I-BSA degradation by proteinase-K in a dose-dependent manner (Figure 3C) 
with IC50 values of 4 and 91 μM, respectively. Maximal inhibition was more than 95% at 50 
μM [K1]. The considerably lower potency of K1-C suggests that the C-terminal cysteine may 
be important for proteinase-K inhibition.  





























































Figure 3. A) Resistance of selected phage clones 
K1-K3 to proteinase-K mediated degradation 
(Control= no phages, NS= non selected control 
phage). B) Inhibition of proteinase-K induced BSA 
degradation by phage clones K1 to K3. (MW, 
molecular weight marker; BSA, 10 μg BSA; control, 
BSA with proteinase-K). C) Concentration 
dependent inhibition of 125I-BSA degradation by 
synthetic peptides K1 (■) and K1-C (●). The IC50 
value of K1 was calculated to be 4 μM, as 
compared to 91 μM for the truncated peptide (K1-
C). Values are means ± SD of two determinations in 
triplicate. 
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Functional cathepsin-S inhibition by S1 
The inhibitory capacity of the cathepsin-S peptides S1 and S2 was tested in a fluorometric 
activity assay. Both peptides showed concentration dependent inhibition of cathepsin-S with 
IC50 values of 13 and 26 μM, respectively (Figure 4A). S1 gave a maximum inhibition of 75 























The DASPI selected cathepsin-S inhibitors were tested for functionality in a HUVEC 
sprouting assay. Conditioned medium (CM) from cathepsin-S-treated HT29 spheroids 
induced HUVEC sprout formation in a dose dependent manner (0-1000 ng/ml, not shown). 
Cathepsin-S (500 ng/ml) induced sprouting (Figure 4B1/B5) depended on the presence of 
HT29 spheroids (Figure 4B2/B5), probably reflecting cathepsin-S induced release of pro-
angiogenic factors. The S1 peptide (70 μM) completely blunted this cathepsin-S induced 
sprout formation (Figure 4B3/B5). CM from 0 ng/ml cathepsin-S treated HT29 spheroids 













































































































































































) Figure 4. A) Concentration dependent 
inhibition of cathepsin-S activity by S1 (■) and  
S2 (●) peptides. The IC50 value obtained for S1 
was 13 μM and for S2 26 μM. B) S1 inhibits 
cathepsin-S induced sprouting in an in vitro 
angiogenesis assay. Cathepsin-S (500 ng/ml) 
induced sprouting of HUVEC cells (B1) only in 
the presence of HT29 spheroids (B2). 
Cathepsin-S induced sprouting could be 
completely inhibited by the S1 peptide (70 μM, 
B3) comparable to E64, a reference cysteine protease inhibitor (B4, 70 μM). Semi-quantitative analysis (B5) 
shows complete inhibition of cathepsin-S induced sprout formation by S1 and E64. Data are given as 
average percentage sprouting, ± SEM, n=6.  
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showed a minor increase compared to CM that was not incubated with HT29 spheroids, likely 
attributable to endogenous cathepsin-S secreted by the HT29 spheroids (cathepsin-S activity 
assay, not shown).  As a control we included the cysteine protease inhibitor E64, which 
showed a similar dose-dependent inhibition (70 μM, Figure 4B4/B5) as observed for the 
DASPI selected inhibitor. These data illustrate that the DASPI selected S1 peptide is an 
effective cathepsin-S inhibitor, not only in vitro but also in a complex multi-cellular system. 
 
Discussion 
The identification of culprit proteases and their role in the release of growth factors, 
chemoattractants and angiogenic molecules is critical to numerous (patho)-physiological 
processes. Specific protease inhibitors would greatly facilitate functional and therapeutic 
studies. The data presented in this study show that DASPI is an effective strategy, to select 
functionally active protease inhibitors. The mechanism of selection is based on inhibition of 
the protease by the phage displayed peptide. The pComb3 libraries display the peptide on the 
minor coat protein (Figure 1b), which makes it sterically possible to bind the active site of the 
protease. Although it seems unlikely that the displayed 15-mer peptide could prevent the 
whole phage from degradation there are several lines of evidence. In the first selection round 
99.9% of the phages are degraded while after 4 rounds, 40,000 fold enrichment is observed 
and 70% of the phages contain an identical peptide sequence. These phages resist protease 
degradation much better than non-selected phages which are completely degraded by the 
protease. Secondly, synthetic peptides corresponding to the  sequences obtained in selection 
show indeed to be potent protease inhibitors. Protease inhibition by the phage might be 
occurring via binding of the displayed peptide in the active site of the protease and thereby 
preventing its proteolytic activity. As the 6-mer libraries show no enrichment during 
selection, probably 6 amino acid peptides are too short to bind the active site.   
Proteinase-K-resistant phage clones K2 and K3, the less inhibiting sequences, did not exhibit 
significant homology to known protease inhibitors after discontinuous blast search. The most 
abundant and most inhibiting sequence K1 revealed a considerable homology (77%) with a 
short peptide stretch of the Kuniz-type serine-protease inhibitor from C. elegans (nine C-
terminal amino acids including the terminal cysteine residue). Furthermore it showed 
homology to the phage coat protein D, but as non-selected phages are completely degraded by 
proteinase-K is it unlikely that non-specific inhibition by one of the phage coat proteins 
occurs. Furthermore the synthetic K1 peptide appeared to be a potent proteinase-K inhibitor 
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(IC50=4 μM). A truncated peptide lacking the C-terminal cysteine (K1-C) had an almost 25-
fold lower inhibitory activity, suggesting that the C-terminal cysteine is critical to proteinase-
K inhibition. These data show that DASPI is able to identify inhibiting sequences homologous 
to known protease inhibitors, but also new sequences.  
Similarly, we have identified an inhibiting peptide sequence (S1) for cathepsin-S (IC50=13 
μM), which showed homology with serine-protease inhibitor 8 from R. norvegicus. 
Cathepsins are the major lysosomal proteases  involved in degradation of incorporated drug- 
and gene delivery systems, as well as in cleavage of extracellular matrix components24, 25. 
Cathepsin-S is therapeutically of great interest because of its immuno-regulatory properties 
and involvement in atherosclerosis26,27. Furthermore it is regarded as a prognostic marker in 
cancer28,29 and was shown to contribute to cancer progression by facilitating angiogenesis and 
cell migration leading to metastasis formation5,28-30. Several small inhibitors for cathepsin-
S20,31 have been devised and evaluated for therapeutic potential. A major hurdle in the design 
of inhibitors is the general lack of specificity, as the catalytic clefts of most serine- and 
cysteine-proteases are very similar in nature. A biased strategy towards identification of 
functional inhibitors rather than binders may facilitate the design of novel inhibitors with 
more favourable features in that regard. Further incorporation of optimized DASPI selected 
peptide inserts into gene or drug vehicles may reduce the susceptibility of these vectors to 
lysosomal elimination by endopeptidases2 such as cathepsin-S. We demonstrate here that the 
S1 peptide is equally able to inhibit cathepsin-S in an endothelial sprouting model as the 
cysteine-protease inhibitor E64. This confirms that S1 not only inhibits at a biochemical level 
but also functionally inhibits cathepsin-S induced angiogenesis. DASPI selected peptides 
could therefore be valuable lead compounds in the design of specific inhibitors to reduce 
cathepsin-S activity in the aforementioned disorders.  
In summary, we have shown that degradation-aided selection of phage display libraries for 
protease inhibitors is a rapid and powerful strategy to identify novel peptide sequences that 
confer resistance to and act inhibitory on the protease. We do not claim to have identified 
highly potent inhibitors for the mentioned proteases, but show that the pursued strategy may 
yield promising leads in the generation of dedicated protease inhibitors as it, unlike other 
methods, biases towards functionally active inhibitors. Moreover, DASPI is widely applicable 
to any protease, provided it is able to digest and/or inactivate phages. Proteases, which are not 
capable of degrading phages, may even serve as target after prior engineering of the phage 
libraries to render them susceptible to these proteases. 
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Abstract 
Endoglin is a TGF-β co-receptor, mainly expressed on angiogenic endothelial cells. Besides 
membrane-bound also a soluble form exists in the circulation. However, the role and shedding 
mechanism of this soluble receptor has not been established yet. Determination of Endoglin in 
colorectal neoplasia patients by ELISA revealed enhanced levels in carcinomas, but not in 
pre-malignant adenomas. Immunohistochemically, Endoglin was mainly observed in 
angiogenic endothelial cells, but also in fibroblasts in the normal-to-tumour transition zone. 
Pre-operative soluble Endoglin levels of colorectal cancer patients were not significantly 
different from plasmas of healthy controls, although mean levels were lower in these patients. 
We observed that low expression of Endoglin on endothelial cells was accompanied by high 
expression of MMP-14. In vitro experiments revealed high expression of MMP-14 in 
HUVEC endothelial cells, but treatment of these cells with endogenous MMP-14 did not 
increase soluble Endoglin levels in the medium. In contrast, co-transfection of membrane 
bound MMP-14 and Endoglin led to strongly enhanced soluble Endoglin levels. Furthermore, 
addition of MMP inhibitors inhibited the release of sEndoglin from HUVEC cells, in contrast 
to other proteinases inhibitors. In conclusion, we have shown that Endoglin expression is 
enhanced in colorectal cancer and we propose membrane bound MMP-14 to be a major 
candidate in generating soluble Endoglin.  
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Introduction 
Endoglin (CD105) is a 180 kDa integral membrane-bound glycoprotein, which serves as a 
high affinity co-receptor for Transforming Growth Factor (TGF)-β1 and -β31. Two Endoglin 
isoforms are known, L- and S-Endoglin, which differ in their cytoplasmic tail. L-Endoglin is 
mainly expressed on endothelial cells2. Mutations in the gene encoding Endoglin have been 
linked to hereditary haemorrhagic telangiectasia Type I (HHT-1), a multisystemic vascular 
disease characterised by bleeding from small vascular lesions in the mucocutaneous tissues 
and the presence of arteriovenous malformations2,3. Endoglin has a crucial role in 
angiogenesis, as Endoglin knock-out animals die in utero because of defects in the 
vasculature system4. Expression of Endoglin is mostly restricted to angiogenic endothelial 
cells, but has also been shown in tumour cells5, especially those with high invasive potential6, 
cardiac fibroblasts7, hepatocytes5,7 and several other cells5. Expression of Endoglin can be 
induced by hypoxia3,8, TGF-β11,9,10 and/or TGF-β311. Endoglin expression was shown to be 
upregulated in various cancers1 and correlated with development of metastatic disease in 
colorectal cancer (CRC)8. Together these data indicate a crucial role for Endoglin in tumour 
angiogenesis. 
Besides membrane-bound Endoglin, also a soluble form (sEndoglin) exists in the circulation3. 
Elevated levels of sEndoglin have been reported in pregnant women suffering from pre-
eclampsia12,13, patients with liver cirrhosis and hepatocellular carcinoma14, and colorectal- and 
breast cancer patients15-17. The mechanism by which Endoglin is released and the role of 
soluble Endoglin in the circulation has not been revealed yet. Betaglycan (TGF-β RIII), 
another TGF-β co-receptor, also has a soluble form in the circulation18. Shedding of 
membrane bound betaglycan has been found to be mediated by membrane type (MT)-1 
matrix metalloproteinase (MMP-14)19. MMP-14 is a membrane bound MMP which is 
expressed by epithelial cells, endothelial cells and stromal fibroblasts in the colon and is 
upregulated in cancer20. After intracellular activation by furin, MMP-14 is expressed on the 
cell-membrane, where it has a role in degradation of collagens and heparin sulphate 
proteoglycans (HSPGs)21 and is important in the activation of other MMPs22. 
In this study we evaluated if MMPs, in particular MMP-14, could play a role in the generation 
of soluble Endoglin in CRC. First, we examined tissue Endoglin levels in normal colonic 
mucosa, adenomas and carcinomas. Next, we determined pre- and postoperative sEndoglin 
levels in a group of CRC patients. Immunohistochemistry was used to determine cellular 
localisation and expression of Endoglin and MMP-14. Next, we analysed the Endoglin 
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shedding mechanism in vitro. The data indicate that MMP-14 is a major candidate for 
Endoglin shedding from endothelial cells.  
 
Materials and methods 
Patient material 
Pre- and three months postoperative citrate plasma samples (n=14) and tissue specimens 
(n=191) from patients undergoing resection for primary colorectal carcinoma at the 
Department of Oncologic Surgery, Leiden University Medical Centre, were collected as 
described before23,24. Colorectal adenomas (n=82) were removed endoscopically at the 
Department of Gastroenterology-Hepatology. Tissue were homogenised and protein 
concentrations were determined as previously23. For immunohistochemistry, tumour tissue 
and adjacent normal mucosa were collected, fixated, dehydrated and embedded in paraffin. 
Human samples were used according to guidelines of the Medical Ethics Committee of the 
Leiden University Medical Centre. 
 
Endoglin and sEndoglin ELISA 
Endoglin levels in tissue homogenates and cell culture media were determined essentially 
according to the DY1097 human endoglin DuoSet ELISA (R&D Systems, Abingdon, UK.  In 
short, 96 well plates (MaxiSorp, Nunc, Glostrup, Denmark) were coated with mouse 
monoclonal anti-human Endoglin antibodies (R&D Systems, 2 μg/ml in PBS) overnight at 
4˚C. Plates were washed with PBS containing 0.05% Tween-20 (Merck, Darmstadt, 
Germany) after each step. Aspecific binding was blocked with PBS containing 5% Tween-20, 
0.05% NaN3 for 2 h at room temperature (RT). Samples (5 μl tissue homogenates or 50 μl cell 
culture media) or standard (0-4 ng/ml recombinant human Endoglin, R&D Systems) diluted 
in PBS with 1% BSA were incubated during 2h at RT. Immunodetection was performed with 
biotinylated goat anti-human Endoglin antibodies (2 μg/ml in PBS/1% BSA, R&D systems) 
for 2h at RT, and a substrate reagent pack according to the manufacturers’ protocol (R&D 
Systems). Values were calculated in ng/ml for cell-culture media and in ng/mg protein for 
tissue samples. The ELISA was validated by western blot analysis and spiking with a fixed 
amount recombinant human Endoglin. For determination of Endoglin levels in citrate plasma 
samples a cross reactivity of the capture antibody with human serum albumin was observed. 
Therefore the capture antibody was replaced by mouse monoclonal anti-Endoglin (clone E9, 
Cell Sciences, Canton, MA, USA). The standard curve was diluted in PBS containing 40 
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mg/ml Humans Serum Albumin (Sigma) to correct for remaining background absorption. The 
ELISA was performed and validated as described above.  
 
Immunohistochemistry 
To determine cellular localisation of Endoglin immunohistochemistry was performed as 
described previously25. In short, slides were deparaffinised, rehydrated and antigen retrieval 
was performed by boiling in 0.01M sodium citrate buffer pH 6.0. Slides were incubated 
overnight (o/n) at RT with unlabeled primary antibodies: mouse monoclonal anti-
pancytokeratin (1:1000), mouse monoclonal anti-vimentin (1:400, both Santa Cruz 
Biotechnologies, Santa Cruz, USA), mouse monoclonal anti-smooth muscle actin (SMA, 
1:800, Progen, Heidelberg, Germany), mouse monoclonal anti-CD31 (1:400, Dako, Glostrup, 
Denmark), mouse monoclonal anti-MMP-14 (1:1600), or biotinylated goat-anti human 
Endoglin (1:200, both R&D systems). Immunodetection was performed with goat anti-mouse 
antibodies and streptavidin-biotin complex (all Dako). Staining was visualised with 
diaminobenzidine and H2O2. Representative photomicrographs were taken with a Nikon 
Eclipse E900 microscope equipped with a Nikon DXM1200 digital camera. 
 
In vitro experiments 
Human umbilican vein endothelial cells (HUVECs) were isolated26 and cultured as described 
before27. To examine the Endoglin cleavage mechanism HUVECs were seeded in fibronectin 
coated 24 well plates (Greiner Bio-one, 60,000 cells/well). After o/n attachment, cells were 
treated with 0-160 ng/ml recombinant human MMP-14 (Chemicon, Temacula, CA, USA) or 
with proteinase inhibitors: 20 μM E64 (cystein protease inhibitor), 10 μg/ml Aprotinin (serine 
protease inhibitor, both Sigma-Aldrich, Darmstadt, Germany), 1 μM GM6001 (broad 
spectrum MMP inhibitor, 10 μM Marimastat (kindly provided by British Biotech 
Pharmaceuticals), 100 nM MMP-2/MMP-9 inhibitor, 100 nm MMP-13 inhibitor or 1 μM 
specific MMP-3 inhibitor (all Calbiochem, La jolla, CA, USA). Serum Free (SF)-M199 
medium and 0.1% DMSO were included as controls. The percentage inhibition versus the 
appropriate control was calculated. For transfection experiments COS cells were transfected 
with plasmids (pcDNA3.1) encoding full length Endoglin, (kindly provided by Dr. E. Pardali, 
LUMC, Dept. of Molecular Cell Biology), full length MMP-14 or MMP-14 lacking the 
transmembrane domain (MMP-14ΔTM, both kindly provided by Dr. R. Hanemaaijer, TNO 
Quality of life BioSciences, Leiden, the Netherlands) and empty vector. COS cells were 
seeded in 24 well plates (Greiner Bio-one, 10.000 cells per well in DMEM containing 10% 
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FCS and penicillin/streptomycin) and after 48 hours cells were transfected with in total 0.4 μg 
plasmid DNA using Lipofectamin as a tranfection reagent, according to the manufacturers 
protocol (Invitrogen). 24 hours after transfection cells were incubated with SF-DMEM for 16 
hours and sEndoglin levels were determined by ELISA as described above. All experiments 
were performed in triplicate. 
 
Statistical analysis 
Differences were calculated using the Mann-Whitney U-test, or the Wilcoxon signed rank test  
using SPSS 14.0 statistical package. Correlation analysis was performed using Spearman’s 
correlation. P values <0.05 were considered statistically significant. 
 
Results 
Tissue Endoglin levels 
Before analysing the tissue and cell culture samples the Endoglin ELISA was validated.  
Standard curves of recombinant human Endoglin were linear in a 0-4 ng/ml range, with a 
detection limit was 0.125 ng/ml Endoglin. Spiking of tissue samples with a fixed amount 
recombinant Endoglin revealed an equal increase in signal (not shown). Figure 1A shows 
decreasing absorbance values with increasing dilution of a colorectal cancer tissue 
homogenate. Western blot analysis of the same sample revealed a similar pattern as observed 
by ELISA (figure 1B).  
Tissue Endoglin levels were determined in homogenates of 191 CRC homogenates, 
corresponding normal mucosa and 82 colorectal adenomas. Endoglin levels were significantly 
increased in carcinomas compared to mucosa, 2.72 ng/mg versus 5.36 ng/mg, p< 0.0001) or 
adenomas (2.45 ng/mg). Adenoma Endoglin levels were lower than normal mucosa (Figure 
1C). Analysis of clinico-pathological parameters revealed no associations between presence 
of dysplasia in adenomas and Endoglin levels, whereas in carcinomas the highest Endoglin 
levels were detected in Dukes stage C carcinomas (not shown). There were no significant 
associations between carcinoma tissue Endoglin levels and other clinicopathological 
parameters of the tumours.  
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Immunohistochemistry 
Immunohistochemistry on CRCs and normal mucosa revealed that Endoglin expression was 
low in normal mucosa except for some staining in the submucosal area (Figure 2, left panel, 
arrowhead). In tumours strongly increased Endoglin expression in angiogenic endothelial was 
observed in the proximity of tumour cells. Furthermore, expression of Endoglin was 
occasionally observed in fibroblasts, especially in the normal to tumour transition zone 
(Figure 2, right panel, arrowhead). CD31 stained all blood vessels in normal and tumour 
tissue (not shown). MMP-14 expression was observed in epithelial cells and endothelial cells. 
Interestingly, tumour endothelial cells strongly expressing MMP-14 were negative for 









Figure 1. Validation Endoglin ELISA and CRC tissue Endoglin levels. A) Endoglin ELISA absorbance values
for a increasing dilution series of a CRC homogenate. B) Endoglin western blot on the same CRC homogenate
rh= recombinant human Endoglin. C) Tissue Endoglin levels in normal colon mucosa, adenomas and
carcinomas 


































































Soluble Endoglin levels in CRC patients 
To detect soluble Endoglin in plasma samples, we developed an ELISA which was validated 
using a serially diluted plasma sample series and spiking of these samples with a fixed 
amount recombinant Endoglin (Figure 3A). To examine the presence of sEndoglin in the 
circulation of CRC patients we determined sEndoglin in pre- and three months postoperative 
plasma samples (Figure 3B). Table 1 shows median pre- and postoperative sEndoglin levels 
in patients (n=19) and in a group of healthy volunteers (n=15). Mean pre-operative sEndoglin 
levels were lower than the controls and increased post-operatively (Table 1), although these 
differences were not statistically significant. Interestingly, individual changes in sEndoglin 
levels pre- versus post-operation were apparent. There was no relation between sEndoglin 






Figure 2. Endoglin (CD105)immunohistochemistry on  normal mucosa (N, left panel) and colorectal cancer 
specimens. The lower panels  show staining on sequential sections for Endoglin and MMP-14. Full-colour 
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The role of MMPs in Endoglin shedding 
Since soluble Endoglin was detectable in CRC patients, where it might have an anti-
angiogenic role as has been described for other pathological conditions12, we analysed if 
MMPs could play a role in Endoglin shedding from the endothelial cell membrane. Analysis 
of the Endoglin amino acid sequence revealed that it contains at least two MMP sensitive 
cleavage sites indicated by arrows (Figure 4), of which one is located in the transmembrane 




Figure 3. sEndoglin in CRC. A) Validation of sEndoglin plasma ELISA. A control serum sample was spiked with a
fixed amount of recombinant human Endoglin. B) sEndoglin levels in 19 CRC patients pre-and post-operation and 
15 healthy controls. Lines indicate median values, whereas lines with dots represent mean values. Dukes stage of
the tumours is indicated (A, B2, C1, C2 and D). 
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MMP-14 is a membrane-bound MMP, which has been shown to be capable of shedding of 
membrane bound receptors19. To evaluate if MMP-14 is able to shed Endoglin from the 
endothelium membrane we treated HUVECs, expressing high levels of Endoglin (Figure 5A), 
with recombinant MMP-14. Figure 5B shows high levels of sEndoglin in control medium, 
which was not increased by treatment with recombinant human MMP-14. To further analyse 
if MMP-14 was capable of mediating Endoglin cleavage we co-transfected COS cells with 
plasmids encoding Endoglin, full length membrane bound MMP-14 or MMP-14 lacking the 
transmembrane domain (MMP-14 ΔTM). As shown in figure 5C co-transfection of Endoglin 
only with membrane bound MMP-14, and not with MMP-14ΔTM, led to increased sEndoglin 
levels in the medium. To further analyse if endothelial MMP-14 could mediate shedding of 
Endoglin from endothelial cells, HUVEC cells were treated with various proteinases 
inhibitors. Inhibitors of cystein and serine proteases (including cathepsins and plasmin) did 
not reduce sEndoglin levels, in contrast to broad spectrum MMP inhibitors GM6001 and 
Marimastat, which have been described to also inhibit MMP-1428. Inhibition of soluble 
Endoglin release was 50% by both GM6001 and Marimastat (Figure 5D). Specific inhibitors 
of gelatinases (MMP-2 and MMP-9), Stromelysins (MMP-3) had only a mild effect on 
sEndoglin release, whereas and an MMP-13 inhibitor did not affect levels at all. This 
indicates that these classes of MMPs are probably not involved in the shedding process. 
 
1    mdrgtlplav alllascsls ptslaetvhc dlqpvgperg evtyttsqvs kgcvaqapna   
61  ilevhvlfle fptgpsqlel tlqaskqngt wprevllvls vnssvflhlq algiplhlay   
121 nsslvtfqep pgvnttelps fpktqilewa aergpitsaa elndpqsill rlgqaqgsls   
181 fcmleasqdm grtlewrprt palvrgchle gvaghkeahi lrvlpghsag prtvtvkvel   
241 scapgdldav lilqgppyvs wlidanhnmq iwttgeysfk ifpeknirgf klpdtpqgll   
301 gearmlnasi vasfvelpla sivslhassc ggrlqtspap iqttppkdtc spellmsliq   
361 tkcaddamtl vlkkelvahl kctitgltfw dpsceaedrg dkfvlrsays scgmqvsasm  
421 isneavvnil sssspqrkkv hclnmdslsf qlglylsphf lqasntiepg qqsfvqvrvs   
481 psvsefllql dschldlgpe ggtveliqgr aakgncvsll spspegdprf sfllhfytvp   
541 ipktgtlsct valrpktgsq dqevhrtvfm rlniispdls gctskglvlp avlgitfgaf   
601 ligalltaal wyiyshtrsp skrepvvava apassessst nhsigstqst pcstssma 
Figure 4. Amino acid sequence of  Endoglin with two possible MMP sensitive cleavage sites (arrows) of 
which one is located in the trans-membrane domain (bold) 
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Of several membrane receptors like the VEGF receptor and Endoglin also soluble variants 
have been described, which seem to be involved in several pathological conditions. Increased 
levels of sEndoglin have been reported in pre-eclampsia patients12,13, whereas studies 
describing sEndoglin levels in malignancies are not conclusive. Several studies revealed 
increased levels in cancer patients compared to controls15,17,29, whereas other showed no 
increased levels30,31. In our study we found that pre-operative sEndoglin in levels in CRC 
patients appeared to be lower than controls, although differences did not reach statistical 
significance. This would correspond to a possible anti-angiogenic role by savaging of pro-
angiogenic molecules, like TGF-β or VEGF30,31. In contrast, sEndoglin might also function as 
Figure 5. A) Western blot analysis of MMP-14 expression in HUVEC and ECRF endothelial cell lysates. B)
sEndoglin medium levels after treatment of HUVEC cells with recombinant human MMP-14 (Three 
independent experiment in triplo). C) sEndoglin medium levels in COS cells after transfection with Endoglin,
Empty vector (EV), full length MMP-14, or MMP-14 lacking the transmembrane domain (MMP-14 Δ TM) 
plasmids Data represent mean+ standard deviation of one experiment in triplo. D) Soluble Endoglin levels in
HUVEC medium after treatment with various proteinases inhibitors (% versus appropriate control, n=5
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a circulating TGF-β reservoir10,32. The role of sEndoglin might also depend on the cell type it 
is cleaved from. High expression of the TGF-β co-receptor Endoglin on angiogenic 
endothelial cells has been associated with poor survival in various types of cancers1,8,16, even 
being prognostic superior to other angiogenic markers like CD31 or CD3416,33,34. We 
observed strongly increased tissue Endoglin levels in colorectal carcinoma, but not in pre-
malignant adenomas, corresponding to what has previously been shown for benign gastric 
lesions34. Endoglin expression was mainly observed in angiogenic endothelial cells, but also 
in fibroblasts especially in the normal to tumour transition zone. Expression of Endoglin on 
non-endothelial cells seems to play a role in invasive processes. Recently it was shown that 
over-expression of Endoglin in MDA epithelial breast cancer cells increases their invasive 
behaviour by upregulation of MMP expression and the formation of invadipodia6. In contrast, 
another study showed that shedding of Endoglin from mouse keratinocytes increases their 
invasive potential35. Our immunohistochemical analysis revealed expression of Endoglin 
specifically in fibroblasts in the normal to tumour transition zone and could therefore be 
involved in the invasion of fibroblasts into the surrounding normal tissue.  
Betaglycan another TGF-β co-receptor can be released into the circulation by proteolytic 
cleavage by MMP-1419. Because Endoglin shows high homology with betaglycan and 
contains and MMP sensitive cleavage sequence in the transmembrane domain, we examined 
the role of MMP-14 in Endoglin shedding. Treatment of endothelial cells with recombinant 
MMP-14 did not increase soluble Endoglin levels. Further analysis using co-transfection of 
Endoglin with a MMP-14 revealed that the localisation of MMP-14 on the cell membrane is 
crucial for shedding Endoglin into the medium as MMP-14 lacking the transmembrane 
domain was not capable of shedding Endoglin. The contribution of MMP-14 to Endoglin 
shedding from endothelial cells was further supported by the fact that immunohistochemical 
analysis showed that endothelial cells highly expressing MMP-14 did not stain for Endoglin. 
Next to that, addition of only broad spectrum MMP inhibitors could reduce sEndoglin release 
into the medium. Cystein-, or serine-protease inhibitors did not reduce sEndoglin levels, 
whereas gelatinase, stromelysin-, or collagenase specific inhibitors had only a mild effect. 
Broad spectrum MMP inhibitors inhibit, besides the specific MMP classes mentioned before, 
also MMP-14, and showed a 50% reduction in sEndoglin levels. Preliminary data using 
shRNA mediated knockdown of MMP-14 in endothelial cells revealed a comparable 
inhibition as observed with the MMP inhibitors. This would further extent the important role 
MMP-14 has in cancer progression besides its pro-tumerogenic role in the activation of 
MMP-2, cleavage of ECM component22,36, and its role in angiogenesis37. Shedding of 
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Figure 6. Proposed mechanism of Endoglin expression and generation of sEndoglin in colorectal cancer. 
Full-colour illustration at page 208. 
Endoglin releasing an anti-angiogenic soluble variant could act tumour-suppressive by 
reduction of angiogenesis.  
In conclusion, we have shown increased Endoglin expression in CRC, but not in pre-
malignant adenomas and that mean pre-operative sEndoglin levels in CRC patients seem to be 
lower compared to controls. Based on in vitro experiments we propose MMP-14 to be an 
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1    Summary main observations 
The general purpose of the studies described in this thesis was to evaluate how cell-cell 
interactions within the gastrointestinal tumour-microenvironment contribute to the 
progression of tumours. Based on clinical data from gastrointestinal cancer patients, we 
developed different cell-culture models to resemble, as closely as possible, the human 
situation. Using these models we examined the interaction between tumour cells, tumour-
associated myofibroblasts, endothelial cells, inflammatory cells and the extracellular matrix 
(ECM), together creating the tumour-microenvironment. We showed that these interactions 
are crucial for two major processes associated with cancer progression, the accumulation of 
myofibroblasts and the regulation of angiogenesis. The major interactions studied in this 


















Figure 1. Cell-cell-ECM interaction within the gastrointestinal tumour-microenvironment. Myofibroblasts are 
generated by interaction between tumour cells and  fibroblasts by activation of TGF-β1. In turn myofibroblasts 
secrete high amounts of TGF-β and invasion related proteinases, including MMP-9. MMP-9 is capable of 
cleaving ECM localised HSPGs releasing VEGF-165. However, the majority of MMP-9 required  for initiating 
the angiogenic switch is retrieved from tumour-infiltrating neutrophils. VEGF and cathepsin S-released pro-
angiogenic ECM molecules bind to quiescent endothelial cells turning them into angiogenic endothelial cells 
expressing Endoglin. MMP-7 is upregulated in angiogenic endothelial cells facilitating matrix degradation and 
subsequent invasion and sprout formation. Membrane-bound endothelial MMP-14 is the most appropriate 
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2    Tumour-cell – fibroblast interactions; TGF-β activation and generation of 
myofibroblasts 
Already in 1986 Dvorak et al.1 described that tumours resemble “wounds that do not heal” 
indicating that the interaction of cells within the tumour-microenvironment has strong 
similarities to a chronic wound healing process. One of the cell types involved in both 
processes is the myofibroblast2, a hyper-activated fibroblast displaying both vimentin and 
smooth muscle actin (SMA) expression3. The numbers of myofibroblasts are low in normal 
tissue except during wound healing and fibrosis, where myofibroblasts play a major role in 
the deposition of ECM components like collagen type-I4. When we evaluated gastric and 
colorectal cancers we observed strongly increased numbers of myofibroblasts being present in 
tumours compared to normal tissue (chapter 3 and 4). This increase is not yet present in pre-
malignant colorectal adenomas, indicating the importance of cancer-associated myofibroblast 
in the malignant progression of tumours. The origin of myofibroblasts in colorectal cancer is 
still a subject of many investigations3,5-9. Cancer-associated myofibroblasts probably arise 
from the interaction between (pre-)malignant epithelial cells and surrounding tissue 
fibroblasts via direct cell-cell contact through membrane bound proteins like EMMPRIN 10, 
but also by secretion and activation of soluble growth factors like TGF-β. When we analysed 
TGF-β1 levels in tissue homogenates we observed that endogenously active TGF-β1 levels 
correlated with the SMA content in these homogenates, indicating a prominent role for TGF-
β1 in the generation of cancer-associated myofibroblasts. 
TGF-β has a dual role in cancer because it is tumour-suppressive in the pre-malignant stage 
and tumour-promoting in later stages11,12. This is likely attributable to the switch of TGF-β 
signalling from epithelial cells in normal tissue to increased mesenchymal signalling in 
cancers as we have shown in chapter 3 and 5. In contrast to normal tissue myofibroblasts, 
cancer-associated fibroblasts display increased TGF-β signalling. This process involves the 
activation of the latent TGF-β1 complex, which is the crucial regulation mechanism for TGF-
β1 activity13. Other studies on TGF-β have mostly focussed on total TGF-β levels in clinical 
samples, including both latent ECM-bound TGF-β and the endogenously active TGF-β14, 15. 
In contrast, we have shown that primarily active TGF-β1 levels are related to survival of both 
gastric and colorectal cancer patients (chapter 3 and 4). Upregulation of synthesis of the 
latent TGF-β1 complex is already seen early in the normal-adenoma-carcinoma sequence, 
however, increased activation is solely present in carcinomas, indicating that over-activation 
rather than over-expression of TGF-β1 enables transition from benign to malignant tumours.  
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TGF-β activation is mediated by the interaction between tumour cells and fibroblasts 
(chapter 5). In contrast to previous observations in the literature13,16 and our expectations, the 
activation of tumour cell-derived large latent TGF-β1 by tumour cells interacting with cancer-
associated fibroblasts, does not seem to involve a proteolytic activation cascade in our model.  
Rather the minor amounts active TGF-β, secreted and possibly proteolytically activated at the 
tumour cell surface, mediate the first trans-differentiation of fibroblasts into myofibroblasts. 
Hereafter myofibroblasts probably use tumour cell-derived TGF-β, which is bound via LAP 
to ECM localised αvβ5 integrin. Binding of LAP to αvβ5 integrin has been described17 and 
recently it was shown that myofibroblasts can use their contractile properties to non-
proteolytically activate large latent TGF-β via binding to this integrin18. This could result in 
increased trans-differentiation of more myofibroblasts. Based on our data the TGF-β mediated 
trans-differentiation of resident fibroblasts accounts for the majority of the cancer-associated 
myofibroblasts and the interaction between tumour cells and fibroblasts is crucial in initiation 
of this process. In turn, myofibroblasts show increased secretion of TGF-β, MMPs, TIMPs 
and plasminogen activation system components. The strong upregulation of TGF-β in 
myofibroblasts both on the RNA as well as the protein level, together with upregulation of 
invasion and growth factor releasing related proteinases, creates a cancer enhancing feedback 
loop.  
Chapter 5 further revealed that next to myofibroblasts also HT29 and HCT116 tumour cells 
are responsive to TGF-β1, but show no growth inhibition by TGF-β1. Moreover, the 
interaction between fibroblasts and tumour cells enhances TGF-β signalling in tumour cells, 
which increases the synthesis and secretion of proteolytic enzymes. Normal and pre-
malignant epithelial cells are growth inhibited by TGF-β treatment, but in cancers these cells 
are often refractory to growth inhibiting properties by TGF-β. This might partly be due to 
epithelial TGF-β RI or RII mutations as observed in colorectal cancer19, but also result from 
mutations in downstream TGF-β signalling molecules like Smad-420. These mutations might 
only effect the epithelial cells and not the stromal cells which particularly show increased 
TGF-β signalling in colorectal cancer specimens. However, staining for nuclear accumulation 
of p-Smad-2 illustrated that in the majority of the tumours epithelial Smad-dependent TGF-β 
signalling was reduced. The tumour-promoting effects of TGF-β on epithelial cells could also 
involve Smad-independent pathways19,21. Many colon cancer cells like HT29 do not express 
the Smad-4 protein, but nevertheless are still responsive to stimulation with high doses TGF-
β1. Stimulation of HT29 cells resulted in upregulation of many proteolytic enzymes which 
consequently resulted in increased invasive growth and the formation of distant metastasis- 
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like cell clusters, when embedded in a stroma-like ECM environment. Taken together these 
data imply that the interaction between tumour cells and fibroblasts generates active TGF-β1 
that not induces the trans-differentiation of fibroblasts into myofibroblasts, but also 
upregulates MMP secretion by tumour-cells and fibroblasts, illustrating a double paracrine 
interaction mechanism. Other studies revealed that myofibroblasts are indeed capable of 
inducing invasiveness of cancer cells via upregulation of MMPs and uPA22 or through 
hepatocyte growth factor/scatter factor dependent mechanisms9,23.  
Enhanced secretion of MMPs is associated with increased invasiveness of cancer cells, but 
more importantly also with the regulation of growth factor bioavailability (Chapter 1). TGF-
β enhances MMP-2 and MMP-9 secretion by myofibroblasts (Chapter 5 and 6), which have 
often been associated with tumour angiogenesis through regulation of VEGF bioavailability. 
This results in another interaction within the tumour-microenvironment, i.e. with endothelial 
cells and thereby affecting angiogenesis.  
 
3    Tumour- mesenchymal- endothelial cell interaction in angiogenesis 
Tumour angiogenesis is of major importance for the outgrowth of tumours to provide them 
with nutrients and oxygen24 and enabling tumour cells to enter the circulation and form distant 
metastasis25. When the tumour reaches the critical size of 1-2 mm the angiogenic switch 
occurs, resulting in the formation of its own vasculature system. The microvessel density (the 
number of blood vessels in tumours) is a strong prognostic parameter for the survival of 
cancer patients26,27 and is analysed by specific markers on angiogenic endothelial cells, like 
CD34 and Endoglin27,28. We have shown that Endoglin levels in pre-malignant adenomas are 
comparable to normal mucosa, whereas in carcinomas strongly increased Endoglin levels 
were present (chapter 10). Interactions within the early malignant tumour-microenvironment 
are instrumental in the initiation of the angiogenic switch. Initiating factors include a hypoxic 
environment24, infiltrating neutrophils29 and the secretion of angiogenic growth factors by 
tumour cells30. For example TGF-β1, besides contributing directly to angiogenesis via 
Endoglin, has been shown to enhance secretion of VEGF25,31 and in gastric cancer patients 
TGF-β1 levels in gastric cancers are correlated to VEGF expression32. In chapter 6 we show 
that tumour cells produce high amounts of VEGF, the major angiogenic factor in vivo24. 
Secreted VEGF is bound to heparan sulphate proteoglycans (HSPGs) in the ECM in vivo33. 
Spheroids of HT29 cells represent a good model for the human in vivo situation as they 
produce ECM components, including HSPGs, which are able to bind growth factors like 
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TGF-β and VEGF34. In this way tumour cells are the first players in the network of interacting 
cell types. VEGF bound to HSPGs has no biological activity and processing of the HSPGs or 
VEGF protein is required. Therefore, the second player in the initiation of the angiogenic 
switch are the cells capable of secreting the proteolytic enzyme required for increasing VEGF 
bioavailability under given conditions; i.e., a non-vascularised hypoxic tumour environment. 
We have shown that MMP-9 is a major contributor of regulating VEGF bioavailability. Both 
neutrophils and myofibroblast show strong secretion of MMP-9. However, in our model, 
representing the initiation of the angiogenic switch, it seems that neutrophils are the major 
source of MMP-9 in vivo. This is probably caused by the fact that neutrophils contain MMP-9 
in granules and active MMP-9 can be directly secreted upon a activation signal like a hypoxic 
environment. Besides MMP-9 neutrophils also contain MMP-8, which is, although to a lesser 
extent, also capable of releasing VEGF. In later stages, MMP-9 producing macrophages 
which are present at the periphery of the tumours could also contribute to VEGF release29. 
Furthermore myofibroblasts might release VEGF through secretion of MMP-2 and MMP-9 
both capable of releasing VEGF if the appropriate proteolytic activators of MMP-2 and -9 are 
present. In addition myofibroblasts have been shown to secrete VEGF and TGF-β, which is 
capable of inducing angiogenesis35. Finally, the third player in the complex interaction 
between cell types regulating tumour angiogenesis is the effector cell (endothelium). To study 
the angiogenic switch we used 3-dimensional cultured HUVEC endothelial cells embedded in 
a collagen type 1 matrix. Under these conditions HUVECs represent the non-activated stage. 
However, in the presence of angiogenic stimuli cells enter the initiation phase of 
angiogenesis, followed by the resolution phase and the formation of a lumen36. Sprout 
formation requires proteolytic activity37, and as we have shown in chapter 7, MMP-7 is 
expressed by sprouting endothelial cells. MMP-7 has previously been described to be an 
“epithelial” MMP, contributing to cancer progression for example by its capacity to cleave 
VE-cadherin from endothelial cells enhancing their proliferation38. In addition, MMP-7 can 
also cleave E-cadherin from epithelial cells, which is one of the hallmarks of epithelial cells 
undergoing epithelial to mesenchymal transition (EMT). EMT is a process in which epithelial 
cells lose epithelial markers en gain mesenchymal markers, like vimentin and smooth muscle 
actin. This process is thought to contribute to both metastasis of cancer and the generation of 
part of the myofibroblast population. Furthermore, it was shown that expression of MMP-7 
regulates VEGF release from fibroblast ECM39 and might enhance myofibroblast 
differentiation40. Our observation that endothelial MMP-7 also plays a role in angiogenic 
processes might render it as a new therapeutic target.  
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Using the bio-activity assay as described in chapter 8, a pilot study on colorectal (pre-) 
malignancies revealed that pro-MMP-7 is already upregulated in pre-malignant colorectal 
adenomas, whereas upregulation of MMP-7 activity is merely seen in carcinomas. This is the 
same phenomenon as we observed for TGF-β1 activity and further emphasizes that 
upregulation of protein expression can occur early in the development of carcinomas, but 
increased activation is merely seen in carcinomas, and therefore the activating proteins might 
be attractive therapeutic candidates. 
To study possible therapeutic targets within the tumour-microenvironment it is important to 
take the human microenvironment into account. In chapter 6 we have shown that MMP-9 
mediated VEGF release involves cleavage of HSPGs, releasing VEGF-165, the most potent 
isoform capable of inducing angiogenesis41. This is in contrast to what has previously been 
shown for mouse VEGF-164 which is cleaved by human MMP-9 to a smaller isoform instead 
of being released42. This clearly illustrates the importance of studying cell-cell interactions 
within the human tumour-microenvironment. Recent advancements in the development of 
model systems, using human 3-dimensional endothelial spheroids and grafting them into 
mice43 to create the complexity of a living organism, is a valuable contribution to study 
interactions in the tumour-microenvironment.   
Tumour angiogenesis is not solely dependent on cell-cell interactions involving VEGF 
release. We have shown in chapter 9 that cathepsins S releases pro-angiogenic molecules 
from the ECM. Cathepsin S in tumours is mainly produced by tumour cells and cancer-
associated macrophages44. Interestingly, we observed increased cathepsin S secretion when 










Figure 2. Cathepsin S activity in HT29 homogenates cultured under monolayer or spheroid conditions (A). 
Staining for laminin on HT29 spheroids (B). Full colour illustration at page 201. 
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It has been described that cathepsins S is capable of cleaving laminin-5, one of the major 
constituents of the ECM and also produced by HT29 cells45 and unpublished data (Figure 
2B). One of the proteolytically generated laminin-5 subchains, the γ-2 fragment has been 
shown to have angiogenic properties44. This implies that in the tumour-microenvironment 
macrophages and/or tumour cells secrete cathepsins S which could generate laminin-5 γ2 
fragments from the ECM, which could in turn induce endothelial sprouting. 
Equally important to regulation of angiogenesis by the presence of angiogenic factors equally 
important is the presence of appropriate receptors on the target cells. TGF-β is capable of 
inducing angiogenesis via binding to the TGF-β co-receptor Endoglin35. Besides membrane 
bound also a soluble form of Endoglin (sEndoglin) is detected in the circulation. Soluble 
receptors, like Endoglin and the soluble VEGF receptor, can still bind their ligands and can 
therefore act anti-angiogenic by scavaging pro-angiogenic factors. Several studies addressed 
the levels of soluble Endoglin in pathologic conditions, but are not conclusive46-51. We 
observed lower circulating sEndoglin in colorectal cancer patients levels pre-operatively, 
(chapter 10) which increased to reach levels observed in healthy controls after operation. 
This phenomenon might correspond to an anti-angiogenic role of sEndoglin in colorectal 
cancer. Furthermore, we evaluated the potential role of MMPs in the generation of this 
sEndoglin and show that membrane type-1 MMP (MMP-14) is the most likely candidate to 
mediate the cleavage of Endoglin to generate the soluble form. This indicates a possible 
tumour-suppressive role for MMP-14 besides its described pro-tumourogenic effects like 
activation of MMP-252 and a role vascular tubulogenesis53. In contrast, shedding of Endoglin 
from non-endothelial cells might result in a highly invasive phenotype as shown for mouse 
keratinocytes54. In human tumours MMP-14 is also highly expressed by epithelial cells and 
fibroblasts in malignant transformed tumours55,56. We also observed Endoglin expression in 
the normal to tumour transition zone (chapter 10). Further studies are required to examine the 
role of Endoglin and the role of epithelial or fibroblast-associated MMP-14 in shedding of 
non-endothelial Endoglin and elucidating another network of cell-cell interactions in the 
gastrointestinal tumour-microenvironment.  
 
4    Clinical implications and perspectives of targeting the tumour-
microenvironment 
In this thesis studies are described on the interactions of cell-types within the tumour-
microenvironment, focussing on four key players: MMPs, cathepsin S, VEGF and TGF-β in 
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two major processes: the generation of myofibroblasts and tumour angiogenesis. We have 
shown that several MMPs and cathepsins S contribute to invasive and angiogenic processes in 
the initiation and progression of carcinoma. Therefore, the development of therapeutic 
applicable inhibitors for cathepsins S, MMP-9 or MMP-7 might pose new opportunities to 
inhibit tumour angiogenesis. However, further studies are required to exactly evaluate the role 
of these proteinases in tumour-suppressive processes like the degradation of angiogenic 
molecules57 or the generation of anti-angiogenic molecules58. Previous clinical trails with 
broad spectrum MMP inhibitors did not show therapeutic effects on cancer progression59. 
This might partly be explained by the fact that these inhibitors were broad spectrum MMP 
inhibitors inhibiting both the tumour-promoting effect of a subset of MMPs, but also 
impairing the tumour-suppressing effects generated by several MMPs. Furthermore, studies 
showing effectiveness of MMP inhibitors were mainly based on in vitro studies and animal 
models. Mouse models do not have to represent the human situation60, as we have shown for 
the mechanism of VEGF release. This illustrates that both simple and complex in vitro 
systems together with animal models should be used to evaluate biological processes and 
therapeutic application of inhibitors61. Clinical MMP inhibition should therefore be examined 
in a human setting, taken the tumour-microenvironment, including activators, docking 
molecules and inhibitors, into account59. Next to that, the selection of specific inhibitors for 
certain proteinases might be a challenge. Most MMPs and cathepsins have similar catalytic 
clefts. Using the phage display technique as described in chapter 9 it might be easier to bias 
selection of specific proteinases inhibitors towards specific and functionally active inhibitors. 
Besides inhibition of MMPs or other cancer-related proteinases another therapeutic approach 
could be to use the proteolytic activity to deliver pro-drug constructs which are locally 
activated by the increased proteolytic activity in the tumour, more specifically targeting 
tumour cells and create high intra-tumour concentrations of anti-cancer drugs. As we have 
shown, for example, MMP-7 activity is low in normal tissue and adenomas, whereas 
activation is strongly increased in carcinomas, also in tumour-associated endothelial cells. 
MMP-7 sensitive pro-drug constructs might therefore provide possible advantages above 
systemic delivery of anti-cancer drugs. 
Finally targeting the tumour-microenvironment via direct inhibition of growth factors could 
offer therapeutical benefits. Clinical inhibition of angiogenesis by neutralizing the effect of 
VEGF is used for the treatment of CRC and still many new inhibiting antibodies and receptor 
kinase inhibitors are being developed62-64. Clinical trails have been initiated to inhibit TGF-β 
activity in pathological conditions, including fibrosis and cancer. Strategies include 
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neutralizing TGF-β activity by monoclonal antibodies, soluble TGF-β Receptors, or ALK-5 
inhibitors31. Based on our data targeting specifically active TGF-β, rather than the latent TGF-
β reservoir, or targeting activators of latent TGF-β might have therapeutic potential. However, 
TGF-β plays an important role in normal tissue homeostasis and acts as a tumour suppressor 
in early stages of cancer development. Therefore, the therapeutic inhibition of TGF-β should 
be carefully considered65, for example, by stringent selection criteria for patients applicable to 
receive anti-TGF-β treatment. 
 
5    Concluding remarks 
The interplay between tumour cells, inflammatory cells and fibroblasts plays a major role in 
cancer progression by influencing myofibroblast trans-differentiation and inducing 
angiogenesis in gastrointestinal cancer. For the elucidation of these processes and the 
development of therapeutic agents, research should be focussed on the role of the tumour-
microenvironment including cells, ECM, proteolytic enzymes and their activation cascades, 
using 3-dimensional cell culture models to study gastrointestinal carcinogenesis. The studies 
described in this thesis illustrated the importance of proteolytic regulation of VEGF and TGF-
β bioavailability by specific cell-cell interactions in the tumour-microenvironment. 
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1    Inleiding 
Kanker is tegenwoordig tweede meest voorkomende doodsoorzaak in de westerse wereld. 
Met name het colorectaal carcinoom (dikke darmkanker) wordt vaak gediagnosticeerd en veel 
mensen overlijden eraan. De primaire behandeling voor deze vorm van kanker bestaat uit het 
operatief verwijderen van de tumor en adjuvante (aanvullende) chemotherapie of bestraling. 
Tumoren bestaan uit verschillende cel typen, tezamen vaak de tumor micro-environment 
(tumor micro-omgeving) genoemd. Cellen in zowel normale als pathologische condities 
communiceren met elkaar en zijn afhankelijk van de “ondergrond” waar ze op vastzitten, de 
zogenaamde extracellulaire matrix (ECM). Communicatie tussen cellen gebeurt door 
directe contacten tussen de cellen, maar ook door groeifactoren die deze cellen uitscheiden. 
Deze interacties liggen ten grondslag aan twee processen die bijdragen aan de initiatie (het 
ontstaan), progressie (vergroting en invasieve groei in omliggend weefsel) en uiteindelijk 
metastasering (uitzaaiing) van tumoren, te weten myofibroblast differentiatie en angiogenese 
(bloedvatvorming). Deze processen worden gestuurd door groeifactoren die al aanwezig zijn 
in de ECM, maar gebonden aan het ECM zijn deze groeifactoren niet actief. Ze moeten 
gereleased (losgemaakt en geactiveerd) worden, vaak door zogenaamde proteolytische 
enzymen (eiwit knippende enzymen, die in staat zijn om door een gedeelte van een voorloper 
eiwit af te knippen en het daardoor te activeren). Een belangrijke groep van deze 
proteolytische enzymen vormen de matrix metalloproteinasen (MMPs), aangezien die in staat 
zijn een grote variëteit aan groeifactoren te activeren. In dit proefschrift worden de studies 
beschreven naar twee groeifactoren (VEGF en TGF-β) die ten grondslag liggen aan twee 
belangrijke tumor stimulerende processen, te weten angiogenese en differentiatie van 
myofibroblasten.  
Tumoren worden wel eens vergeleken met een “wond die niet heelt”. Dit geeft aan dat er 
speciale cel typen zijn, zoals de myofibroblast, die zowel een rol spelen bij wondheling als bij 
tumorprogressie. Fibroblasten, oftewel bindweefsel cellen, zijn cellen die een ondersteunende 
rol hebben voor epitheelcellen (epitheel cellen zijn bijvoorbeeld huidcellen en 
darmwandcellen). Myofibroblasten zijn hyper-geactiveerde fibroblasten en komen in 
normaal weefsel maar weinig voor, in tumoren daarentegen is hun expressie sterk verhoogd. 
Waar deze cellen vandaan komen is niet opgehelderd, maar er wordt gedacht dat een 
groeifactor, uitgescheiden door tumorcellen, wat ook epitheelcellen zijn, de omringende 
fibroblasten kan hyper-activeren. Deze groeifactor wordt transforming growth factor β (TGF-
β) genoemd en is normaal aanwezig als een niet-actieve pro-groeifactor genaamd latent TGF-
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β. Na activatie, door bijvoorbeeld MMPs, kan TGF-β vele processen initiëren, zoals het 
ontstaan van myofibroblasten, verhoging van secretie van andere groei-stimulerende factoren 
en de inductie van angiogenese via een receptor genaamd Endogline. 
Angiogenese is van groot belang voor de uitgroei van tumoren. Wanneer tumoren 1-2 mm 
groot zijn kunnen ze niet verder groeien door een gebrek aan zuurstof (hypoxie) en 
voedingstoffen tot dat ze hun eigen bloedvatstelsel hebben gecreëerd (angiogenetische 
switch). Vascular endothelial growth factor (VEGF) wordt beschouwd als een van de 
belangrijkste initiatoren van angiogenese in tumoren. VEGF wordt na synthese eerst als een 
inactief molecuul in de ECM vastgezet en moet door proteolytische activiteit geactiveerd 
(losgeknipt worden van de matrix) worden. Er zijn aanwijzingen dat de proteolytische MMP 
enzymengroep hierbij een belangrijke rol speelt. Eenmaal geactiveerd kan VEGF ervoor 
zorgen dat omringende endotheelcellen (bloedvatcellen) uitlopers gaan vormen in de richting 
van de tumor, waardoor het een eigen bloedvatstelsel krijgt.  
Beide hierboven beschreven processen omvatten dus de interactie tussen verschillende 
celtypen, zoals de fibroblasten met de tumorcellen en de endotheelcellen, in het geheel van de 
tumor micro-omgeving. Deze interacties zijn complex en om dit te bestuderen kan gebruik 
gemaakt worden van diermodellen, maar die hebben als nadeel dat ze niet representatief 
hoeven te zijn voor de humane situatie, omdat een muis geen klein mens is. Daarom werd in 
dit proefschrift gebruik gemaakt van 3-dimensionale celkweek modellen. De situatie in 
patiënten werd bestudeerd door het bepalen van de groeifactor en proteolytische enzym 
(MMP) niveaus in een homogenaat (extract) van tumorweefsel. Met behulp van specifieke 
antilichaamkleuringen is bekeken in welke cellen deze groeifactoren en enzymen voorkomen. 
Vervolgens werden deze bevindingen vertaald naar een in vitro systeem (de cellen worden los 
in een laboratorium gekweekt) om het onderliggende mechanisme te kunnen onderzoeken. 
 
2   Doel 
Het doel van de studies beschreven dit proefschrift was om de interacties tussen verschillende 
celtypen (fibroblasten, tumorcellen, endotheel) door proteolytische activatie van latente 
groeifactoren in de colorectale tumor micro-omgeving te onderzoeken. Hierbij staan twee 
processen centraal, het ontstaan van myofibroblasten en het proces van initiatie van 
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3   Resultaten  
In hoofdstuk 3 werd de hoeveelheid latent en actief TGF-β in een groep patiënten met 
maagtumoren bepaald. De belangrijkste resultaten waren dat alhoewel zowel de hoeveelheid 
latent als actief TGF-β verhoogd is in tumoren, met name het actieve TGF-β belangrijk is 
voor de prognose van de patiënten. Patiënten met hoge actieve TGF-β niveaus hebben een 
slechtere prognose (kortere overleving). Kleuringen op weefsel van deze patiënten toonden 
aan dat de TGF-β activiteit met name gezien wordt in de myofibroblasten. Deze data werden 
in hoofdstuk 4 bevestigd op een grote groep colorectaal tumor patiënten. Uit deze resultaten 
bleek tevens dat de toename van latent TGF-β al zichtbaar is in pre-maligne (goedaardige) 
poliepen, terwijl actief TGF-β alleen verhoogd is in tumoren (maligne, kwaadaardig) en dus 
een grote rol zou kunnen spelen in de maligne ontaarding van goedaardige poliepen. Verder 
staat in dit hoofdstuk de ontwikkeling van een bepaling om de hoeveelheid myofibroblasten te 
kunnen vaststellen in deze monsters beschreven. Uit de resultaten bleek dat er een relatie is 
tussen de hoeveelheid TGF-β activiteit en de hoeveelheid myofibroblasten in deze patiënten. 
Om dit mogelijk causale verband te onderzoeken staat in hoofdstuk 5 de vertaling van de 
observaties in patiënten naar een in vitro cel kweek systeem beschreven. Er werd aangetoond 
dat de interactie tussen tumorcellen en omringende fibroblasten leidt tot activatie van het 
latent TGF-β en daarop volgend het ontstaan van myofibroblasten (hyperactivatie). De 
interactie tussen deze twee cel typen was van cruciaal belang voor initiatie van dit proces. 
Deze cellen sterk hebben tevens verhoogde uitscheiding van TGF-β en MMPs die vervolgens 
in staat zijn om invasie van tumoren te veroorzaken. Dus de interactie tussen de cellen leidt 
tot hyperactivatie van de fibroblasten, maar die beïnvloeden op hun beurt weer de tumor 
cellen tot verhoogde secretie van groeifactoren en MMPs. Gevolg is dat na hyperactivatie er 
meer TGF-β komt, wat weer meer hyperactivatie geeft en dus meer TGF-β, waardoor een 
vicieuze cirkel ontstaat.  
De myofibroblasten geven ook een verhoogde secretie van MMP-9, waarvan beschreven is 
dat er een mogelijk verband bestaat met de angiogenetische switch. Vandaar dat in hoofdstuk 
6 de studie naar de rol van MMP-9 in de angiogenetische switch is beschreven. Analyse van 
patiënten materiaal liet zien dat er een verband is tussen de hoeveelheid VEGF in de circulatie 
(bloed) en MMP-9 niveaus in de tumoren. Kleuringen lieten zien dat VEGF uit de 
tumorcellen komt en MMP-9 uit de fibroblasten en immuuncellen. Deze bevindingen werden 
vervolgens vertaald naar een 3 dimensionaal in vitro model wat zo samengesteld was dat het 
zo goed als mogelijk overeenkwam met de situatie in de patiënten. De colon tumor 
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spheroiden (bolletjes tumorcellen) maken een ECM (matrix) waar VEGF aan gebonden wordt 
als een inactief molecuul. Wanneer deze werden behandeld met MMP-9 afkomstig van 
myofibroblasten en infiltrerende immuuncellen (neutrofielen) bleek dat het VEGF geactiveerd 
wordt door directe degradatie (knippen) van de matrix waaraan het VEGF gebonden zit. 
Hierdoor wordt het VEGF vrijgemaakt wordt en was het in staat tot vorming van endotheel 
uitlopers (sprouting) wanneer endotheelcellen hiermee behandeld werden, vergelijkbaar met 
de angiogenetische switch. Deze resultaten geven wederom aan dat de interactie tussen met 
name de neutrofielen, tumorcellen en hun ECM en de endotheelcellen belangrijk is voor de 
initiatie van dit proces. Tevens bleek het knip mechanisme in mensen anders is dan in muizen. 
Behalve MMP-9 heeft ook een ander proteolytisch enzym uit dezelfde MMP familie, MMP-7, 
hier een rol in zoals beschreven staat in hoofdstuk 7. Deze MMP komt tot expressie in de 
uitlopers van endotheelcellen en wanneer MMP-7 geremd wordt, konden er geen uitlopers 
meer ontstaan. Om dit fenomeen verder te onderzoek is in hoofdstuk 8 de ontwikkeling van 
een bepaling (bio-activiteits assay, BIA) om MMP-7 niveaus in patiënten materiaal, zoals 
homogenaten van tumor weefsel, plasma en urine te kunnen meten beschreven. Uit de 
voorlopige analyses bleek dat, net als bij TGF-β, de productie van het inactieve proteolytische 
enzym al in poliepen verhoogd is, maar dat verhoogde activatie pas plaatsvindt in tumoren. 
Behalve de voorgenoemde MMPs speelt ook het proteolytische enzym cathepsine S een rol in 
het activeren van matrix moleculen die angiogenese kunnen induceren (hoofdstuk 9). Verder 
staan in dit hoofdstuk de studies beschreven naar de aanpassing van een bestaande screenings 
techniek (faag display) voor de selectie van specifieke remmers voor deze enzymen die na 
doorontwikkeling mogelijk als medicijn zouden kunnen dienen. Tot slot staat in hoofdstuk 10 
beschreven hoe Endogline, een receptor voor TGF-β, die sterk tot expressie komt op nieuw 
gevormde bloedvaten, van deze vaten geknipt wordt en laten zien dat met name een MMP die 
aan de membranen gebonden zit, MMP-14, hierin een belangrijk rol zou kunnen spelen. Dit 
“vloeibaar” Endogline komt in de circulatie (bloed) terecht en heeft daar mogelijk een 
beschermend effect, aangezien het factoren die angiogenese kunnen initiëren kan wegvangen.  
 
4   Conclusies 
De data beschreven in dit proefschrift onderbouwen de belangrijke rol van de interactie tussen 
verschillende celtypen en de matrix in de progressie van tumoren. Activatie van TGF-β en 
VEGF is alleen mogelijk waneer er verschillende celtypen aanwezig zijn die elkaar onderling 
beïnvloeden. De diverse studies laten tevens zien dat humane celkweekmodellen een 
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belangrijke toevoeging kunnen zijn voor het onderzoek naar deze processen in de humane 
model-omgeving. 
 
5   Klinische en therapeutische implicaties 
Uit dit onderzoek blijkt dat de tumor micro-omgeving een belangrijke rol speelt bij de 
progressie van tumoren en dat met name de activatie van latente groeifactoren hierin van 
groot belang is. Uit de data blijkt dat MMPs hierin een belangrijke rol spelen. Op langere 
termijn, na meer onderzoek zou het specifiek remmen van deze MMPs, gericht op de humane 
situatie en in een vroeg stadium van tumorontwikkeling een belangrijk therapeutisch 
perspectief kunnen bieden. Nader onderzoek, gebruik makend van de diverse 
celkweekmodellen, kan de voorgenoemde processen verder ophelderen en kunnen nieuwe 
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HT29 spheroid stained for laminin (chapter 12) 
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Figure 2. Cellular localisation of active TGF-β1 in gastric cancer. Immunohistochemical staining of gastric
carcinomas (sequential frozen sections). Staining pattern for active TGF-β1 (A) corresponds to phospho-smad 2 
staining (B). Inserts B1 and B2 show respectively nuclear localisation (arrowheads) of p-smad-2 in the 
myofibroblasts and malignant cells. As shown by staining for pan-Cytokeratin (C, epithelial marker), Vimentin 
(Vim, D, mesenchymal marker) and Smooth Muscle Actin (SMA, E smooth muscle/myofibroblast marker ) TGF-β1 
activity is observed in malignant cells and in Vim+/SMA+ cells (myofibroblasts). Magnification 200x, B1-B2 630x. 
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Figure 3. Total TGF-β and p-smad-2 staining on paraffin embedded gastric cancer tissue sections. 
Staining on normal gastric mucosa shows some staining for total TGF-β (A) and almost no staining for p-smad-
2 (B, insert 400x). Both are strongly increased in corresponding tumour tissue (C, total TGF-β1, D, p-smad-2, 
insert 400x). Figure E-G shows p-smad 2 staining in 3 different gastric carcinomas with high (81.3 pg/mg, E),
median (21.1 pg/mg, F) and low active TGF-β1 levels (1.6 pg/mg, G). A strong decrease in nuclear staining
(inserts E-G, magnification 630x, arrowheads indicate intense nuclear staining in myofibroblasts in E) is
observed with especially in myofibroblasts (staining for pan-Cytokeratin, Vimentin and Smooth Muscle Actin on 
sequential sections, not shown). Magnification 200x.
Full-colour illustrations 







SMA VIM Desmin panCyt
Figure 3F. Immunohistochemistry on Tu1-Tu4 samples, SMA = smooth muscle actin, myofibroblast and 
smooth muscle cell marker; Vim = vimentin, stromal cell marker; desmin, smooth muscle cell marker; pan-
cytokeratin, epithelial marker). 
Full-colour illustrations 




































Figure 1. Immunohistochemistry on CRC tissue samples. Normal colonic mucosa displays a single layer of SMA 
positive myofibroblasts along the crypt axis, which show no nuclear staining for pSmad2, in contrast to epithelial 
cells, which show a gradient in staining from bottom to top of the crypt. Total TGF-β is present in low levels in 
normal mucosa, whereas it is strongly increased in CRC (A). Strongly increased SMA expression and a shift 
from epithelial to mesenchymal nuclear 
 accumulation of pSmad2 occurs in CRC, although some samples, like CRC-46, still show nuclear accumulation 
of pSmad2 in malignant cells next to myofibroblasts (B).  
Full-colour illustrations 
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Figure 2. Immunohistochemical staining of normal and tumour colon tissues and 3-dimensional cell culture 
models showing the resemblance between patients derived tissue and in vitro cell culture models. VEGF 
expression was very low in normal colon tissue (A) and strongly increased in colon tumour cells (B, 
arrowheads). HT29 colon cancer spheroids strongly express VEGF (C). MMP-9 was hardly detectable in 
normal colon tissue (D) and strongly expressed in stromal cells in colorectal cancer (E), especially in 
neutrophils (enlarged insert, 630x). HT29 spheroids were negative for MMP-9 (F), and produced VEGF 
binding HSPGs (G, left) and the ECM molecule laminin (G, right).  Fibroblast spheroids (H) were positive for 
vimentin (VIM) and for SMA. MMP-9 was expressed, but MMP-2 was more abundant. CD34 showed minor 
staining in normal colon except for the submucosal area (I, insert). In tumours many neo-angiogenic CD34 
positive vessels are present in the proximity of tumour cells (J, insert, 630x).  HUVEC spheroids were positive 
for CD31 (K) while sprouting endothelial cells showed additional positivity for the angiogenesis marker 
CD105 (L). 
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Figure 4. A) Immunohistochemical staining for HSPGs with monoclonal antibody 10E4 of HT29 spheroids after 
treatment with MMP-9 or heparitinase resulting in decreased extracellular localization of HSPGs (magnification 
630x). B) Western blot of medium from HT29 spheroids treated with MMP-9 and subsequently stained with 
monoclonal antibody 3G10, specifically recognizing epitopes on HSPGs after cleavage. 
Figure 1. Immunohistochemical staining of endothelial cells for MMP-7, indicated by arrows in gastric 
cancer (A), colonic cancer (B), breast cancer (C), cervical cancer (D), prostate cancer (E), and in in vitro 
sprouting HUVEC cells (F). Inserts I and II indicate respectively CD34 and CD105 staining in sequential 
section from the same tissue. The inserts in (F) show VEGF-induced endothelial cell sprouting in control and 
marimastat-treated HUVEC spheroids. Arrowheads indicate epithelial cell staining. Bars correspond with 
100 μm in (A-E) and with 300 μm in (F).  
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Figure 2 Endoglin (CD105)immunohistochemistry on  normal mucosa (N, left panel) and colorectal cancer 
specimens. The lower panels  show staining on sequential sections for Endoglin and MMP-14.  
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